{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Starting the script...\n"
     ]
    }
   ],
   "source": [
    "print(\"Starting the script...\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import glob\n",
    "import os"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 34,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from dotenv import load_dotenv\n",
    "from openai import OpenAI\n",
    "\n",
    "env_path = '/home/chb3333/yulab/chb3333/gem-patho/data_extraction/cancertype_location_description/OpenAI_key.env'\n",
    "load_dotenv(env_path)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "# ----- Part 1: Process the TCGA sample sheet -----"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Loading the cleaned TCGA samples without ICD data...\n",
      "Sample sheet loaded. Total rows: 204\n"
     ]
    }
   ],
   "source": [
    "print(\"Loading the cleaned TCGA samples without ICD data...\")\n",
    "sample_sheet_path = \"/home/chb3333/yulab/chb3333/gem-patho/data_extraction/cancertype_location_description/location_desciption_withoutICD/patients_missing_icd.parquet\"\n",
    "sample_df = pd.read_parquet(sample_sheet_path)\n",
    "print(\"Sample sheet loaded. Total rows:\", len(sample_df))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "Project ID",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Case ID",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Sample ID",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Sample Type",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Normalized Sample Type",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Study Abbreviation",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Study Name",
         "rawType": "object",
         "type": "string"
        }
       ],
       "conversionMethod": "pd.DataFrame",
       "ref": "4dd38b22-1db1-41d6-9a42-78779c0cefae",
       "rows": [
        [
         "69",
         "TCGA-GBM",
         "TCGA-06-6391",
         "TCGA-06-6391-10A, TCGA-06-6391-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "GBM",
         "Glioblastoma multiforme"
        ],
        [
         "144",
         "TCGA-KICH",
         "TCGA-KN-8430",
         "TCGA-KN-8430-11A, TCGA-KN-8430-01A",
         "Solid Tissue Normal, Primary Tumor",
         "Primary Tumor, Solid Tissue Normal",
         "KICH",
         "Kidney Chromophobe"
        ],
        [
         "431",
         "TCGA-KIRC",
         "TCGA-BP-4986",
         "TCGA-BP-4986-01A, TCGA-BP-4986-11A",
         "Primary Tumor, Solid Tissue Normal",
         "Primary Tumor, Solid Tissue Normal",
         "KIRC",
         "Kidney renal clear cell carcinoma"
        ],
        [
         "435",
         "TCGA-KIRC",
         "TCGA-CZ-4865",
         "TCGA-CZ-4865-01A, TCGA-CZ-4865-11A",
         "Primary Tumor, Solid Tissue Normal",
         "Primary Tumor, Solid Tissue Normal",
         "KIRC",
         "Kidney renal clear cell carcinoma"
        ],
        [
         "440",
         "TCGA-KIRC",
         "TCGA-BP-4988",
         "TCGA-BP-4988-01A, TCGA-BP-4988-11A",
         "Primary Tumor, Solid Tissue Normal",
         "Primary Tumor, Solid Tissue Normal",
         "KIRC",
         "Kidney renal clear cell carcinoma"
        ],
        [
         "474",
         "TCGA-KIRC",
         "TCGA-B2-5636",
         "TCGA-B2-5636-10A, TCGA-B2-5636-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "KIRC",
         "Kidney renal clear cell carcinoma"
        ],
        [
         "531",
         "TCGA-KIRP",
         "TCGA-BQ-7056",
         "TCGA-BQ-7056-11A, TCGA-BQ-7056-01A",
         "Solid Tissue Normal, Primary Tumor",
         "Primary Tumor, Solid Tissue Normal",
         "KIRP",
         "Kidney renal papillary cell carcinoma"
        ],
        [
         "533",
         "TCGA-KIRC",
         "TCGA-BP-4976",
         "TCGA-BP-4976-01A, TCGA-BP-4976-11A",
         "Primary Tumor, Solid Tissue Normal",
         "Primary Tumor, Solid Tissue Normal",
         "KIRC",
         "Kidney renal clear cell carcinoma"
        ],
        [
         "536",
         "TCGA-KIRC",
         "TCGA-DV-5573",
         "TCGA-DV-5573-10A, TCGA-DV-5573-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "KIRC",
         "Kidney renal clear cell carcinoma"
        ],
        [
         "543",
         "TCGA-KIRC",
         "TCGA-BP-5199",
         "TCGA-BP-5199-01A, TCGA-BP-5199-11A",
         "Primary Tumor, Solid Tissue Normal",
         "Primary Tumor, Solid Tissue Normal",
         "KIRC",
         "Kidney renal clear cell carcinoma"
        ],
        [
         "553",
         "TCGA-LUSC",
         "TCGA-21-1070",
         "TCGA-21-1070-11A, TCGA-21-1070-01A",
         "Solid Tissue Normal, Primary Tumor",
         "Primary Tumor, Solid Tissue Normal",
         "LUSC",
         "Lung squamous cell carcinoma"
        ],
        [
         "557",
         "TCGA-LUSC",
         "TCGA-60-2715",
         "TCGA-60-2715-01A, TCGA-60-2715-11A",
         "Primary Tumor, Solid Tissue Normal",
         "Primary Tumor, Solid Tissue Normal",
         "LUSC",
         "Lung squamous cell carcinoma"
        ],
        [
         "562",
         "TCGA-LUSC",
         "TCGA-NK-A5D1",
         "TCGA-NK-A5D1-10A, TCGA-NK-A5D1-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "LUSC",
         "Lung squamous cell carcinoma"
        ],
        [
         "567",
         "TCGA-LUSC",
         "TCGA-21-1078",
         "TCGA-21-1078-01A, TCGA-21-1078-11A",
         "Primary Tumor, Solid Tissue Normal",
         "Primary Tumor, Solid Tissue Normal",
         "LUSC",
         "Lung squamous cell carcinoma"
        ],
        [
         "571",
         "TCGA-LUSC",
         "TCGA-18-3409",
         "TCGA-18-3409-11A, TCGA-18-3409-01A",
         "Solid Tissue Normal, Primary Tumor",
         "Primary Tumor, Solid Tissue Normal",
         "LUSC",
         "Lung squamous cell carcinoma"
        ],
        [
         "619",
         "TCGA-KIRC",
         "TCGA-B0-5700",
         "TCGA-B0-5700-01A, TCGA-B0-5700-11A",
         "Primary Tumor, Solid Tissue Normal",
         "Primary Tumor, Solid Tissue Normal",
         "KIRC",
         "Kidney renal clear cell carcinoma"
        ],
        [
         "755",
         "TCGA-CHOL",
         "TCGA-5A-A8ZF",
         "TCGA-5A-A8ZF-01A, TCGA-5A-A8ZF-10A",
         "Primary Tumor, Blood Derived Normal",
         "Blood Derived Normal, Primary Tumor",
         "CHOL",
         "Cholangiocarcinoma"
        ],
        [
         "756",
         "TCGA-COAD",
         "TCGA-AA-3662",
         "TCGA-AA-3662-01A, TCGA-AA-3662-11A",
         "Primary Tumor, Solid Tissue Normal",
         "Primary Tumor, Solid Tissue Normal",
         "COAD",
         "Colon adenocarcinoma"
        ],
        [
         "758",
         "TCGA-COAD",
         "TCGA-G4-6314",
         "TCGA-G4-6314-10A, TCGA-G4-6314-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "COAD",
         "Colon adenocarcinoma"
        ],
        [
         "781",
         "TCGA-CESC",
         "TCGA-C5-A902",
         "TCGA-C5-A902-01A, TCGA-C5-A902-10A",
         "Primary Tumor, Blood Derived Normal",
         "Blood Derived Normal, Primary Tumor",
         "CESC",
         "Cervical squamous cell carcinoma and endocervical adenocarcinoma"
        ],
        [
         "830",
         "TCGA-CESC",
         "TCGA-VS-A8EK",
         "TCGA-VS-A8EK-10A, TCGA-VS-A8EK-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "CESC",
         "Cervical squamous cell carcinoma and endocervical adenocarcinoma"
        ],
        [
         "833",
         "TCGA-CESC",
         "TCGA-C5-A901",
         "TCGA-C5-A901-01A, TCGA-C5-A901-10A",
         "Primary Tumor, Blood Derived Normal",
         "Blood Derived Normal, Primary Tumor",
         "CESC",
         "Cervical squamous cell carcinoma and endocervical adenocarcinoma"
        ],
        [
         "865",
         "TCGA-COAD",
         "TCGA-AA-3815",
         "TCGA-AA-3815-10A, TCGA-AA-3815-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "COAD",
         "Colon adenocarcinoma"
        ],
        [
         "953",
         "TCGA-CHOL",
         "TCGA-4G-AAZG",
         "TCGA-4G-AAZG-01A, TCGA-4G-AAZG-10A",
         "Primary Tumor, Blood Derived Normal",
         "Blood Derived Normal, Primary Tumor",
         "CHOL",
         "Cholangiocarcinoma"
        ],
        [
         "957",
         "TCGA-COAD",
         "TCGA-AA-3967",
         "TCGA-AA-3967-10A, TCGA-AA-3967-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "COAD",
         "Colon adenocarcinoma"
        ],
        [
         "958",
         "TCGA-COAD",
         "TCGA-G4-6310",
         "TCGA-G4-6310-01A, TCGA-G4-6310-10A",
         "Primary Tumor, Blood Derived Normal",
         "Blood Derived Normal, Primary Tumor",
         "COAD",
         "Colon adenocarcinoma"
        ],
        [
         "959",
         "TCGA-CHOL",
         "TCGA-W7-A93P",
         "TCGA-W7-A93P-01A, TCGA-W7-A93P-11A",
         "Primary Tumor, Solid Tissue Normal",
         "Primary Tumor, Solid Tissue Normal",
         "CHOL",
         "Cholangiocarcinoma"
        ],
        [
         "961",
         "TCGA-CHOL",
         "TCGA-W5-AA2J",
         "TCGA-W5-AA2J-10A, TCGA-W5-AA2J-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "CHOL",
         "Cholangiocarcinoma"
        ],
        [
         "963",
         "TCGA-CHOL",
         "TCGA-W7-A93O",
         "TCGA-W7-A93O-01A, TCGA-W7-A93O-11A",
         "Primary Tumor, Solid Tissue Normal",
         "Primary Tumor, Solid Tissue Normal",
         "CHOL",
         "Cholangiocarcinoma"
        ],
        [
         "965",
         "TCGA-CHOL",
         "TCGA-4G-AAZF",
         "TCGA-4G-AAZF-11A, TCGA-4G-AAZF-01A",
         "Solid Tissue Normal, Primary Tumor",
         "Primary Tumor, Solid Tissue Normal",
         "CHOL",
         "Cholangiocarcinoma"
        ],
        [
         "972",
         "TCGA-CHOL",
         "TCGA-W7-A93N",
         "TCGA-W7-A93N-11A, TCGA-W7-A93N-01A",
         "Solid Tissue Normal, Primary Tumor",
         "Primary Tumor, Solid Tissue Normal",
         "CHOL",
         "Cholangiocarcinoma"
        ],
        [
         "981",
         "TCGA-COAD",
         "TCGA-AA-A02K",
         "TCGA-AA-A02K-10A, TCGA-AA-A02K-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "COAD",
         "Colon adenocarcinoma"
        ],
        [
         "996",
         "TCGA-CESC",
         "TCGA-DS-A1OB",
         "TCGA-DS-A1OB-10A, TCGA-DS-A1OB-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "CESC",
         "Cervical squamous cell carcinoma and endocervical adenocarcinoma"
        ],
        [
         "1045",
         "TCGA-CESC",
         "TCGA-C5-A905",
         "TCGA-C5-A905-01A, TCGA-C5-A905-10A",
         "Primary Tumor, Blood Derived Normal",
         "Blood Derived Normal, Primary Tumor",
         "CESC",
         "Cervical squamous cell carcinoma and endocervical adenocarcinoma"
        ],
        [
         "1066",
         "TCGA-CESC",
         "TCGA-DS-A1OD",
         "TCGA-DS-A1OD-10A, TCGA-DS-A1OD-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "CESC",
         "Cervical squamous cell carcinoma and endocervical adenocarcinoma"
        ],
        [
         "1178",
         "TCGA-COAD",
         "TCGA-G4-6625",
         "TCGA-G4-6625-01A, TCGA-G4-6625-11A",
         "Primary Tumor, Solid Tissue Normal",
         "Primary Tumor, Solid Tissue Normal",
         "COAD",
         "Colon adenocarcinoma"
        ],
        [
         "1189",
         "TCGA-CHOL",
         "TCGA-4G-AAZR",
         "TCGA-4G-AAZR-11A, TCGA-4G-AAZR-01A",
         "Solid Tissue Normal, Primary Tumor",
         "Primary Tumor, Solid Tissue Normal",
         "CHOL",
         "Cholangiocarcinoma"
        ],
        [
         "1207",
         "TCGA-COAD",
         "TCGA-AA-3861",
         "TCGA-AA-3861-01A, TCGA-AA-3861-10A",
         "Primary Tumor, Blood Derived Normal",
         "Blood Derived Normal, Primary Tumor",
         "COAD",
         "Colon adenocarcinoma"
        ],
        [
         "1511",
         "TCGA-ACC",
         "TCGA-P6-A5OG",
         "TCGA-P6-A5OG-10A, TCGA-P6-A5OG-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "ACC",
         "Adrenocortical carcinoma"
        ],
        [
         "1628",
         "TCGA-LUSC",
         "TCGA-21-1077",
         "TCGA-21-1077-01A, TCGA-21-1077-11A",
         "Primary Tumor, Solid Tissue Normal",
         "Primary Tumor, Solid Tissue Normal",
         "LUSC",
         "Lung squamous cell carcinoma"
        ],
        [
         "1835",
         "TCGA-BLCA",
         "TCGA-E7-A8O8",
         "TCGA-E7-A8O8-10A, TCGA-E7-A8O8-01A",
         "Blood Derived Normal, Primary Tumor",
         "Blood Derived Normal, Primary Tumor",
         "BLCA",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "1875",
         "TCGA-LIHC",
         "TCGA-G3-A3CG",
         "TCGA-G3-A3CG-01A, TCGA-G3-A3CG-10A",
         "Primary Tumor, Blood Derived Normal",
         "Blood Derived Normal, Primary Tumor",
         "LIHC",
         "Liver hepatocellular carcinoma"
        ],
        [
         "1881",
         "TCGA-LUAD",
         "TCGA-44-6147",
         "TCGA-44-6147-01A, TCGA-44-6147-10A",
         "Primary Tumor, Blood Derived Normal",
         "Blood Derived Normal, Primary Tumor",
         "LUAD",
         "Lung adenocarcinoma"
        ],
        [
         "1883",
         "TCGA-LUAD",
         "TCGA-44-6147",
         "TCGA-44-6147-01A, TCGA-44-6147-10A",
         "Primary Tumor, Blood Derived Normal",
         "Blood Derived Normal, Primary Tumor",
         "LUAD",
         "Lung adenocarcinoma"
        ],
        [
         "1890",
         "TCGA-LIHC",
         "TCGA-BD-A3ER",
         "TCGA-BD-A3ER-01A, TCGA-BD-A3ER-11A",
         "Primary Tumor, Solid Tissue Normal",
         "Primary Tumor, Solid Tissue Normal",
         "LIHC",
         "Liver hepatocellular carcinoma"
        ],
        [
         "1897",
         "TCGA-LIHC",
         "TCGA-T1-A6J8",
         "TCGA-T1-A6J8-01A, TCGA-T1-A6J8-10A",
         "Primary Tumor, Blood Derived Normal",
         "Blood Derived Normal, Primary Tumor",
         "LIHC",
         "Liver hepatocellular carcinoma"
        ],
        [
         "2105",
         "TCGA-LUAD",
         "TCGA-44-2661",
         "TCGA-44-2661-01A, TCGA-44-2661-10A",
         "Primary Tumor, Blood Derived Normal",
         "Blood Derived Normal, Primary Tumor",
         "LUAD",
         "Lung adenocarcinoma"
        ],
        [
         "2316",
         "TCGA-LUAD",
         "TCGA-38-4630",
         "TCGA-38-4630-01A, TCGA-38-4630-11A",
         "Primary Tumor, Solid Tissue Normal",
         "Primary Tumor, Solid Tissue Normal",
         "LUAD",
         "Lung adenocarcinoma"
        ],
        [
         "2326",
         "TCGA-LUAD",
         "TCGA-05-5420",
         "TCGA-05-5420-01A, TCGA-05-5420-11A",
         "Primary Tumor, Solid Tissue Normal",
         "Primary Tumor, Solid Tissue Normal",
         "LUAD",
         "Lung adenocarcinoma"
        ],
        [
         "2499",
         "TCGA-LUAD",
         "TCGA-44-6147",
         "TCGA-44-6147-01A, TCGA-44-6147-10A",
         "Primary Tumor, Blood Derived Normal",
         "Blood Derived Normal, Primary Tumor",
         "LUAD",
         "Lung adenocarcinoma"
        ]
       ],
       "shape": {
        "columns": 7,
        "rows": 204
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Project ID</th>\n",
       "      <th>Case ID</th>\n",
       "      <th>Sample ID</th>\n",
       "      <th>Sample Type</th>\n",
       "      <th>Normalized Sample Type</th>\n",
       "      <th>Study Abbreviation</th>\n",
       "      <th>Study Name</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>69</th>\n",
       "      <td>TCGA-GBM</td>\n",
       "      <td>TCGA-06-6391</td>\n",
       "      <td>TCGA-06-6391-10A, TCGA-06-6391-01A</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>GBM</td>\n",
       "      <td>Glioblastoma multiforme</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>144</th>\n",
       "      <td>TCGA-KICH</td>\n",
       "      <td>TCGA-KN-8430</td>\n",
       "      <td>TCGA-KN-8430-11A, TCGA-KN-8430-01A</td>\n",
       "      <td>Solid Tissue Normal, Primary Tumor</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>KICH</td>\n",
       "      <td>Kidney Chromophobe</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>431</th>\n",
       "      <td>TCGA-KIRC</td>\n",
       "      <td>TCGA-BP-4986</td>\n",
       "      <td>TCGA-BP-4986-01A, TCGA-BP-4986-11A</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>KIRC</td>\n",
       "      <td>Kidney renal clear cell carcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>435</th>\n",
       "      <td>TCGA-KIRC</td>\n",
       "      <td>TCGA-CZ-4865</td>\n",
       "      <td>TCGA-CZ-4865-01A, TCGA-CZ-4865-11A</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>KIRC</td>\n",
       "      <td>Kidney renal clear cell carcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>440</th>\n",
       "      <td>TCGA-KIRC</td>\n",
       "      <td>TCGA-BP-4988</td>\n",
       "      <td>TCGA-BP-4988-01A, TCGA-BP-4988-11A</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>KIRC</td>\n",
       "      <td>Kidney renal clear cell carcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10483</th>\n",
       "      <td>TCGA-UCEC</td>\n",
       "      <td>TCGA-EY-A1G7</td>\n",
       "      <td>TCGA-EY-A1G7-10A, TCGA-EY-A1G7-01A</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>UCEC</td>\n",
       "      <td>Uterine Corpus Endometrial Carcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10484</th>\n",
       "      <td>TCGA-UCEC</td>\n",
       "      <td>TCGA-EY-A1G8</td>\n",
       "      <td>TCGA-EY-A1G8-10A, TCGA-EY-A1G8-01A</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>UCEC</td>\n",
       "      <td>Uterine Corpus Endometrial Carcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10486</th>\n",
       "      <td>TCGA-UCEC</td>\n",
       "      <td>TCGA-AX-A2H8</td>\n",
       "      <td>TCGA-AX-A2H8-01A, TCGA-AX-A2H8-11A</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>UCEC</td>\n",
       "      <td>Uterine Corpus Endometrial Carcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10514</th>\n",
       "      <td>TCGA-UCEC</td>\n",
       "      <td>TCGA-BG-A221</td>\n",
       "      <td>TCGA-BG-A221-10A, TCGA-BG-A221-01A</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>UCEC</td>\n",
       "      <td>Uterine Corpus Endometrial Carcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10597</th>\n",
       "      <td>TCGA-UCEC</td>\n",
       "      <td>TCGA-AX-A1CP</td>\n",
       "      <td>TCGA-AX-A1CP-01A, TCGA-AX-A1CP-10A</td>\n",
       "      <td>Primary Tumor, Blood Derived Normal</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>UCEC</td>\n",
       "      <td>Uterine Corpus Endometrial Carcinoma</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>204 rows × 7 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      Project ID       Case ID                           Sample ID  \\\n",
       "69      TCGA-GBM  TCGA-06-6391  TCGA-06-6391-10A, TCGA-06-6391-01A   \n",
       "144    TCGA-KICH  TCGA-KN-8430  TCGA-KN-8430-11A, TCGA-KN-8430-01A   \n",
       "431    TCGA-KIRC  TCGA-BP-4986  TCGA-BP-4986-01A, TCGA-BP-4986-11A   \n",
       "435    TCGA-KIRC  TCGA-CZ-4865  TCGA-CZ-4865-01A, TCGA-CZ-4865-11A   \n",
       "440    TCGA-KIRC  TCGA-BP-4988  TCGA-BP-4988-01A, TCGA-BP-4988-11A   \n",
       "...          ...           ...                                 ...   \n",
       "10483  TCGA-UCEC  TCGA-EY-A1G7  TCGA-EY-A1G7-10A, TCGA-EY-A1G7-01A   \n",
       "10484  TCGA-UCEC  TCGA-EY-A1G8  TCGA-EY-A1G8-10A, TCGA-EY-A1G8-01A   \n",
       "10486  TCGA-UCEC  TCGA-AX-A2H8  TCGA-AX-A2H8-01A, TCGA-AX-A2H8-11A   \n",
       "10514  TCGA-UCEC  TCGA-BG-A221  TCGA-BG-A221-10A, TCGA-BG-A221-01A   \n",
       "10597  TCGA-UCEC  TCGA-AX-A1CP  TCGA-AX-A1CP-01A, TCGA-AX-A1CP-10A   \n",
       "\n",
       "                               Sample Type  \\\n",
       "69     Blood Derived Normal, Primary Tumor   \n",
       "144     Solid Tissue Normal, Primary Tumor   \n",
       "431     Primary Tumor, Solid Tissue Normal   \n",
       "435     Primary Tumor, Solid Tissue Normal   \n",
       "440     Primary Tumor, Solid Tissue Normal   \n",
       "...                                    ...   \n",
       "10483  Blood Derived Normal, Primary Tumor   \n",
       "10484  Blood Derived Normal, Primary Tumor   \n",
       "10486   Primary Tumor, Solid Tissue Normal   \n",
       "10514  Blood Derived Normal, Primary Tumor   \n",
       "10597  Primary Tumor, Blood Derived Normal   \n",
       "\n",
       "                    Normalized Sample Type Study Abbreviation  \\\n",
       "69     Blood Derived Normal, Primary Tumor                GBM   \n",
       "144     Primary Tumor, Solid Tissue Normal               KICH   \n",
       "431     Primary Tumor, Solid Tissue Normal               KIRC   \n",
       "435     Primary Tumor, Solid Tissue Normal               KIRC   \n",
       "440     Primary Tumor, Solid Tissue Normal               KIRC   \n",
       "...                                    ...                ...   \n",
       "10483  Blood Derived Normal, Primary Tumor               UCEC   \n",
       "10484  Blood Derived Normal, Primary Tumor               UCEC   \n",
       "10486   Primary Tumor, Solid Tissue Normal               UCEC   \n",
       "10514  Blood Derived Normal, Primary Tumor               UCEC   \n",
       "10597  Blood Derived Normal, Primary Tumor               UCEC   \n",
       "\n",
       "                                 Study Name  \n",
       "69                  Glioblastoma multiforme  \n",
       "144                      Kidney Chromophobe  \n",
       "431       Kidney renal clear cell carcinoma  \n",
       "435       Kidney renal clear cell carcinoma  \n",
       "440       Kidney renal clear cell carcinoma  \n",
       "...                                     ...  \n",
       "10483  Uterine Corpus Endometrial Carcinoma  \n",
       "10484  Uterine Corpus Endometrial Carcinoma  \n",
       "10486  Uterine Corpus Endometrial Carcinoma  \n",
       "10514  Uterine Corpus Endometrial Carcinoma  \n",
       "10597  Uterine Corpus Endometrial Carcinoma  \n",
       "\n",
       "[204 rows x 7 columns]"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sample_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [],
   "source": [
    "result_df = sample_df.drop(['Project ID', \"Study Abbreviation\", \"Sample ID\", \"Sample Type\"], axis=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "Case ID",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Normalized Sample Type",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Study Name",
         "rawType": "object",
         "type": "string"
        }
       ],
       "conversionMethod": "pd.DataFrame",
       "ref": "8b0d9247-0f19-4a1d-995a-0255d66d8575",
       "rows": [
        [
         "69",
         "TCGA-06-6391",
         "Blood Derived Normal, Primary Tumor",
         "Glioblastoma multiforme"
        ],
        [
         "144",
         "TCGA-KN-8430",
         "Primary Tumor, Solid Tissue Normal",
         "Kidney Chromophobe"
        ],
        [
         "431",
         "TCGA-BP-4986",
         "Primary Tumor, Solid Tissue Normal",
         "Kidney renal clear cell carcinoma"
        ],
        [
         "435",
         "TCGA-CZ-4865",
         "Primary Tumor, Solid Tissue Normal",
         "Kidney renal clear cell carcinoma"
        ],
        [
         "440",
         "TCGA-BP-4988",
         "Primary Tumor, Solid Tissue Normal",
         "Kidney renal clear cell carcinoma"
        ],
        [
         "474",
         "TCGA-B2-5636",
         "Blood Derived Normal, Primary Tumor",
         "Kidney renal clear cell carcinoma"
        ],
        [
         "531",
         "TCGA-BQ-7056",
         "Primary Tumor, Solid Tissue Normal",
         "Kidney renal papillary cell carcinoma"
        ],
        [
         "533",
         "TCGA-BP-4976",
         "Primary Tumor, Solid Tissue Normal",
         "Kidney renal clear cell carcinoma"
        ],
        [
         "536",
         "TCGA-DV-5573",
         "Blood Derived Normal, Primary Tumor",
         "Kidney renal clear cell carcinoma"
        ],
        [
         "543",
         "TCGA-BP-5199",
         "Primary Tumor, Solid Tissue Normal",
         "Kidney renal clear cell carcinoma"
        ],
        [
         "553",
         "TCGA-21-1070",
         "Primary Tumor, Solid Tissue Normal",
         "Lung squamous cell carcinoma"
        ],
        [
         "557",
         "TCGA-60-2715",
         "Primary Tumor, Solid Tissue Normal",
         "Lung squamous cell carcinoma"
        ],
        [
         "562",
         "TCGA-NK-A5D1",
         "Blood Derived Normal, Primary Tumor",
         "Lung squamous cell carcinoma"
        ],
        [
         "567",
         "TCGA-21-1078",
         "Primary Tumor, Solid Tissue Normal",
         "Lung squamous cell carcinoma"
        ],
        [
         "571",
         "TCGA-18-3409",
         "Primary Tumor, Solid Tissue Normal",
         "Lung squamous cell carcinoma"
        ],
        [
         "619",
         "TCGA-B0-5700",
         "Primary Tumor, Solid Tissue Normal",
         "Kidney renal clear cell carcinoma"
        ],
        [
         "755",
         "TCGA-5A-A8ZF",
         "Blood Derived Normal, Primary Tumor",
         "Cholangiocarcinoma"
        ],
        [
         "756",
         "TCGA-AA-3662",
         "Primary Tumor, Solid Tissue Normal",
         "Colon adenocarcinoma"
        ],
        [
         "758",
         "TCGA-G4-6314",
         "Blood Derived Normal, Primary Tumor",
         "Colon adenocarcinoma"
        ],
        [
         "781",
         "TCGA-C5-A902",
         "Blood Derived Normal, Primary Tumor",
         "Cervical squamous cell carcinoma and endocervical adenocarcinoma"
        ],
        [
         "830",
         "TCGA-VS-A8EK",
         "Blood Derived Normal, Primary Tumor",
         "Cervical squamous cell carcinoma and endocervical adenocarcinoma"
        ],
        [
         "833",
         "TCGA-C5-A901",
         "Blood Derived Normal, Primary Tumor",
         "Cervical squamous cell carcinoma and endocervical adenocarcinoma"
        ],
        [
         "865",
         "TCGA-AA-3815",
         "Blood Derived Normal, Primary Tumor",
         "Colon adenocarcinoma"
        ],
        [
         "953",
         "TCGA-4G-AAZG",
         "Blood Derived Normal, Primary Tumor",
         "Cholangiocarcinoma"
        ],
        [
         "957",
         "TCGA-AA-3967",
         "Blood Derived Normal, Primary Tumor",
         "Colon adenocarcinoma"
        ],
        [
         "958",
         "TCGA-G4-6310",
         "Blood Derived Normal, Primary Tumor",
         "Colon adenocarcinoma"
        ],
        [
         "959",
         "TCGA-W7-A93P",
         "Primary Tumor, Solid Tissue Normal",
         "Cholangiocarcinoma"
        ],
        [
         "961",
         "TCGA-W5-AA2J",
         "Blood Derived Normal, Primary Tumor",
         "Cholangiocarcinoma"
        ],
        [
         "963",
         "TCGA-W7-A93O",
         "Primary Tumor, Solid Tissue Normal",
         "Cholangiocarcinoma"
        ],
        [
         "965",
         "TCGA-4G-AAZF",
         "Primary Tumor, Solid Tissue Normal",
         "Cholangiocarcinoma"
        ],
        [
         "972",
         "TCGA-W7-A93N",
         "Primary Tumor, Solid Tissue Normal",
         "Cholangiocarcinoma"
        ],
        [
         "981",
         "TCGA-AA-A02K",
         "Blood Derived Normal, Primary Tumor",
         "Colon adenocarcinoma"
        ],
        [
         "996",
         "TCGA-DS-A1OB",
         "Blood Derived Normal, Primary Tumor",
         "Cervical squamous cell carcinoma and endocervical adenocarcinoma"
        ],
        [
         "1045",
         "TCGA-C5-A905",
         "Blood Derived Normal, Primary Tumor",
         "Cervical squamous cell carcinoma and endocervical adenocarcinoma"
        ],
        [
         "1066",
         "TCGA-DS-A1OD",
         "Blood Derived Normal, Primary Tumor",
         "Cervical squamous cell carcinoma and endocervical adenocarcinoma"
        ],
        [
         "1178",
         "TCGA-G4-6625",
         "Primary Tumor, Solid Tissue Normal",
         "Colon adenocarcinoma"
        ],
        [
         "1189",
         "TCGA-4G-AAZR",
         "Primary Tumor, Solid Tissue Normal",
         "Cholangiocarcinoma"
        ],
        [
         "1207",
         "TCGA-AA-3861",
         "Blood Derived Normal, Primary Tumor",
         "Colon adenocarcinoma"
        ],
        [
         "1511",
         "TCGA-P6-A5OG",
         "Blood Derived Normal, Primary Tumor",
         "Adrenocortical carcinoma"
        ],
        [
         "1628",
         "TCGA-21-1077",
         "Primary Tumor, Solid Tissue Normal",
         "Lung squamous cell carcinoma"
        ],
        [
         "1835",
         "TCGA-E7-A8O8",
         "Blood Derived Normal, Primary Tumor",
         "Bladder Urothelial Carcinoma"
        ],
        [
         "1875",
         "TCGA-G3-A3CG",
         "Blood Derived Normal, Primary Tumor",
         "Liver hepatocellular carcinoma"
        ],
        [
         "1881",
         "TCGA-44-6147",
         "Blood Derived Normal, Primary Tumor",
         "Lung adenocarcinoma"
        ],
        [
         "1883",
         "TCGA-44-6147",
         "Blood Derived Normal, Primary Tumor",
         "Lung adenocarcinoma"
        ],
        [
         "1890",
         "TCGA-BD-A3ER",
         "Primary Tumor, Solid Tissue Normal",
         "Liver hepatocellular carcinoma"
        ],
        [
         "1897",
         "TCGA-T1-A6J8",
         "Blood Derived Normal, Primary Tumor",
         "Liver hepatocellular carcinoma"
        ],
        [
         "2105",
         "TCGA-44-2661",
         "Blood Derived Normal, Primary Tumor",
         "Lung adenocarcinoma"
        ],
        [
         "2316",
         "TCGA-38-4630",
         "Primary Tumor, Solid Tissue Normal",
         "Lung adenocarcinoma"
        ],
        [
         "2326",
         "TCGA-05-5420",
         "Primary Tumor, Solid Tissue Normal",
         "Lung adenocarcinoma"
        ],
        [
         "2499",
         "TCGA-44-6147",
         "Blood Derived Normal, Primary Tumor",
         "Lung adenocarcinoma"
        ]
       ],
       "shape": {
        "columns": 3,
        "rows": 204
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Case ID</th>\n",
       "      <th>Normalized Sample Type</th>\n",
       "      <th>Study Name</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>69</th>\n",
       "      <td>TCGA-06-6391</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Glioblastoma multiforme</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>144</th>\n",
       "      <td>TCGA-KN-8430</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Kidney Chromophobe</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>431</th>\n",
       "      <td>TCGA-BP-4986</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Kidney renal clear cell carcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>435</th>\n",
       "      <td>TCGA-CZ-4865</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Kidney renal clear cell carcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>440</th>\n",
       "      <td>TCGA-BP-4988</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Kidney renal clear cell carcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10483</th>\n",
       "      <td>TCGA-EY-A1G7</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Uterine Corpus Endometrial Carcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10484</th>\n",
       "      <td>TCGA-EY-A1G8</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Uterine Corpus Endometrial Carcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10486</th>\n",
       "      <td>TCGA-AX-A2H8</td>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Uterine Corpus Endometrial Carcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10514</th>\n",
       "      <td>TCGA-BG-A221</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Uterine Corpus Endometrial Carcinoma</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10597</th>\n",
       "      <td>TCGA-AX-A1CP</td>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Uterine Corpus Endometrial Carcinoma</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>204 rows × 3 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "            Case ID               Normalized Sample Type  \\\n",
       "69     TCGA-06-6391  Blood Derived Normal, Primary Tumor   \n",
       "144    TCGA-KN-8430   Primary Tumor, Solid Tissue Normal   \n",
       "431    TCGA-BP-4986   Primary Tumor, Solid Tissue Normal   \n",
       "435    TCGA-CZ-4865   Primary Tumor, Solid Tissue Normal   \n",
       "440    TCGA-BP-4988   Primary Tumor, Solid Tissue Normal   \n",
       "...             ...                                  ...   \n",
       "10483  TCGA-EY-A1G7  Blood Derived Normal, Primary Tumor   \n",
       "10484  TCGA-EY-A1G8  Blood Derived Normal, Primary Tumor   \n",
       "10486  TCGA-AX-A2H8   Primary Tumor, Solid Tissue Normal   \n",
       "10514  TCGA-BG-A221  Blood Derived Normal, Primary Tumor   \n",
       "10597  TCGA-AX-A1CP  Blood Derived Normal, Primary Tumor   \n",
       "\n",
       "                                 Study Name  \n",
       "69                  Glioblastoma multiforme  \n",
       "144                      Kidney Chromophobe  \n",
       "431       Kidney renal clear cell carcinoma  \n",
       "435       Kidney renal clear cell carcinoma  \n",
       "440       Kidney renal clear cell carcinoma  \n",
       "...                                     ...  \n",
       "10483  Uterine Corpus Endometrial Carcinoma  \n",
       "10484  Uterine Corpus Endometrial Carcinoma  \n",
       "10486  Uterine Corpus Endometrial Carcinoma  \n",
       "10514  Uterine Corpus Endometrial Carcinoma  \n",
       "10597  Uterine Corpus Endometrial Carcinoma  \n",
       "\n",
       "[204 rows x 3 columns]"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "result_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [],
   "source": [
    "group_cols = ['Normalized Sample Type', 'Study Name']\n",
    "\n",
    "# Group by these columns and aggregate the Case IDs into a list\n",
    "grouped_df = result_df.groupby(group_cols, dropna=False)['Case ID'].apply(list).reset_index()\n",
    "\n",
    "\n",
    "# If you prefer a comma-separated string instead of a list, you can convert it as follows:\n",
    "grouped_df['Case IDs'] = grouped_df['Case ID'].apply(lambda ids: ', '.join(ids))\n",
    "\n",
    "# Drop the original 'Case ID' column (if only the aggregated version is needed)\n",
    "grouped_df = grouped_df.drop(columns=['Case ID'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "Normalized Sample Type",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Study Name",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Case IDs",
         "rawType": "object",
         "type": "string"
        }
       ],
       "conversionMethod": "pd.DataFrame",
       "ref": "f3c1794a-54c1-4291-9cc5-af6b9377164a",
       "rows": [
        [
         "0",
         "Blood Derived Normal, Metastatic",
         "Skin Cutaneous Melanoma",
         "TCGA-WE-A8ZR"
        ],
        [
         "1",
         "Blood Derived Normal, Metastatic",
         "Thyroid carcinoma",
         "TCGA-EM-A2CS"
        ],
        [
         "2",
         "Blood Derived Normal, Primary Tumor",
         "Adrenocortical carcinoma",
         "TCGA-P6-A5OG"
        ],
        [
         "3",
         "Blood Derived Normal, Primary Tumor",
         "Bladder Urothelial Carcinoma",
         "TCGA-E7-A8O8"
        ],
        [
         "4",
         "Blood Derived Normal, Primary Tumor",
         "Brain Lower Grade Glioma",
         "TCGA-HT-A619, TCGA-R8-A73M"
        ],
        [
         "5",
         "Blood Derived Normal, Primary Tumor",
         "Breast invasive carcinoma",
         "TCGA-AR-A2LR, TCGA-D8-A146, TCGA-BH-A0B6, TCGA-AR-A2LL, TCGA-5L-AAT1, TCGA-A8-A08S, TCGA-E2-A572, TCGA-A8-A09E, TCGA-A8-A08F, TCGA-A8-A09K"
        ],
        [
         "6",
         "Blood Derived Normal, Primary Tumor",
         "Cervical squamous cell carcinoma and endocervical adenocarcinoma",
         "TCGA-C5-A902, TCGA-VS-A8EK, TCGA-C5-A901, TCGA-DS-A1OB, TCGA-C5-A905, TCGA-DS-A1OD, TCGA-EX-A449"
        ],
        [
         "7",
         "Blood Derived Normal, Primary Tumor",
         "Cholangiocarcinoma",
         "TCGA-5A-A8ZF, TCGA-4G-AAZG, TCGA-W5-AA2J, TCGA-ZH-A8Y3, TCGA-ZK-AAYZ, TCGA-W5-AA2M, TCGA-ZH-A8Y7, TCGA-5A-A8ZG, TCGA-W6-AA0T, TCGA-W5-AA2K"
        ],
        [
         "8",
         "Blood Derived Normal, Primary Tumor",
         "Colon adenocarcinoma",
         "TCGA-G4-6314, TCGA-AA-3815, TCGA-AA-3967, TCGA-G4-6310, TCGA-AA-A02K, TCGA-AA-3861, TCGA-AA-3672, TCGA-AA-3556, TCGA-AA-3862, TCGA-AA-3972, TCGA-AA-3860"
        ],
        [
         "9",
         "Blood Derived Normal, Primary Tumor",
         "Esophageal carcinoma",
         "TCGA-IC-A6RF"
        ],
        [
         "10",
         "Blood Derived Normal, Primary Tumor",
         "Glioblastoma multiforme",
         "TCGA-06-6391, TCGA-19-1788, TCGA-06-0209, TCGA-28-1745"
        ],
        [
         "11",
         "Blood Derived Normal, Primary Tumor",
         "Head and Neck squamous cell carcinoma",
         "TCGA-BA-4075, TCGA-CX-7082, TCGA-CQ-A4C7, TCGA-BA-4077, TCGA-CQ-6221"
        ],
        [
         "12",
         "Blood Derived Normal, Primary Tumor",
         "Kidney renal clear cell carcinoma",
         "TCGA-B2-5636, TCGA-DV-5573, TCGA-DV-5568, TCGA-B8-A54K"
        ],
        [
         "13",
         "Blood Derived Normal, Primary Tumor",
         "Kidney renal papillary cell carcinoma",
         "TCGA-AL-3468, TCGA-5P-A9KF, TCGA-AL-A5DJ, TCGA-SX-A71W, TCGA-PJ-A8JU, TCGA-B1-A47O"
        ],
        [
         "14",
         "Blood Derived Normal, Primary Tumor",
         "Liver hepatocellular carcinoma",
         "TCGA-G3-A3CG, TCGA-T1-A6J8, TCGA-XR-A8TC, TCGA-CC-A8HS"
        ],
        [
         "15",
         "Blood Derived Normal, Primary Tumor",
         "Lung adenocarcinoma",
         "TCGA-44-6147, TCGA-44-6147, TCGA-44-2661, TCGA-44-6147, TCGA-44-6147, TCGA-44-6147"
        ],
        [
         "16",
         "Blood Derived Normal, Primary Tumor",
         "Lung squamous cell carcinoma",
         "TCGA-NK-A5D1, TCGA-21-A5DI, TCGA-96-A4JK, TCGA-77-8146, TCGA-77-A5GA, TCGA-37-A5EM"
        ],
        [
         "17",
         "Blood Derived Normal, Primary Tumor",
         "Ovarian serous cystadenocarcinoma",
         "TCGA-24-2036, TCGA-36-2539"
        ],
        [
         "18",
         "Blood Derived Normal, Primary Tumor",
         "Pancreatic adenocarcinoma",
         "TCGA-IB-7654"
        ],
        [
         "19",
         "Blood Derived Normal, Primary Tumor",
         "Pheochromocytoma and Paraganglioma",
         "TCGA-WB-A820"
        ],
        [
         "20",
         "Blood Derived Normal, Primary Tumor",
         "Prostate adenocarcinoma",
         "TCGA-G9-A9S4, TCGA-XK-AAK1, TCGA-XK-AAJ3, TCGA-EJ-7312"
        ],
        [
         "21",
         "Blood Derived Normal, Primary Tumor",
         "Rectum adenocarcinoma",
         "TCGA-G5-6235, TCGA-G5-6572, TCGA-AG-A00H, TCGA-AG-3891, TCGA-G5-6233, TCGA-AG-3906, TCGA-AG-A023, TCGA-AG-A014, TCGA-AH-6549, TCGA-BM-6198"
        ],
        [
         "22",
         "Blood Derived Normal, Primary Tumor",
         "Sarcoma",
         "TCGA-PC-A5DM"
        ],
        [
         "23",
         "Blood Derived Normal, Primary Tumor",
         "Skin Cutaneous Melanoma",
         "TCGA-BF-AAOX, TCGA-BF-A9VF, TCGA-EB-A82C, TCGA-EB-A82B, TCGA-XV-A9W2, TCGA-YG-AA3N, TCGA-XV-A9VZ, TCGA-EB-A97M, TCGA-EB-A51B, TCGA-XV-A9W5, TCGA-BF-AAP2, TCGA-BF-AAP8, TCGA-XV-AAZV, TCGA-BF-AAP1, TCGA-XV-AAZW, TCGA-XV-AAZY, TCGA-EB-A550, TCGA-WE-A8K4, TCGA-BF-AAOU, TCGA-EB-A85J, TCGA-DA-A960, TCGA-EB-A85I, TCGA-BF-AAP6, TCGA-HR-A5NC, TCGA-BF-AAP7, TCGA-BF-AAP4, TCGA-GN-A8LN"
        ],
        [
         "24",
         "Blood Derived Normal, Primary Tumor",
         "Stomach adenocarcinoma",
         "TCGA-HF-7131, TCGA-CG-5716, TCGA-CG-4460"
        ],
        [
         "25",
         "Blood Derived Normal, Primary Tumor",
         "Testicular Germ Cell Tumors",
         "TCGA-2G-AAFE"
        ],
        [
         "26",
         "Blood Derived Normal, Primary Tumor",
         "Thyroid carcinoma",
         "TCGA-E8-A2JQ, TCGA-EL-A3D5, TCGA-EL-A3D0, TCGA-DJ-A3UV, TCGA-BJ-A0ZF, TCGA-DJ-A3V6, TCGA-EM-A2CM, TCGA-EM-A2CS"
        ],
        [
         "27",
         "Blood Derived Normal, Primary Tumor",
         "Uterine Corpus Endometrial Carcinoma",
         "TCGA-BG-A0M8, TCGA-BG-A220, TCGA-AP-A053, TCGA-AX-A3G3, TCGA-AX-A2HF, TCGA-AX-A1CR, TCGA-B5-A0KB, TCGA-D1-A3JP, TCGA-BG-A0MS, TCGA-EY-A1G7, TCGA-EY-A1G8, TCGA-BG-A221, TCGA-AX-A1CP"
        ],
        [
         "28",
         "Blood Derived Normal, Recurrent Tumor",
         "Rectum adenocarcinoma",
         "TCGA-G5-6572"
        ],
        [
         "29",
         "Primary Tumor, Solid Tissue Normal",
         "Cholangiocarcinoma",
         "TCGA-W7-A93P, TCGA-W7-A93O, TCGA-4G-AAZF, TCGA-W7-A93N, TCGA-4G-AAZR"
        ],
        [
         "30",
         "Primary Tumor, Solid Tissue Normal",
         "Colon adenocarcinoma",
         "TCGA-AA-3662, TCGA-G4-6625, TCGA-AA-3697, TCGA-AA-3509, TCGA-AZ-6601, TCGA-AZ-6608"
        ],
        [
         "31",
         "Primary Tumor, Solid Tissue Normal",
         "Esophageal carcinoma",
         "TCGA-L5-A88T"
        ],
        [
         "32",
         "Primary Tumor, Solid Tissue Normal",
         "Kidney Chromophobe",
         "TCGA-KN-8430"
        ],
        [
         "33",
         "Primary Tumor, Solid Tissue Normal",
         "Kidney renal clear cell carcinoma",
         "TCGA-BP-4986, TCGA-CZ-4865, TCGA-BP-4988, TCGA-BP-4976, TCGA-BP-5199, TCGA-B0-5700, TCGA-BP-5009, TCGA-BP-5006, TCGA-BP-5181, TCGA-BP-4995, TCGA-CW-5590"
        ],
        [
         "34",
         "Primary Tumor, Solid Tissue Normal",
         "Kidney renal papillary cell carcinoma",
         "TCGA-BQ-7056, TCGA-BQ-7049"
        ],
        [
         "35",
         "Primary Tumor, Solid Tissue Normal",
         "Liver hepatocellular carcinoma",
         "TCGA-BD-A3ER"
        ],
        [
         "36",
         "Primary Tumor, Solid Tissue Normal",
         "Lung adenocarcinoma",
         "TCGA-38-4630, TCGA-05-5420, TCGA-38-4629"
        ],
        [
         "37",
         "Primary Tumor, Solid Tissue Normal",
         "Lung squamous cell carcinoma",
         "TCGA-21-1070, TCGA-60-2715, TCGA-21-1078, TCGA-18-3409, TCGA-21-1077, TCGA-21-1083, TCGA-21-1078, TCGA-18-5595, TCGA-21-1077, TCGA-60-2712, TCGA-21-1070, TCGA-60-2715, TCGA-21-1083, TCGA-60-2696, TCGA-51-6867, TCGA-60-2712"
        ],
        [
         "38",
         "Primary Tumor, Solid Tissue Normal",
         "Ovarian serous cystadenocarcinoma",
         "TCGA-09-2056"
        ],
        [
         "39",
         "Primary Tumor, Solid Tissue Normal",
         "Rectum adenocarcinoma",
         "TCGA-AF-3913, TCGA-AF-3914, TCGA-AG-A036"
        ],
        [
         "40",
         "Primary Tumor, Solid Tissue Normal",
         "Sarcoma",
         "TCGA-IF-A4AK"
        ],
        [
         "41",
         "Primary Tumor, Solid Tissue Normal",
         "Uterine Corpus Endometrial Carcinoma",
         "TCGA-AX-A2H8"
        ]
       ],
       "shape": {
        "columns": 3,
        "rows": 42
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Normalized Sample Type</th>\n",
       "      <th>Study Name</th>\n",
       "      <th>Case IDs</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Blood Derived Normal, Metastatic</td>\n",
       "      <td>Skin Cutaneous Melanoma</td>\n",
       "      <td>TCGA-WE-A8ZR</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Blood Derived Normal, Metastatic</td>\n",
       "      <td>Thyroid carcinoma</td>\n",
       "      <td>TCGA-EM-A2CS</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Adrenocortical carcinoma</td>\n",
       "      <td>TCGA-P6-A5OG</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Bladder Urothelial Carcinoma</td>\n",
       "      <td>TCGA-E7-A8O8</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Brain Lower Grade Glioma</td>\n",
       "      <td>TCGA-HT-A619, TCGA-R8-A73M</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Breast invasive carcinoma</td>\n",
       "      <td>TCGA-AR-A2LR, TCGA-D8-A146, TCGA-BH-A0B6, TCGA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Cervical squamous cell carcinoma and endocervi...</td>\n",
       "      <td>TCGA-C5-A902, TCGA-VS-A8EK, TCGA-C5-A901, TCGA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Cholangiocarcinoma</td>\n",
       "      <td>TCGA-5A-A8ZF, TCGA-4G-AAZG, TCGA-W5-AA2J, TCGA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Colon adenocarcinoma</td>\n",
       "      <td>TCGA-G4-6314, TCGA-AA-3815, TCGA-AA-3967, TCGA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Esophageal carcinoma</td>\n",
       "      <td>TCGA-IC-A6RF</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Glioblastoma multiforme</td>\n",
       "      <td>TCGA-06-6391, TCGA-19-1788, TCGA-06-0209, TCGA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Head and Neck squamous cell carcinoma</td>\n",
       "      <td>TCGA-BA-4075, TCGA-CX-7082, TCGA-CQ-A4C7, TCGA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Kidney renal clear cell carcinoma</td>\n",
       "      <td>TCGA-B2-5636, TCGA-DV-5573, TCGA-DV-5568, TCGA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Kidney renal papillary cell carcinoma</td>\n",
       "      <td>TCGA-AL-3468, TCGA-5P-A9KF, TCGA-AL-A5DJ, TCGA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Liver hepatocellular carcinoma</td>\n",
       "      <td>TCGA-G3-A3CG, TCGA-T1-A6J8, TCGA-XR-A8TC, TCGA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Lung adenocarcinoma</td>\n",
       "      <td>TCGA-44-6147, TCGA-44-6147, TCGA-44-2661, TCGA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Lung squamous cell carcinoma</td>\n",
       "      <td>TCGA-NK-A5D1, TCGA-21-A5DI, TCGA-96-A4JK, TCGA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Ovarian serous cystadenocarcinoma</td>\n",
       "      <td>TCGA-24-2036, TCGA-36-2539</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Pancreatic adenocarcinoma</td>\n",
       "      <td>TCGA-IB-7654</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Pheochromocytoma and Paraganglioma</td>\n",
       "      <td>TCGA-WB-A820</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Prostate adenocarcinoma</td>\n",
       "      <td>TCGA-G9-A9S4, TCGA-XK-AAK1, TCGA-XK-AAJ3, TCGA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Rectum adenocarcinoma</td>\n",
       "      <td>TCGA-G5-6235, TCGA-G5-6572, TCGA-AG-A00H, TCGA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Sarcoma</td>\n",
       "      <td>TCGA-PC-A5DM</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Skin Cutaneous Melanoma</td>\n",
       "      <td>TCGA-BF-AAOX, TCGA-BF-A9VF, TCGA-EB-A82C, TCGA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Stomach adenocarcinoma</td>\n",
       "      <td>TCGA-HF-7131, TCGA-CG-5716, TCGA-CG-4460</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Testicular Germ Cell Tumors</td>\n",
       "      <td>TCGA-2G-AAFE</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Thyroid carcinoma</td>\n",
       "      <td>TCGA-E8-A2JQ, TCGA-EL-A3D5, TCGA-EL-A3D0, TCGA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Uterine Corpus Endometrial Carcinoma</td>\n",
       "      <td>TCGA-BG-A0M8, TCGA-BG-A220, TCGA-AP-A053, TCGA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>Blood Derived Normal, Recurrent Tumor</td>\n",
       "      <td>Rectum adenocarcinoma</td>\n",
       "      <td>TCGA-G5-6572</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Cholangiocarcinoma</td>\n",
       "      <td>TCGA-W7-A93P, TCGA-W7-A93O, TCGA-4G-AAZF, TCGA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Colon adenocarcinoma</td>\n",
       "      <td>TCGA-AA-3662, TCGA-G4-6625, TCGA-AA-3697, TCGA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Esophageal carcinoma</td>\n",
       "      <td>TCGA-L5-A88T</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Kidney Chromophobe</td>\n",
       "      <td>TCGA-KN-8430</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Kidney renal clear cell carcinoma</td>\n",
       "      <td>TCGA-BP-4986, TCGA-CZ-4865, TCGA-BP-4988, TCGA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Kidney renal papillary cell carcinoma</td>\n",
       "      <td>TCGA-BQ-7056, TCGA-BQ-7049</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Liver hepatocellular carcinoma</td>\n",
       "      <td>TCGA-BD-A3ER</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Lung adenocarcinoma</td>\n",
       "      <td>TCGA-38-4630, TCGA-05-5420, TCGA-38-4629</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Lung squamous cell carcinoma</td>\n",
       "      <td>TCGA-21-1070, TCGA-60-2715, TCGA-21-1078, TCGA...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Ovarian serous cystadenocarcinoma</td>\n",
       "      <td>TCGA-09-2056</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Rectum adenocarcinoma</td>\n",
       "      <td>TCGA-AF-3913, TCGA-AF-3914, TCGA-AG-A036</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Sarcoma</td>\n",
       "      <td>TCGA-IF-A4AK</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Uterine Corpus Endometrial Carcinoma</td>\n",
       "      <td>TCGA-AX-A2H8</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                   Normalized Sample Type  \\\n",
       "0        Blood Derived Normal, Metastatic   \n",
       "1        Blood Derived Normal, Metastatic   \n",
       "2     Blood Derived Normal, Primary Tumor   \n",
       "3     Blood Derived Normal, Primary Tumor   \n",
       "4     Blood Derived Normal, Primary Tumor   \n",
       "5     Blood Derived Normal, Primary Tumor   \n",
       "6     Blood Derived Normal, Primary Tumor   \n",
       "7     Blood Derived Normal, Primary Tumor   \n",
       "8     Blood Derived Normal, Primary Tumor   \n",
       "9     Blood Derived Normal, Primary Tumor   \n",
       "10    Blood Derived Normal, Primary Tumor   \n",
       "11    Blood Derived Normal, Primary Tumor   \n",
       "12    Blood Derived Normal, Primary Tumor   \n",
       "13    Blood Derived Normal, Primary Tumor   \n",
       "14    Blood Derived Normal, Primary Tumor   \n",
       "15    Blood Derived Normal, Primary Tumor   \n",
       "16    Blood Derived Normal, Primary Tumor   \n",
       "17    Blood Derived Normal, Primary Tumor   \n",
       "18    Blood Derived Normal, Primary Tumor   \n",
       "19    Blood Derived Normal, Primary Tumor   \n",
       "20    Blood Derived Normal, Primary Tumor   \n",
       "21    Blood Derived Normal, Primary Tumor   \n",
       "22    Blood Derived Normal, Primary Tumor   \n",
       "23    Blood Derived Normal, Primary Tumor   \n",
       "24    Blood Derived Normal, Primary Tumor   \n",
       "25    Blood Derived Normal, Primary Tumor   \n",
       "26    Blood Derived Normal, Primary Tumor   \n",
       "27    Blood Derived Normal, Primary Tumor   \n",
       "28  Blood Derived Normal, Recurrent Tumor   \n",
       "29     Primary Tumor, Solid Tissue Normal   \n",
       "30     Primary Tumor, Solid Tissue Normal   \n",
       "31     Primary Tumor, Solid Tissue Normal   \n",
       "32     Primary Tumor, Solid Tissue Normal   \n",
       "33     Primary Tumor, Solid Tissue Normal   \n",
       "34     Primary Tumor, Solid Tissue Normal   \n",
       "35     Primary Tumor, Solid Tissue Normal   \n",
       "36     Primary Tumor, Solid Tissue Normal   \n",
       "37     Primary Tumor, Solid Tissue Normal   \n",
       "38     Primary Tumor, Solid Tissue Normal   \n",
       "39     Primary Tumor, Solid Tissue Normal   \n",
       "40     Primary Tumor, Solid Tissue Normal   \n",
       "41     Primary Tumor, Solid Tissue Normal   \n",
       "\n",
       "                                           Study Name  \\\n",
       "0                             Skin Cutaneous Melanoma   \n",
       "1                                   Thyroid carcinoma   \n",
       "2                            Adrenocortical carcinoma   \n",
       "3                        Bladder Urothelial Carcinoma   \n",
       "4                            Brain Lower Grade Glioma   \n",
       "5                           Breast invasive carcinoma   \n",
       "6   Cervical squamous cell carcinoma and endocervi...   \n",
       "7                                  Cholangiocarcinoma   \n",
       "8                                Colon adenocarcinoma   \n",
       "9                                Esophageal carcinoma   \n",
       "10                            Glioblastoma multiforme   \n",
       "11              Head and Neck squamous cell carcinoma   \n",
       "12                  Kidney renal clear cell carcinoma   \n",
       "13              Kidney renal papillary cell carcinoma   \n",
       "14                     Liver hepatocellular carcinoma   \n",
       "15                                Lung adenocarcinoma   \n",
       "16                       Lung squamous cell carcinoma   \n",
       "17                  Ovarian serous cystadenocarcinoma   \n",
       "18                          Pancreatic adenocarcinoma   \n",
       "19                 Pheochromocytoma and Paraganglioma   \n",
       "20                            Prostate adenocarcinoma   \n",
       "21                              Rectum adenocarcinoma   \n",
       "22                                            Sarcoma   \n",
       "23                            Skin Cutaneous Melanoma   \n",
       "24                             Stomach adenocarcinoma   \n",
       "25                        Testicular Germ Cell Tumors   \n",
       "26                                  Thyroid carcinoma   \n",
       "27               Uterine Corpus Endometrial Carcinoma   \n",
       "28                              Rectum adenocarcinoma   \n",
       "29                                 Cholangiocarcinoma   \n",
       "30                               Colon adenocarcinoma   \n",
       "31                               Esophageal carcinoma   \n",
       "32                                 Kidney Chromophobe   \n",
       "33                  Kidney renal clear cell carcinoma   \n",
       "34              Kidney renal papillary cell carcinoma   \n",
       "35                     Liver hepatocellular carcinoma   \n",
       "36                                Lung adenocarcinoma   \n",
       "37                       Lung squamous cell carcinoma   \n",
       "38                  Ovarian serous cystadenocarcinoma   \n",
       "39                              Rectum adenocarcinoma   \n",
       "40                                            Sarcoma   \n",
       "41               Uterine Corpus Endometrial Carcinoma   \n",
       "\n",
       "                                             Case IDs  \n",
       "0                                        TCGA-WE-A8ZR  \n",
       "1                                        TCGA-EM-A2CS  \n",
       "2                                        TCGA-P6-A5OG  \n",
       "3                                        TCGA-E7-A8O8  \n",
       "4                          TCGA-HT-A619, TCGA-R8-A73M  \n",
       "5   TCGA-AR-A2LR, TCGA-D8-A146, TCGA-BH-A0B6, TCGA...  \n",
       "6   TCGA-C5-A902, TCGA-VS-A8EK, TCGA-C5-A901, TCGA...  \n",
       "7   TCGA-5A-A8ZF, TCGA-4G-AAZG, TCGA-W5-AA2J, TCGA...  \n",
       "8   TCGA-G4-6314, TCGA-AA-3815, TCGA-AA-3967, TCGA...  \n",
       "9                                        TCGA-IC-A6RF  \n",
       "10  TCGA-06-6391, TCGA-19-1788, TCGA-06-0209, TCGA...  \n",
       "11  TCGA-BA-4075, TCGA-CX-7082, TCGA-CQ-A4C7, TCGA...  \n",
       "12  TCGA-B2-5636, TCGA-DV-5573, TCGA-DV-5568, TCGA...  \n",
       "13  TCGA-AL-3468, TCGA-5P-A9KF, TCGA-AL-A5DJ, TCGA...  \n",
       "14  TCGA-G3-A3CG, TCGA-T1-A6J8, TCGA-XR-A8TC, TCGA...  \n",
       "15  TCGA-44-6147, TCGA-44-6147, TCGA-44-2661, TCGA...  \n",
       "16  TCGA-NK-A5D1, TCGA-21-A5DI, TCGA-96-A4JK, TCGA...  \n",
       "17                         TCGA-24-2036, TCGA-36-2539  \n",
       "18                                       TCGA-IB-7654  \n",
       "19                                       TCGA-WB-A820  \n",
       "20  TCGA-G9-A9S4, TCGA-XK-AAK1, TCGA-XK-AAJ3, TCGA...  \n",
       "21  TCGA-G5-6235, TCGA-G5-6572, TCGA-AG-A00H, TCGA...  \n",
       "22                                       TCGA-PC-A5DM  \n",
       "23  TCGA-BF-AAOX, TCGA-BF-A9VF, TCGA-EB-A82C, TCGA...  \n",
       "24           TCGA-HF-7131, TCGA-CG-5716, TCGA-CG-4460  \n",
       "25                                       TCGA-2G-AAFE  \n",
       "26  TCGA-E8-A2JQ, TCGA-EL-A3D5, TCGA-EL-A3D0, TCGA...  \n",
       "27  TCGA-BG-A0M8, TCGA-BG-A220, TCGA-AP-A053, TCGA...  \n",
       "28                                       TCGA-G5-6572  \n",
       "29  TCGA-W7-A93P, TCGA-W7-A93O, TCGA-4G-AAZF, TCGA...  \n",
       "30  TCGA-AA-3662, TCGA-G4-6625, TCGA-AA-3697, TCGA...  \n",
       "31                                       TCGA-L5-A88T  \n",
       "32                                       TCGA-KN-8430  \n",
       "33  TCGA-BP-4986, TCGA-CZ-4865, TCGA-BP-4988, TCGA...  \n",
       "34                         TCGA-BQ-7056, TCGA-BQ-7049  \n",
       "35                                       TCGA-BD-A3ER  \n",
       "36           TCGA-38-4630, TCGA-05-5420, TCGA-38-4629  \n",
       "37  TCGA-21-1070, TCGA-60-2715, TCGA-21-1078, TCGA...  \n",
       "38                                       TCGA-09-2056  \n",
       "39           TCGA-AF-3913, TCGA-AF-3914, TCGA-AG-A036  \n",
       "40                                       TCGA-IF-A4AK  \n",
       "41                                       TCGA-AX-A2H8  "
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "grouped_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {},
   "outputs": [],
   "source": [
    "chatgpt_query_info = grouped_df\n",
    "chatgpt_query_info = chatgpt_query_info.rename(columns={\"Study Name\": \"CANCER_TYPE_NAME\"})\n",
    "chatgpt_query_info = chatgpt_query_info.rename(columns={\"Normalized Sample Type\": \"Normalized_Sample_Type\"})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [],
   "source": [
    "# ChatGPT\n",
    "# Here we just reaplce the fine grained information with Cancer Type Nme"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Define the prompt template\n",
    "template = \"\"\"\n",
    "response = client.chat.completions.create(\n",
    "  model=\"gpt-4o\",\n",
    "  messages=[\n",
    "    {{\n",
    "      \"role\": \"system\",\n",
    "      \"content\": [\n",
    "        {{\n",
    "          \"type\": \"text\",\n",
    "          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n",
    "        }}\n",
    "      ]\n",
    "    }},\n",
    "    {{\n",
    "      \"role\": \"user\",\n",
    "      \"content\": [\n",
    "        {{\n",
    "          \"type\": \"text\",\n",
    "          \"text\": \"Describe how {CANCER_TYPE_NAME} impacts survival, focusing on:\\n- Tumor Origin: How {CANCER_TYPE_NAME} influences metastatic patterns, patient survival, and treatment accessibility.\\n- Histology: How {CANCER_TYPE_NAME} interacts with mutation profiles to drive outcomes.\\n- Sampling Bias: Limitations of {Normalized_Sample_Type} in genomic analysis.\\n- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\\n\\nFor each aspect, explain step by step:\\n- How it influences survival (positive/negative)\\n- Biological rationale without excessive jargon\\n- Potential biases in genomic interpretation\\n\\nConclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n",
    "        }}\n",
    "      ]\n",
    "    }}\n",
    "  ],\n",
    "  response_format={{ \"type\": \"text\" }},\n",
    "  temperature=1,\n",
    "  max_completion_tokens=2048,\n",
    "  top_p=1,\n",
    "  frequency_penalty=0,\n",
    "  presence_penalty=0\n",
    ")\n",
    "\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "First prompt example:\n",
      "\n",
      "response = client.chat.completions.create(\n",
      "  model=\"gpt-4o\",\n",
      "  messages=[\n",
      "    {\n",
      "      \"role\": \"system\",\n",
      "      \"content\": [\n",
      "        {\n",
      "          \"type\": \"text\",\n",
      "          \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n",
      "        }\n",
      "      ]\n",
      "    },\n",
      "    {\n",
      "      \"role\": \"user\",\n",
      "      \"content\": [\n",
      "        {\n",
      "          \"type\": \"text\",\n",
      "          \"text\": \"Describe how Skin Cutaneous Melanoma impacts survival, focusing on:\n",
      "- Tumor Origin: How Skin Cutaneous Melanoma influences metastatic patterns, patient survival, and treatment accessibility.\n",
      "- Histology: How Skin Cutaneous Melanoma interacts with mutation profiles to drive outcomes.\n",
      "- Sampling Bias: Limitations of Blood Derived Normal, Metastatic in genomic analysis.\n",
      "- Key Genes: Identify 5-8 survival-associated genes, explaining their biological mechanisms (e.g., proliferation, immune response, apoptosis regulation).\n",
      "\n",
      "For each aspect, explain step by step:\n",
      "- How it influences survival (positive/negative)\n",
      "- Biological rationale without excessive jargon\n",
      "- Potential biases in genomic interpretation\n",
      "\n",
      "Conclude with a synthesis of key survival risk factors, emphasizing clinically relevant insights and their impact on patient survival.\"\n",
      "        }\n",
      "      ]\n",
      "    }\n",
      "  ],\n",
      "  response_format={ \"type\": \"text\" },\n",
      "  temperature=1,\n",
      "  max_completion_tokens=2048,\n",
      "  top_p=1,\n",
      "  frequency_penalty=0,\n",
      "  presence_penalty=0\n",
      ")\n",
      "\n",
      "Processing prompt 1/42...\n",
      "Response received.\n",
      "Processing prompt 2/42...\n",
      "Response received.\n",
      "Processing prompt 3/42...\n",
      "Response received.\n",
      "Processing prompt 4/42...\n",
      "Response received.\n",
      "Processing prompt 5/42...\n",
      "Response received.\n",
      "Processing prompt 6/42...\n",
      "Response received.\n",
      "Processing prompt 7/42...\n",
      "Response received.\n",
      "Processing prompt 8/42...\n",
      "Response received.\n",
      "Processing prompt 9/42...\n",
      "Response received.\n",
      "Processing prompt 10/42...\n",
      "Response received.\n",
      "Processing prompt 11/42...\n",
      "Response received.\n",
      "Processing prompt 12/42...\n",
      "Response received.\n",
      "Processing prompt 13/42...\n",
      "Response received.\n",
      "Processing prompt 14/42...\n",
      "Response received.\n",
      "Processing prompt 15/42...\n",
      "Response received.\n",
      "Processing prompt 16/42...\n",
      "Response received.\n",
      "Processing prompt 17/42...\n",
      "Response received.\n",
      "Processing prompt 18/42...\n",
      "Response received.\n",
      "Processing prompt 19/42...\n",
      "Response received.\n",
      "Processing prompt 20/42...\n",
      "Response received.\n",
      "Processing prompt 21/42...\n",
      "Response received.\n",
      "Processing prompt 22/42...\n",
      "Response received.\n",
      "Processing prompt 23/42...\n",
      "Response received.\n",
      "Processing prompt 24/42...\n",
      "Response received.\n",
      "Processing prompt 25/42...\n",
      "Response received.\n",
      "Processing prompt 26/42...\n",
      "Response received.\n",
      "Processing prompt 27/42...\n",
      "Response received.\n",
      "Processing prompt 28/42...\n",
      "Response received.\n",
      "Processing prompt 29/42...\n",
      "Response received.\n",
      "Processing prompt 30/42...\n",
      "Response received.\n",
      "Processing prompt 31/42...\n",
      "Response received.\n",
      "Processing prompt 32/42...\n",
      "Response received.\n",
      "Processing prompt 33/42...\n",
      "Response received.\n",
      "Processing prompt 34/42...\n",
      "Response received.\n",
      "Processing prompt 35/42...\n",
      "Response received.\n",
      "Processing prompt 36/42...\n",
      "Response received.\n",
      "Processing prompt 37/42...\n",
      "Response received.\n",
      "Processing prompt 38/42...\n",
      "Response received.\n",
      "Processing prompt 39/42...\n",
      "Response received.\n",
      "Processing prompt 40/42...\n",
      "Response received.\n",
      "Processing prompt 41/42...\n",
      "Response received.\n",
      "Processing prompt 42/42...\n",
      "Response received.\n"
     ]
    }
   ],
   "source": [
    "# Build the list of prompts and store the corresponding Case IDs\n",
    "prompts = []\n",
    "case_ids_list = []\n",
    "\n",
    "for index, row in chatgpt_query_info.iterrows():\n",
    "    prompt_filled = template.format(\n",
    "        CANCER_TYPE_NAME=row[\"CANCER_TYPE_NAME\"],\n",
    "        Normalized_Sample_Type=row[\"Normalized_Sample_Type\"]\n",
    "    )\n",
    "    prompts.append(prompt_filled)\n",
    "    case_ids_list.append(row[\"Case IDs\"])\n",
    "\n",
    "print(\"First prompt example:\")\n",
    "print(prompts[0])\n",
    "\n",
    "# %%\n",
    "client = OpenAI(api_key=os.getenv(\"OPENAI_API_KEY\"))\n",
    "\n",
    "responses = []\n",
    "\n",
    "for idx, prompt in enumerate(prompts):\n",
    "    print(f\"Processing prompt {idx+1}/{len(prompts)}...\")\n",
    "    try:\n",
    "        response = client.chat.completions.create(\n",
    "            model=\"gpt-4o\",\n",
    "            messages=[\n",
    "                {\n",
    "                    \"role\": \"system\",\n",
    "                    \"content\": [\n",
    "                        {\n",
    "                            \"type\": \"text\",\n",
    "                            \"text\": \"You are an expert oncologist specializing in cancer survival. You are explaining complex oncological and genomic factors to another expert in a structured, precise manner. Focus on step-by-step reasoning, integrating knowledge of tumor origin, histology, genetic mutations, and sampling biases. Avoid redundant explanations and ensure biological clarity while emphasizing survival impact.\"\n",
    "                        }\n",
    "                    ]\n",
    "                },\n",
    "                {\n",
    "                    \"role\": \"user\",\n",
    "                    \"content\": [\n",
    "                        {\n",
    "                            \"type\": \"text\",\n",
    "                            \"text\": prompt\n",
    "                        }\n",
    "                    ]\n",
    "                }\n",
    "            ],\n",
    "            response_format={\"type\": \"text\"},\n",
    "            temperature=1,\n",
    "            max_completion_tokens=2048,\n",
    "            top_p=1,\n",
    "            frequency_penalty=0,\n",
    "            presence_penalty=0\n",
    "        )\n",
    "        responses.append(response)\n",
    "        print(\"Response received.\")\n",
    "    except Exception as e:\n",
    "        print(f\"Error processing prompt {idx+1}: {e}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Build a DataFrame that includes the prompt, response, and associated Case IDs\n",
    "data = []\n",
    "for prompt, resp, case_ids in zip(prompts, responses, case_ids_list):\n",
    "    try:\n",
    "        answer_text = resp.choices[0].message.content\n",
    "    except Exception as e:\n",
    "        answer_text = None\n",
    "        print(f\"Error extracting answer: {e}\")\n",
    "    data.append({\n",
    "        \"prompt\": prompt,\n",
    "        \"response\": answer_text,\n",
    "        \"Case IDs\": case_ids\n",
    "    })"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {},
   "outputs": [],
   "source": [
    "df_responses = pd.DataFrame(data)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {},
   "outputs": [],
   "source": [
    "csv_path = \"/home/chb3333/yulab/chb3333/gem-patho/data_extraction/cancertype_location_description/location_desciption_withoutICD/chat_responses.csv\"\n",
    "parquet_path = \"/home/chb3333/yulab/chb3333/gem-patho/data_extraction/cancertype_location_description/location_desciption_withoutICD/chat_responses.parquet\"\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Responses saved to /home/chb3333/yulab/chb3333/gem-patho/data_extraction/cancertype_location_description/location_desciption_withoutICD/chat_responses.csv\n",
      "Responses saved to /home/chb3333/yulab/chb3333/gem-patho/data_extraction/cancertype_location_description/location_desciption_withoutICD/chat_responses.parquet\n"
     ]
    }
   ],
   "source": [
    "df_responses.to_csv(csv_path, index=False)\n",
    "print(f\"Responses saved to {csv_path}\")\n",
    "\n",
    "df_responses.to_parquet(parquet_path, index=False)\n",
    "print(f\"Responses saved to {parquet_path}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Row counts match. Proceeding with validation...\n"
     ]
    }
   ],
   "source": [
    "description_meta = grouped_df\n",
    "\n",
    "if len(description_meta) != len(df_responses):\n",
    "    print(\"Warning: The number of rows differ!\")\n",
    "else:\n",
    "    print(\"Row counts match. Proceeding with validation...\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [],
   "source": [
    "description_meta[\"generated_description\"] = df_responses[\"response\"].values\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "Normalized Sample Type",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Study Name",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Case IDs",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "generated_description",
         "rawType": "object",
         "type": "string"
        }
       ],
       "conversionMethod": "pd.DataFrame",
       "ref": "31769f20-4ca1-4594-b1ee-5c36abcb6a5b",
       "rows": [
        [
         "0",
         "Blood Derived Normal, Metastatic",
         "Skin Cutaneous Melanoma",
         "TCGA-WE-A8ZR",
         "## Tumor Origin and Its Influence on Survival\n\n**Influence on Survival:**\n1. **Metastatic Patterns:** Skin Cutaneous Melanoma (SCM) originates in melanocytes and is highly metastatic. It can disseminate early to distant organs like the brain, lungs, and liver. This propensity for early and widespread dissemination makes it highly lethal and complex to treat, negatively impacting long-term survival.\n   \n2. **Treatment Accessibility:** The primary dermal location of SCM initially facilitates surgical intervention and direct skin access chemotherapies. However, once metastasized, treatment options become limited and less effective, underscoring the criticality of early detection and treatment accessibility in survival outcomes.\n\n**Biological Rationale:** \n- SCM's aggressive migration and invasion capabilities stem from its neural crest origin, which inherently supports extensive migratory potential — aiding in rapid metastasis.\n \n**Potential Biases in Genomic Interpretation:**\n- Tumor heterogeneity and subclonal structures add complexity to treatment and prognosis, possibly leading to varied responses to treatment based on the specific mutational profile of metastatic sites.\n\n## Histology and Interaction with Mutation Profiles\n\n**Influence on Survival:**\n1. **Mutational Influence:** The histological type of melanoma correlates with distinct mutational profiles. For instance, BRAF mutations are more prevalent in superficial spreading melanoma. The type of mutation can determine responsiveness to targeted therapies (e.g., BRAF inhibitors) positively influencing survival.\n   \n2. **Histological Subtypes:** Variations like acral lentiginous melanoma may present without UV exposure implications, often being diagnosed at a more advanced stage, leading to poorer survival outcomes.\n\n**Biological Rationale:**\n- Specific mutations such as BRAF and NRAS influence cell cycle regulation, promoting tumor proliferation and survival. Oncogene addiction in certain histological subtypes can thus drive focused treatment strategies.\n\n**Potential Biases in Genomic Interpretation:**\n- Discrepancies in mutational analysis due to sampling (e.g., primary vs. metastatic lesions) may not reflect the full mutational landscape, impacting treatment strategies and survival projections.\n\n## Sampling Biases and Limitations\n\n**Influence on Survival:**\n1. **Blood-Derived Normal vs. Tumor Samples:** Blood samples often used as normal controls may omit information on tumor-specific mutations, leading to incomplete genomic profiling and treatment strategies.\n   \n2. **Metastatic Sampling:** Biopsies of metastatic tissue may contain different dominant clones compared to the primary tumor, potentially skewing genomic data towards features of metastatic progression rather than primary oncogenesis.\n\n**Biological Rationale:**\n- Sampling variability can introduce bias in interpreting the aggressiveness and treatment responsiveness of melanoma, affecting survival-related decision-making.\n\n**Potential Biases in Genomic Interpretation:**\n- Misrepresentation of diversity in tumor clonal populations due to selective biopsy can bias therapeutic targeting and thus impact predicted survival outcomes.\n\n## Key Genes Related to Survival\n\n1. **BRAF:** Mutations lead to constitutive activation of the MAPK pathway, promoting tumor cell proliferation; targeted therapies (e.g., vemurafenib) can substantially improve survival if mutations are present.\n   \n2. **NRAS:** Mutations drive parallel pathways (MAPK/PI3K), often indicating poor prognosis due to lack of effective targeted inhibitors.\n\n3. **TP53:** Encodes a critical part of the DNA damage response; loss of TP53 functionality through mutations facilitates uncontrolled proliferation and apoptosis evasion.\n\n4. **PTEN:** Tumor suppressor that when mutated, results in heightened PI3K/AKT signaling, supporting survival and growth of melanoma cells.\n\n5. **KIT:** Mutations are common in mucosal and acral melanomas, offering a potential target for tyrosine kinase inhibitors, although the response is variable.\n\n6. **MC1R:** Variants influence susceptibility and potentially melanoma progression, implying a complex role in melanoma survival.\n\n**Biological Mechanisms:**\n- Mutations in these genes interact with cellular pathways governing proliferation, survival, apoptosis, and immune evasion — all critical to melanoma progression.\n\n**Potential Biases in Genomic Interpretation:**\n- Discrepancies in mutation prevalence across tumor type or stage need careful interpretation as they may reflect either true biological differences or sample selection biases.\n\n## Synthesis of Key Survival Risk Factors\n\n**Clinically Relevant Insights:**\n- Early detection and targeted intervention are crucial in improving SCM survival, leveraging biological understanding of mutational landscapes to tailor treatments.\n- Addressing sampling biases by comprehensive and repeated biopsies can improve genomic interpretation accuracy, steering personalized treatment strategies.\n- Genetic profiling focusing on actionable mutations and immune signaling pathways prognosticates improved survival when combined with immune checkpoint inhibitors or targeted therapies.\n\n**Impact on Patient Survival:**\n- Understanding melanoma’s genomic and histological complexity forms the crux of optimizing survival outcomes through precise, personalized therapy approaches. The heterogeneity in melanoma demands a dynamic assessment strategy to tailor interventions effectively across different stages of disease progression."
        ],
        [
         "1",
         "Blood Derived Normal, Metastatic",
         "Thyroid carcinoma",
         "TCGA-EM-A2CS",
         "Thyroid carcinoma showcases distinct influences on patient survival through various interconnected aspects including tumor origin, histology, and genetic variability. I'll delve into each component methodically:\n\n### Tumor Origin\n\n**Influence on Survival:**  \nThyroid carcinoma's origin typically influences its metastatic patterns and subsequent survival outcomes. Differentiated thyroid cancers (DTCs) such as papillary (PTC) and follicular (FTC) tend to have a higher survival rate due to their relatively slow progression and responsiveness to radioiodine treatment. In contrast, poorly differentiated and anaplastic thyroid carcinomas (ATC) often exhibit aggressive behavior with earlier and widespread metastasis, severely compromising survival.\n\n**Biological Rationale:**  \nThe thyroid gland's propensity to concentrate iodine is leveraged therapeutically in differentiated thyroid cancers, aiding in the treatment of metastasis via radioiodine. The less-differentiated variants lack this trait, resulting in fewer available effective therapies.\n\n**Potential Biases:**  \nAnalysis typically emphasizes primary tumor characteristics, possibly under-representing metastatic dynamics, especially in aggressive variants like ATC, where early systemic spread significantly decreases survival prospects.\n\n### Histology\n\n**Influence on Survival:**  \nHistological subtypes of thyroid carcinoma, along with their associated mutation profiles, critically influence prognosis. PTC, FTC, medullary (MTC), and ATC each have unique molecular signatures impacting therapeutic outcomes.\n\n**Biological Rationale:**  \nPTC often harbor BRAF mutations, notably V600E, linked to higher recurrence but still robust survival with appropriate treatment. Conversely, RAS mutations in FTC can influence a more aggressive disease course. MTC's association with RET mutations often dictates the need for genetic counseling and specific targeted therapies. The histological groundwork intertwines with these mutations to delineate therapeutic efficacy and guide surveillance strategies.\n\n**Potential Biases:**  \nHistological assessments may miss or downplay heterogeneity and rare variants, leading to potential misrepresentation in survival projections and treatment assessments. Tumor sampling might not capture intratumoral genetic diversity, which contributes to treatment resistance and variable prognoses.\n\n### Sampling Bias\n\n**Limitations in Genomic Analysis:**  \nBlood-derived normal controls, typically used as baselines, may not fully represent the tumor-harboring organ's molecular landscape. More so, metastatic samples may amplify genomic alterations absent in primary tumors, skewing mutation frequency interpretations.\n\n**Biological Rationale:**  \nGenes unequally expressed in thyroid tissue versus blood may lead to underestimation or overestimation of relevant genetic changes critical to accurate prognosis and personalized therapy development.\n\n**Potential Biases:**  \nMetastatic focus can introduce artifacts since these samples typically undergo distinct selective pressures compared to primary tumors, potentially misguiding mutation-treatment correlation studies.\n\n### Key Genes\n\n**1. BRAF:** Frequently mutated in PTC, particularly the V600E variant, influencing aggressive tumorigenic pathways. It affects kinase activity, driving cell proliferation.\n\n**2. RAS (NRAS, HRAS, KRAS):** Common in FTC and follicular variants, RAS mutations contribute to dedifferentiation and resistance to standard therapies by activating MAPK pathways.\n\n**3. RET:** Found predominantly in MTC, RET mutations drive downstream signaling modalities tied to cellular growth and a challenge to treatment paradigms without appropriate targeting.\n\n**4. TP53:** Critical in ATC, where mutations lead to rampant proliferation and genomic instability, dramatically reducing survival rates.\n\n**5. TERT Promoter:** Mutations here indicate poor prognosis across various thyroid cancer forms, linked to accelerated growth and resistance mechanisms.\n\n**6. PIK3CA:** Often found when thyroid cancers progress into more aggressive states, affecting pathways that regulate apoptosis and cellular metabolism.\n\n**7. NTRK1/3 and ALK:** Gene rearrangements involving these pathways frequently alter cellular signaling and are emerging targets in personalized therapy approaches.\n\n**8. PTEN:** Loss or mutations can overlap with aggressive clinical features, enhancing pathways that drive cellular survival and resistance to conventional therapies.\n\n### Conclusion\n\nSynthesis of these elements highlights several key survival determinants: the specific histological subtype, genomic characteristics, and distinct pathway activations. Understanding these factors is critical to optimizing patient-specific therapeutic strategies and improving survival. However, potential sampling biases and heterogeneity must be acknowledged to enhance precision. Therefore, a combined approach leveraging genomic insights and thorough histopathological evaluation remains the vanguard for enhancing thyroid carcinoma management. By refining diagnostic accuracy and treatment specificity, we can elevate survival rates and patient quality of life."
        ],
        [
         "2",
         "Blood Derived Normal, Primary Tumor",
         "Adrenocortical carcinoma",
         "TCGA-P6-A5OG",
         "### Tumor Origin\n\n**Influence on Survival:**\n- Adrenocortical carcinoma (ACC) originates from the adrenal cortex, affecting survival primarily through its potential for early metastasis and aggressive local invasion.\n- The metastatic pattern typically includes the liver, lungs, and lymph nodes, which complicates surgical intervention and reduces survival rates.\n- Due to the rare nature of ACC, accessibility to specialized treatment centers can be limited, affecting survival outcomes negatively.\n\n**Biological Rationale:**\n- Adrenal tumors produce hormones like cortisol, which can lead to clinical syndromes (e.g., Cushing's syndrome) exacerbating patient conditions.\n- The high mitotic rate and the potential for hormone secretion contribute to systemic effects that accelerate disease progression.\n\n**Potential Biases:**\n- Given the aggressive nature and rarity of ACC, clinical data is often derived from specialized centers, leading to a possible selection bias.\n\n### Histology\n\n**Influence on Survival:**\n- ACC's histological features, such as high-grade nuclear atypia and necrosis, correlate with poorer survival.\n- Histology also intersects with genomic profiles, where specific mutation patterns (e.g., TP53 mutations) indicate worse prognosis.\n\n**Biological Rationale:**\n- The high cellularity and atypical mitotic figures in ACC reflect its aggressive nature.\n- Hormone-producing tumor cells can alter systemic homeostasis, compounding survival challenges.\n\n**Potential Biases:**\n- Biopsies providing histological samples might not capture the tumor heterogeneity, impacting genomic interpretation linked to histology.\n\n### Sampling Bias\n\n**Limitations in Genomic Analysis:**\n- Blood-derived normal samples can introduce contamination from circulating tumor DNA, skewing mutation profile interpretations.\n- Primary tumor samples may not reflect the metastatic landscape, leading to an incomplete survival prediction if metastases are genetically distinct.\n\n**Influences on Survival:**\n- Misinterpretation of genomic data may hinder the development of targeted therapies, thereby reducing effective treatment options.\n\n**Biological Rationale:**\n- Tumor heterogeneity implies that a single sampling site might not reflect the entirety of the disease’s genetic landscape.\n\n### Key Genes\n\n**Influence on Survival:**\n1. **TP53**: Mutations here disrupt cell cycle regulation, increasing tumor invasiveness and reducing survival.\n2. **CTNNB1 (Beta-catenin)**: Involved in cell proliferation pathways; its dysregulation is linked to poor prognosis.\n3. **MEN1**: Mutations can influence tumor suppressor pathways, affecting survival.\n4. **IGF2**: Overexpression can enhance cell proliferation, impacting ACC aggressiveness.\n5. **BUB1B**: Involved in mitotic checkpoint; dysfunction leads to chromosomal instability, worsening outcomes.\n6. **NR5A1**: Alters steroidogenic pathways, potentially contributing to endocrine disturbances.\n7. **SIRT1**: Affects apoptosis; its role in cellular longevity and stress resistance can be pivotal in survival.\n\n**Biological Mechanisms:**\n- These genes are integral to cell cycle control, apoptosis, hormonal regulation, and metastatic potential.\n\n**Potential Biases:**\n- Focusing on gene mutations without considering epigenetic and post-translational modifications might limit understanding of survival impacts.\n\n### Synthesis of Key Survival Risk Factors\n\nACC presents significant survival challenges due to its origin, aggressive histological features, and complex genomic landscape marked by critical mutations such as TP53 and CTNNB1. The rarity of the tumor introduces biases in sampling and treatment access, which can further affect patient outcomes. For impactful clinical strategies, a consideration of tumor heterogeneity and a multi-faceted approach that includes genetic, histological, and clinical data are essential. Understanding these elements can drive better-targeted therapies and personalized treatment approaches, ultimately improving survival rates in ACC patients."
        ],
        [
         "3",
         "Blood Derived Normal, Primary Tumor",
         "Bladder Urothelial Carcinoma",
         "TCGA-E7-A8O8",
         "### Tumor Origin and Metastatic Patterns\n\n**Influence on Survival:**\nBladder Urothelial Carcinoma (BUC) typically originates from the urothelial cells lining the bladder. This origin is crucial as it dictates the tumor’s tendency to invade either locally into the bladder muscle or metastasize to distant sites, such as lymph nodes, lungs, liver, and bones.\n\n1. **Local Invasion:** BUC's propensity for local invasion into the bladder muscle significantly impacts patient survival. Muscle-invasive bladder cancer (MIBC) often necessitates more aggressive treatment approaches, such as radical cystectomy, which can improve survival compared to non-muscle-invasive forms.\n\n2. **Metastasis:** The metastatic pattern stemming from BUC contributes to a poorer prognosis. Metastasis often results in complex treatment regimens involving chemotherapy and immunotherapy, further affecting survival rates negatively.\n\n3. **Treatment Accessibility:** Treatment accessibility varies according to tumor stage and available regional health resources, influencing overall outcomes. For instance, the availability of platinum-based chemotherapy and immune checkpoint inhibitors can extend survival for advanced stages.\n\n**Biological Rationale:**\nThe propensity for local muscle invasion and systemic spread arises from the tumor's ability to manipulate different cell adhesion molecules and proteolytic enzymes, facilitating tissue penetration and vascular entry.\n\n**Biases in Interpretation:**\nSampling biases may occur due to tissue heterogeneity between primary and metastatic sites, potentially underrepresenting aggressive subclones in genomic studies.\n\n### Histology and Mutation Profiles\n\n**Influence on Survival:**\nHistologically, BUC is mostly high-grade, which correlates with poor prognosis owing to its association with aggressive clinical behavior and high metastatic potential.\n\n1. **Mutation Interaction:** Common mutation profiles in BUC, such as those involving FGFR3, TP53, and ERCC2, significantly dictate survival outcomes. FGFR3 mutations typically indicate non-muscle-invasive, less aggressive forms—generally translating to better prognoses.\n\n2. **Biological Implications:** Mutations like TP53, which disrupt the cell cycle and apoptosis, often correlate with more aggressive disease, whereas mutations in FGFR3 might lead to low-grade cancer with better survival odds.\n\n**Potential Biases in Genomic Analysis:**\nBiases in genomic data may arise due to differing mutational signatures between cancer subclones and varying sampling from tumors at different evolutionary stages.\n\n### Key Genes Associated with Survival\n\n**Key Genes and Their Mechanisms:**\n1. **TP53:** Known for its role in genomic integrity, TP53 mutations typically lead to poorer survival by enabling cell cycle progression and evasion of apoptosis.\n\n2. **FGFR3:** Frequently mutated in non-muscle-invasive BUC, it generally suggests a favorable prognosis by driving proliferation that maintains lower tumor grade.\n\n3. **ERBB2:** Overexpression or amplification predicts poor survival, as it acts through pathways promoting aggressive proliferation and metastatic potential.\n\n4. **ERCC2:** Involved in nucleotide excision repair, mutations can create sensitivity to platinum-based chemotherapy, potentially improving response and survival.\n\n5. **CDKN2A/p16:** Loss can lead to unchecked cell cycle progression, generally correlating with a negative impact on survival.\n\n6. **PIK3CA:** While associated with oncogenic signaling, mutations in PIK3CA can be present in both low-grade, favorable, and high-grade tumors, complicating survival predictions.\n\n**Bias Considerations:**\nSample collection bias from blood or different tumor sections can obscure the presence or absence of these critical mutations, leading to misleading survival predictions.\n\n### Conclusion and Synthesis\n\n**Key Survival Risk Factors:**\nThe survival outcome in BUC is intricately linked to a combination of histological grade, genetic alterations, metastatic capability, and treatment accessibility. Clinically, early detection and intervention remain crucial, as they can substantially mitigate the negative impacts of aggressive tumor biology and limited treatment options.\n\n**Clinical Relevance:**\nUnderstanding the intersection of tumorigenic origins, molecular profiles, and potential biases allows for more personalized and predictive therapeutic strategies. Improved genomic profiling and targeted therapies that address specific genetic aberrations hold the potential for significantly improved survival outcomes in patients with Bladder Urothelial Carcinoma."
        ],
        [
         "4",
         "Blood Derived Normal, Primary Tumor",
         "Brain Lower Grade Glioma",
         "TCGA-HT-A619, TCGA-R8-A73M",
         "### Tumor Origin\n\n**Influence on Survival:**\n1. **Metastatic Patterns:** Brain Lower Grade Gliomas (LGGs) are primarily central nervous system tumors and rarely metastasize outside the brain. Survival impact is more associated with local invasion rather than systemic spread.\n   \n2. **Patient Survival:** The origin within the brain impacts survival, primarily through location-specific effects on critical neurological functions. Tumors in regions that affect vital functions (e.g., brainstem) have worse prognoses.\n\n3. **Treatment Accessibility:** Surgical accessibility is a major determinant of outcomes. Tumors in deep or eloquent brain areas can limit surgical resection, negatively affecting survival.\n\n**Biological Rationale:** The glial origin (often oligodendrocytes or astrocytes) implies growth conformity within cerebral tissue niches, explaining minimal metastatic potential but local invasiveness.\n\n**Potential Biases:** Data may overrepresent accessible and resectable tumors, skewing survival assumptions favorably.\n\n### Histology\n\n**Influence on Survival:**\n1. **Interaction with Mutation Profiles:** Different histological subtypes (e.g., oligodendroglioma vs. astrocytoma) exhibit distinct genetic changes that influence prognosis.\n   \n2. **Driving Outcomes:** Histology can predict chemotherapy and radiation responses. Oligodendrogliomas with 1p/19q co-deletion tend to have better outcomes due to chemosensitivity.\n\n**Biological Rationale:** Histological features reflect underlying genetic aberrations. For example, 1p/19q co-deleted tumors stabilize the genome, preventing aggressive progression.\n\n**Potential Biases:** Classification precision varies with biopsy quality and interpretation, possibly underestimating minor histological variants affecting survival predictions.\n\n### Sampling Bias\n\n**Issues in Genomic Analysis:**\n1. **Blood-Derived Normal:** Using blood as a germline reference may miss mosaic mutations present only in the brain, leading to incomplete genomic profiling.\n\n2. **Primary Tumor Bias:** Biopsies might not capture tumor heterogeneity or microenvironment nuances, leading to skewed interpretations of mutation impact.\n\n**Potential Impact on Survival Analysis:** Consequently, survival estimations may favor the more prominently sampled and less aggressive regions, missing out on aggressive clones.\n\n### Key Genes and Their Mechanisms\n\n1. **IDH1/2:** Mutations in these genes are associated with improved survival due to altered cellular metabolism that slows tumor progression.\n\n2. **TP53:** Dysfunction often leads to unchecked cell division. Mutations generally correlate with poorer prognosis.\n\n3. **ATRX:** Involved in chromatin remodeling, ATRX mutations can influence patient outcomes by affecting genomic stability.\n\n4. **1p/19q Co-deletion:** Strongly linked with favorable prognosis due to chemosensitivity derived from the genetic stability imparted by these deletions.\n\n5. **TERT Promoter Mutations:** Associated with increased telomerase activity, promoting prolonged cell survival and potentially worsened outcomes.\n\n6. **MGMT Methylation:** Epigenetic silencing confers chemosensitivity to alkylating agents, improving survival in treated patients.\n\n7. **CDKN2A/B:** Deletion or mutation often worsens survival by disrupting cell cycle regulation.\n\n### Conclusion\n\n**Key Survival Risk Factors:**\n- **Genetic Profile:** Genetic alterations (e.g., IDH mutations, 1p/19q co-deletion) heavily dictate clinical outcomes.\n- **Histology and Tumor Locale:** Determine the effectiveness of surgical and adjunctive therapies.\n- **Diagnosis and Sampling Protocols:** Impact the perceived aggressiveness and treatment response reliability.\n\n**Clinically Relevant Insights:**\n- Accurate genetic and histological classification is crucial for prognostication and personalized treatment strategies.\n- Continued refinement of genomic sampling methods is necessary to reduce bias and improve survival prediction accuracy. These insights underscore the necessity of integrative molecular-histological frameworks to optimize Brain LGG patient management and improve survival outcomes."
        ],
        [
         "5",
         "Blood Derived Normal, Primary Tumor",
         "Breast invasive carcinoma",
         "TCGA-AR-A2LR, TCGA-D8-A146, TCGA-BH-A0B6, TCGA-AR-A2LL, TCGA-5L-AAT1, TCGA-A8-A08S, TCGA-E2-A572, TCGA-A8-A09E, TCGA-A8-A08F, TCGA-A8-A09K",
         "### Tumor Origin and Its Influence on Survival\n\n**Step 1: Metastatic Patterns**\n- **Influence on Survival**: Breast invasive carcinoma often metastasizes to bones, lungs, liver, and brain, leading to poor prognosis once metastasis occurs.\n- **Biological Rationale**: The propensity for these specific sites is due to the expression of specific chemokine receptors and adhesion molecules on breast cancer cells. For instance, CXCR4 and CCR7 facilitate migration to common metastatic sites.\n- **Treatment Accessibility**: Metastatic disease diminishes surgical options and often shifts treatment to systemic therapies, which may be less effective than localized treatments.\n\n**Step 2: Treatment Accessibility and Survival**\n- **Influence on survival**: Initial diagnosis of invasive disease limits the effectiveness of local treatments like surgery and radiotherapy, leading to reliance on systemic therapies with variable efficacy.\n- **Biological Rationale**: Tumors not confined locally necessitate chemotherapy, hormonal therapy, or targeted treatments, which may be less efficacious if resistance develops.\n\n### Histology and Mutation Profiles\n\n**Step 1: Interaction with Mutation Profiles**\n- **Influence on Survival**: Histological subtypes such as Luminal A, Luminal B, HER2-enriched, and triple-negative demonstrate distinct outcomes due to associated mutation profiles.\n- **Biological Rationale**: For example, Luminal A cancers, often positive for estrogen receptor (ER) and progesterone receptor (PR), with low proliferation indices (like Ki-67), generally have a better prognosis.\n- **Mutation Profiles**: PIK3CA mutations prevalent in Luminal types, often confer resistance to certain therapies but also provide targets for specific inhibitors, affecting survival positively when effectively targeted.\n\n### Sampling Bias\n\n**Step 1: Limitations of Genomic Analysis**\n- **Influence on Survival Assessment**: Lack of comprehensive tissue sampling can skew genomic interpretations, leading to biased treatment approaches.\n- **Biological Rationale**: Blood-derived normals and primary tumor samples may not fully capture tumor heterogeneity or represent microenvironment influences, leading to inaccurate survival predictions.\n- **Potential Bias**: Sampling primarily from areas with high cellularity might miss subclonal populations, affecting the understanding of resistance mechanisms.\n\n### Key Genes and Their Role in Survival\n\n**Step 1: Identifying Survival-Associated Genes**\n- **PIK3CA**: Frequently mutated in breast cancer; activates the PI3K/AKT pathway promoting cell growth, survival, and metabolism. Targetable by PI3K inhibitors, influencing survival positively when managed.\n- **TP53**: Mutations lead to loss of tumor suppressor function, affecting cell cycle arrest and apoptosis, generally associated with poor prognosis.\n- **BRCA1/2**: Mutational status affects DNA repair mechanisms, influencing responsiveness to PARP inhibitors and affecting progression and survival.\n- **HER2**: Overexpression or amplification predicts response to HER2-targeted therapies, significantly improving survival in HER2-positive cases.\n- **ESR1**: Mutations conferring resistance to hormone therapy; impacts survival negatively if not addressed with effective treatment.\n- **GATA3**: Associated with better prognosis in ER-positive cancers due to its role in lineage differentiation and maintaining hormonal response pathways.\n- **AKT1**: Mutations can activate downstream signaling pathways related to survival, proliferation, and migration, impacting progression and treatment response.\n- **CDH1**: Alterations lead to loss of cell adhesion, increasing invasive potential and negatively affecting survival.\n\n### Synthesis and Clinically Relevant Insights\n\n**Key Survival Risk Factors**\n- **Metastatic Patterns**: Critical factor affecting prognosis due to its widespread impact and difficulty to manage once systemic.\n- **Genetic Mutations and Pathway Alterations**: Provide crucial insights into personalized treatment avenues; however, require comprehensive genomic profiling to effectively manage treatment-resistant cases.\n- **Targeted Therapy Opportunities**: Genes like PIK3CA, HER2, and BRCA1/2 highlight the importance of targeted therapy in improving survival when mutations are present.\n- **Importance of Comprehensive Sampling**: To avoid genomic misinterpretation, extensive and representative sampling is necessary for a nuanced understanding of tumor biology, crucial for guiding effective therapy.\n\nClinically, understanding each of these factors reinforces the importance of personalized medicine approaches, integrating genetic testing and targeted therapies to optimize survival outcomes for breast invasive carcinoma patients."
        ],
        [
         "6",
         "Blood Derived Normal, Primary Tumor",
         "Cervical squamous cell carcinoma and endocervical adenocarcinoma",
         "TCGA-C5-A902, TCGA-VS-A8EK, TCGA-C5-A901, TCGA-DS-A1OB, TCGA-C5-A905, TCGA-DS-A1OD, TCGA-EX-A449",
         "Sure, let's analyze the impact of cervical squamous cell carcinoma (SCC) and endocervical adenocarcinoma on survival by examining each aspect:\n\n### 1. Tumor Origin\n**Influence on Survival:**\n- **Cervical SCC** predominantly arises from the transformation zone of the cervix and typically expands locally before metastasizing to regional lymph nodes or distant organs. Early-stage detection often leads to a favorable prognosis with high survival rates.\n- **Endocervical adenocarcinoma** originates from glandular cells of the cervix, often detected at a later stage due to subtler symptoms, leading to a generally poorer prognosis compared to SCC.\n\n**Biological Rationale:**\n- SCCs are more likely to be caught early due to more definitive symptom presentation and established screening protocols (e.g., PAP smear).\n- Adenocarcinomas tend to spread earlier and asymptomatically, evading early detection, which negatively impacts survival.\n\n**Treatment Accessibility:**\n- SCC generally benefits from established treatment regimens like radiation and chemotherapy. Adenocarcinomas require different approaches, sometimes limited by late-stage diagnosis.\n\n### 2. Histology\n**Influence on Survival:**\n- Histological variance determines how aggressive a tumor might be. SCC typically shows a slower progression compared to adenocarcinoma.\n- Histological grading informs prognosis, with poorly differentiated tumors having worse outcomes.\n\n**Biological Rationale:**\n- The mutation profile—such as PI3K pathway involvement in adenocarcinomas—affects tumorigenesis, influencing treatment responses and survival.\n\n**Genomic Interpretation Bias:**\n- Biopsy samples may miss heterogeneous tumoral components, leading to an underestimation of aggressive clones' presence.\n\n### 3. Sampling Bias\n**Limitations in Genomic Analysis:**\n- **Blood Derived Normal vs. Primary Tumor Samples:** \n   - Blood samples may not accurately reflect tumor mutations, especially when considering circulating tumor DNA which may be low or absent.\n   - Primary tumor samples reveal localized mutational burdens but may miss metastases-driven alterations.\n\n**Potential Biases:**\n- Tissue-specific mutations or resistance mechanisms in metastatic sites might not be captured, biasing survival prediction.\n\n### 4. Key Genes\n**Survival-Associated Genes:**\n\n1. **TP53:** Mutation disrupts apoptotic regulation, fostering unchecked proliferation. A negative impact due to many SCC and adenocarcinomas having p53 pathway disruptions.\n   \n2. **PIK3CA:** Often mutated in adenocarcinoma, enhancing survival signaling. This mutation generally correlates with poor prognosis due to resistance to targeted therapies.\n\n3. **CDKN2A (p16):** Commonly altered in HPV-associated cancers like cervical SCC. Loss of function leads to cell cycle dysregulation, although its presence commonly indicates HPV positivity, which, paradoxically, might imply better outcomes due to responsiveness to treatment.\n\n4. **KMT2C:** Epigenetic regulation is essential in cell differentiation and proliferation, with mutations potentially contributing to worse outcomes by influencing tumor initiation and progression.\n\n5. **TEP1:** A factor in telomerase activity modulating cellular lifespan, where its alteration can promote immortalization of cancerous cells.\n\n6. **BRCA1/2:** Although more known in breast/ovarian cancers, mutations here indicate possible genetic instability and may impact treatment impacts via chemoresistance.\n\n7. **ERBB2 (HER2):** Overexpression conveys aggressive tumor biology, and when present, generally portends a negative impact on survival though new targeted therapies are improving outlooks.\n\n### Conclusion: Key Survival Risk Factors\n\nThe interplay between tumor origin, histological subtype, and genetic mutations fundamentally directs treatment response and survival outcomes. SCC typically presents better due to more predictable symptomatic manifestation and established screening, whereas adenocarcinomas’ insidious nature leads to poorer prognoses. Genetic insights reveal crucial mutations like TP53 impacting regulatory pathways critical for cell survival and apoptosis. Diagnostic challenges remain in genomic analyses owing to sampling biases, highlighting the need for comprehensive tissue analysis to tailor therapies effectively. Clinically, protocols must evolve with a focus on integrating genetic and histological data to personalize treatment strategies, ultimately striving to improve survival outcomes across cervical cancer subtypes."
        ],
        [
         "7",
         "Blood Derived Normal, Primary Tumor",
         "Cholangiocarcinoma",
         "TCGA-5A-A8ZF, TCGA-4G-AAZG, TCGA-W5-AA2J, TCGA-ZH-A8Y3, TCGA-ZK-AAYZ, TCGA-W5-AA2M, TCGA-ZH-A8Y7, TCGA-5A-A8ZG, TCGA-W6-AA0T, TCGA-W5-AA2K",
         "### Tumor Origin\n\n**Influence on Survival:**\n1. **Metastatic Patterns:**\n   - Cholangiocarcinoma (CCA) originates from the bile duct epithelium. Metastasis is typically observed in the liver, lungs, and peritoneum. This metastatic spread accelerates disease progression and reduces survival rates due to the critical functions of affected organs.\n\n2. **Survival Impact:**\n   - Survival is generally poor due to late-stage diagnosis, often only apparent once significant metastasis has occurred.\n\n3. **Treatment Accessibility:**\n   - Treatment is complicated by the tumor's location, impacting surgical resectability and accessibility for therapies such as ablative techniques.\n\n**Biological Rationale:**\n- Tumor location within the bile duct can lead to earlier dissemination via the biliary tract and lymph nodes. This aggressive progression complicates early detection, often resulting in advanced disease states when diagnosed.\n\n**Potential Bias:**\n- Early-stage CCA may be underrepresented in studies due to late diagnosis, leading to an overestimation of mortality rates in analyzed cohorts.\n\n### Histology\n\n**Influence on Survival:**\n1. **Interaction with Mutation Profiles:**\n   - Cholangiocarcinoma exhibits diverse histological types, including intrahepatic, perihilar, and distal forms, each associated with distinct mutational landscapes affecting therapeutic response and survival.\n\n**Biological Rationale:**\n- Tumor histology can indicate specific genetic mutations, such as IDH1/2 and FGFR2, which define the tumor's behavior, including progression speed and resistance to certain treatments.\n\n**Potential Bias:**\n- Histological heterogeneity might lead to sampling biases wherein certain subtypes are underrepresented, skewing data interpretation in genomic studies.\n\n### Sampling Bias\n\n**Influence on Survival:**\n1. **Limitations of Sample Type:**\n   - Blood-derived normals may not reflect the mutational burden present within actual tumor tissues, affecting survival data accuracy.\n\n2. **Impact on Genomic Analysis:**\n   - Primary tumors provide more relevant information but face challenges in obtaining high-quality, representative samples due to tumor heterogeneity.\n\n**Biological Rationale:**\n- Differences in mutation load between blood samples and primary tumors can lead to underestimation of tumor aggression and resistance profiles if not properly accounted for.\n\n**Potential Bias:**\n- Genomic analyses based on non-tumor tissues might misrepresent the tumor's true genetic landscape, impacting the interpretation of prognostic markers.\n\n### Key Genes\n\n**Influence on Survival:**\n1. **IDH1/2:**\n   - Mutations here can lead to altered metabolic pathways, supporting cell growth and decreased apoptosis, thus worsening survival prospects.\n\n2. **FGFR2:**\n   - Fusion events can promote continuous activation of growth signals, leading to uncontrolled proliferation and reduced survival.\n\n3. **KRAS:**\n   - Mutations result in persistent growth factor signaling, promoting survival through enhanced tumor proliferation and resistance to apoptosis.\n\n4. **BAP1:**\n   - Alterations in BAP1 disrupt chromatin, affecting gene expression patterns that regulate cell cycle control and apoptosis.\n\n5. **TP53:**\n   - Mutations in TP53 abolish cell cycle regulation and apoptosis, leading to unchecked tumor growth and poorer outcomes.\n\n6. **ARID1A:**\n   - The loss of function can lead to changes in chromatin remodeling, affecting transcription and increasing cell survival through immune evasion.\n\n7. **NTRK Fusion:**\n   - Promotes tumor growth via constitutive activation of growth pathways, reducing survival due to aggressive cancer progression.\n\n**Biological Mechanisms:**\n- These key genes affect various pathways, including cell growth, apoptosis, and immune response, significantly influencing clinical outcomes.\n\n**Potential Bias:**\n- Variability in detecting these mutations across patient populations can bias survival predictions due to differential expression patterns.\n\n### Synthesis of Key Survival Risk Factors\n\nUnderstanding the interplay of tumor origin, histological type, genetic mutations, and sampling biases is crucial in assessing cholangiocarcinoma prognosis. Late-stage diagnosis due to poor initial symptomatic presentation leads to lower survival rates. Histological and genetic heterogeneity requires personalized approaches for better management and therapeutic outcomes. Recognizing these factors can inform targeted therapies, ultimately improving patient survival by personalizing treatment strategies according to distinct genetic and histological profiles.\n\nIn conclusion, integrating comprehensive genomic profiling with clinical presentation is fundamental in accurately predicting and enhancing survival outcomes in cholangiocarcinoma patients."
        ],
        [
         "8",
         "Blood Derived Normal, Primary Tumor",
         "Colon adenocarcinoma",
         "TCGA-G4-6314, TCGA-AA-3815, TCGA-AA-3967, TCGA-G4-6310, TCGA-AA-A02K, TCGA-AA-3861, TCGA-AA-3672, TCGA-AA-3556, TCGA-AA-3862, TCGA-AA-3972, TCGA-AA-3860",
         "**Tumor Origin and Metastatic Patterns:**\n\n1. **Influence on Survival:**\n   - Colon adenocarcinoma primarily originates from epithelial cells in the colorectal mucosa. Its potential to metastasize significantly impacts patient survival, commonly spreading to the liver, lungs, and peritoneum.\n   - Metastatic spread decreases survival rates due to local complications in affected organs and increased difficulties in surgical resection or targeted therapy.\n   \n2. **Biological Rationale:**\n   - The tumor's origin in the colon enables it to exploit local blood and lymphatic systems, facilitating dissemination.\n   - Liver metastasis is particularly common due to direct drainage from the mesenteric veins into the portal venous system.\n\n3. **Treatment Accessibility:**\n   - Metastatic colon cancer often requires systemic chemotherapy, with limited effectiveness in advanced stages. Surgical options are possible for isolated lesions but typically decrease in feasibility with wider spread.\n\n**Histology and Mutation Profiles:**\n\n1. **Influence on Survival:**\n   - The histological grade (i.e., well-differentiated vs. poorly differentiated) impacts prognosis, with poorer differentiation correlating with worse outcomes.\n   - Mutation profiles, such as KRAS, NRAS, and BRAF, significantly modify treatment options and survival prospects.\n\n2. **Biological Rationale:**\n   - Genetic mutations in colon adenocarcinomas can activate signaling pathways such as MAPK and PI3K, promoting tumor proliferation, angiogenesis, and resistance to apoptosis, crucially modifying survival chances.\n\n**Sampling Bias:**\n\n1. **Influences on Genomic Analysis:**\n   - Biased sampling from blood-derived normal tissue versus primary tumors can lead to inconsistent mutational landscape assessments, potentially misinforming treatment decisions.\n   \n2. **Biological Rationale:**\n   - Blood-derived samples might not reflect the heterogeneous tumor microenvironment or clonal evolution present in primary tumors.\n   - Discrepancies in genomic profiles between primary tumors and distant metastases can impact the therapeutic strategy and outcome.\n\n3. **Potential Biases:**\n   - Sampling techniques that do not consider tumor heterogeneity can overlook significant driver mutations, leading to ineffective targeting of therapies and less accurate prognostication.\n\n**Key Genes Influencing Survival:**\n\n1. **APC (Adenomatous Polyposis Coli):** \n   - Dysfunction in APC leads to Wnt pathway activation, promoting adenomatous growth and potential malignant transformation.\n   \n2. **TP53:**\n   - Mutations disrupt cell cycle regulation and apoptosis, contributing to unchecked proliferation and poor survival.\n   \n3. **KRAS:**\n   - Oncogenic forms of KRAS promote cellular growth and survival, complicating therapeutic targeting (e.g., resistance to EGFR inhibitors).\n\n4. **BRAF:**\n   - Mutations such as V600E in BRAF are associated with poor prognosis due to aggressive tumor behavior and resistance to conventional therapies.\n\n5. **PIK3CA:**\n   - Alterations in PIK3CA enhance PI3K pathway signaling, fostering survival and resistance through metabolic advantages.\n   \n6. **SMAD4:**\n   - Loss of SMAD4 function, involved in TGF-beta signaling, is associated with increased invasiveness and metastasis, reducing survival.\n\n**Key Synthesis:**\n\n- Colon adenocarcinoma survival is multifactorially influenced by tumor origin, metastatic potential, histological properties, genetic mutations, and inherent biases in genomic sampling.\n- Key survival trends indicate a dire need for comprehensive genomic profiling, considering the tumor's heterogeneity to guide precision medicine.\n- Clinically, understanding specific mutational landscapes can refine treatment regimens, tailoring targeted therapies to bolster patient survival rates. Effective management involves a holistic approach integrating surgical, chemotherapeutic, and targeted strategies while considering potential genomic interpretation biases."
        ],
        [
         "9",
         "Blood Derived Normal, Primary Tumor",
         "Esophageal carcinoma",
         "TCGA-IC-A6RF",
         "Certainly, let's delve into the complexities of esophageal carcinoma, focusing on the key factors impacting patient survival.\n\n### Tumor Origin\n- **Influence on Survival**: Esophageal carcinoma originates in the esophagus, a component of the alimentary canal, with cancers generally categorized into squamous cell carcinoma and adenocarcinoma types. This origin dictates both metastatic potential and treatment strategies, thereby influencing survival rates. Adenocarcinoma, often linked to Barrett’s esophagus due to gastroesophageal reflux disease, frequently metastasizes to abdominal lymph nodes and the liver, whereas squamous cell carcinoma more commonly involves the thoracic lymphatic system and lungs.\n  \n- **Biological Rationale**: The location and structural composition of the esophagus allow for extensive lymphatic dissemination, meaning that once cancer penetrates the submucosal layer, it can rapidly spread. This leads to lower survival rates due to the difficulty in early detection and limited curative treatment options once systemic spread occurs.\n\n- **Treatment Accessibility**: The type of esophageal cancer can influence treatment accessibility: for instance, adenocarcinomas may be targeted more effectively with therapies like trastuzumab if HER2 overexpression is present.\n\n### Histology\n- ** Influence on Survival**: Histological differentiation impacts treatment response, with poorly differentiated tumors generally indicated worse prognosis. Histological types interact with specific mutational profiles which correlate with diverse treatment outcomes.\n\n- **Biological Rationale**: Adenocarcinomas often harbor mutations in TP53, ERBB2, and VEGFA, while squamous carcinomas might demonstrate overamplification of the SOX2 gene. The presence or absence of such mutations can influence tumor aggressiveness and response to chemotherapy or targeted therapies.\n\n### Sampling Bias\n- **Influence on Genomic Interpretation**: Sampling biases arise when using blood-derived normal samples or analyzing only primary tumors. These biases can lead to underrepresentation of tumor heterogeneity and an inaccurate estimation of mutational landscapes that influence treatment decisions and survival predictions.\n\n- **Biological Rationale**: Blood-derived normal samples used as controls might introduce noise in genomic analyses because they do not account for field cancerization, a phenomenon where genetic alterations are present in apparently normal tissue adjacent to tumors.\n\n- **Limitations**: Without comprehensive sampling, key driver mutations or mechanisms, such as those conferring drug resistance, may be overlooked.\n\n### Key Genes Impacting Survival\n1. **TP53**: This tumor suppressor gene, when mutated, leads to compromised DNA repair and apoptosis, facilitating unchecked cellular proliferation.\n2. **ERBB2 (HER2)**: Overexpression can be targeted by therapies like trastuzumab, improving survival in adenocarcinomas.\n3. **VEGFA**: Promotes angiogenesis; inhibitors (e.g., bevacizumab) used to counteract this can extend survival.\n4. **CDKN2A**: Mutation results in deregulation of cell cycle control, contributing to tumor growth.\n5. **SOX2**: Often amplified in squamous cell carcinoma, its role in stemness and differentiation promotes aggressive tumor behavior.\n6. **ADAM17**: Contributes to tumor progression and metastasis through the shedding of membrane proteins.\n7. **MET**: Its activation is associated with poor prognosis due to enhanced invasive capabilities and resistance to apoptosis.\n\n### Conclusion\nThe survival impact in esophageal carcinoma is influenced by a multifaceted interplay of tumor origin, histological diversity, genetic mutations, and methodological biases in genomic analyses. Key survival risk factors include early metastatic potential and specific genetic alterations that can be targeted therapeutically, highlighting the importance of personalized treatment strategies. Understanding these elements helps refine prognostic predictions and optimize therapeutic interventions, potentially improving patient outcomes. These insights advocate for a holistic approach towards diagnosis, integrating detailed pathological assessment with advanced genomic profiling to effectively guide clinical decision-making."
        ],
        [
         "10",
         "Blood Derived Normal, Primary Tumor",
         "Glioblastoma multiforme",
         "TCGA-06-6391, TCGA-19-1788, TCGA-06-0209, TCGA-28-1745",
         "### Tumor Origin\n\n**Influence on Survival:**\nGlioblastoma multiforme (GBM) originates in the glial cells of the central nervous system, typically within cerebral hemispheres. As a primary brain tumor, it rarely metastasizes beyond the CNS due to the blood-brain barrier restricting tumor cell dissemination. This tumor's intracranial nature complicates surgical resection and often hampers access to effective treatment modalities like chemotherapy and radiotherapy given their limited penetration through the blood-brain barrier.\n\n**Biological Rationale:**\nThe local aggressiveness of GBM is primarily due to rapid proliferation, infiltration into surrounding brain tissues, and inherent resistance to apoptosis. The inability for the immune system to effectively surveil the CNS further exacerbates its rapid progression.\n\n**Impact on Treatment and Accessibility:**\nDue to its protected and isolated location, treatment strategies are constrained, often relying on maximal surgical resection followed by temozolomide and radiation. However, median survival post-diagnosis remains at roughly 15 months.\n\n### Histology\n\n**Interaction with Mutation Profiles:**\nHistologically, GBM is marked by necrosis and microvascular proliferation. These features correlate with a mutational landscape dominated by alterations like EGFR amplification, IDH mutations, and MGMT promoter methylation, each influencing prognosis and therapeutic effectiveness.\n\n**Biological Rationale:**\n- **EGFR Amplification:** Drives aggressive proliferation.\n- **IDH Mutations:** Typically predict better outcomes as they signify a different GBM subtype with slower progression.\n- **MGMT Promoter Methylation:** Indicates enhanced response to alkylating agents like temozolomide, potentially improving survival.\n\n### Sampling Bias\n\n**Limitations in Genomic Analysis:**\nAnalyses often utilize peripheral blood or primary tumor samples, each presenting inherent biases. Blood-derived normals might miss intra-tumoral genomic heterogeneity, while primary tumor samples could overlook specific mutation profiles due to sampling site variability.\n\n**Potential Biases:**\nTumor heterogeneity within the CNS means that single-region sampling can fail to capture the full genomic landscape, leading to incomplete data and possibly skewed understanding of mutation-driven survival factors.\n\n### Key Genes Influencing Survival\n\n1. **EGFR:** Amplification is indicative of aggressive proliferation.\n2. **TP53:** Mutations here can prevent apoptosis, facilitating tumor survival and growth.\n3. **IDH1/IDH2:** Mutations tend to represent a prognostically favorable subgroup with slower tumor progression.\n4. **MGMT:** Its promoter's methylation status can predict favorable response to chemotherapeutics, enhancing patient survival.\n5. **PTEN:** Loss of function mutations can hyperactivate the PI3K/AKT pathway, promoting survival through enhanced cell growth and survival signaling.\n6. **TERT Promoter:** Mutations often lead to increased telomerase activity, granting cells greater replicative potential and contributing to tumor growth.\n7. **CDKN2A/B:** Deletions lead to loss of tumor suppressive functions, resulting in unchecked cell cycle progression.\n\n**Biological Mechanisms:**\n- Proliferation: EGFR, TERT, CDKN2A/B\n- Apoptosis Regulation: TP53, PTEN\n- Immune Response/Metabolism: IDH1/IDH2, MGMT\n\n### Conclusion\n\nIn summary, the primary and isolated nature of GBM, its aggressive histology, and specific genomic mutations profoundly impact patient survival, often negatively. While certain genetic anomalies such as MGMT promoter methylation and IDH mutations associate with improved outcomes, the overall prognosis remains dire due to late presentation and challenging treatment logistics. Continuous efforts in understanding the complex interplay of these factors are critical for devising more effective therapies, ultimately aiming to improve individualized patient care and survival prospects. Efforts to mitigate sampling biases and improve comprehensive genomic profiling are vital to advancing the precision oncology arena for GBM."
        ],
        [
         "11",
         "Blood Derived Normal, Primary Tumor",
         "Head and Neck squamous cell carcinoma",
         "TCGA-BA-4075, TCGA-CX-7082, TCGA-CQ-A4C7, TCGA-BA-4077, TCGA-CQ-6221",
         "### Tumor Origin\n\n1. **Metastatic Patterns and Survival Impact**:\n   - **Influence on Metastasis**: Head and Neck Squamous Cell Carcinoma (HNSCC) often originates in the mucosal surfaces of the oral cavity, pharynx, and larynx. These regions have rich lymphatic drainage, which predisposes them to regional lymph node metastasis. This pattern significantly impacts survival because metastatic spread to lymph nodes is a strong poor prognostic indicator.\n   - **Treatment Accessibility**: Given their location, tumors in the head and neck often require a multidisciplinary approach, including surgery, radiation, and chemotherapy. Accessibility to comprehensive treatment impacts survival, as delayed or incomplete treatment can lead to poorer outcomes.\n\n2. **Biological Rationale**:\n   - **Regional Spread**: The proximity of primary tumors to vital structures complicates complete surgical excision, often necessitating adjuvant therapies. The ability to access and afford such therapies profoundly impacts long-term survival rates.\n\n### Histology\n\n1. **Histological Characteristics**:\n   - **Interaction with Mutation Profiles**: The squamous histology of these tumors is typically characterized by a high mutation burden, often driven by carcinogenic exposures like tobacco and HPV. These mutations can influence key signaling pathways, affecting tumor growth, apoptosis, and immune evasion.\n\n2. **Impact on Survival**:\n   - **Prognostic Markers**: Certain histological features, such as the degree of keratinization and differentiation, are predictive of outcomes. HPV-positive squamous cell carcinomas, for instance, often respond better to treatment and exhibit improved survival, reflecting the interaction of histology with the viral microbiome component.\n\n### Sampling Bias\n\n1. **Genomic Analysis Challenges**:\n   - **Blood Derived Normal (BDN) vs. Primary Tumor**: BDN samples may not reflect the mutational landscape of the tumor because they lack tumor-specific mutations. Primary tumor samples are ideal but may be subject to intratumoral heterogeneity.\n   \n2. **Potential Biases**:\n   - **Analytical Limitations**: The reliance on BDN samples for a normal genomic baseline can introduce bias, as these samples might miss critical somatic mutations present in the tumor. Additionally, variability within a tumor sample can skew results, impacting the accuracy of mutation identification relevant to patient survival.\n\n### Key Genes\n\n1. **Survival-Associated Genes**:\n   - **TP53**: Mutations in TP53 can lead to loss of apoptosis regulation and increased genomic instability, negatively impacting survival.\n   - **CDKN2A**: This gene regulates cell cycle progression. Mutations here often result in uncontrolled proliferation.\n   - **NOTCH1**: Involved in cell differentiation and survival, with mutations often leading to aberrant cell cycle control.\n   - **EGFR**: Overexpression or mutation drives proliferation, angiogenesis, and metastasis.\n   - **PIK3CA**: Part of the PI3K-AKT pathway, influencing cell growth and survival.\n   - **FAT1**: Mutations can disrupt cell adhesion and migration, contributing to metastatic potential.\n   - **CASP8**: Involves apoptosis; mutations may confer resistance to cell death.\n\n2. **Biological Mechanisms**:\n   - **Proliferation and Apoptosis**: Mutations in these genes often impact pathways governing cell growth, survival, and apoptosis. This dysregulation facilitates tumor growth and resistance to therapies.\n\n### Synthesis of Key Survival Risk Factors\n\nCombining these insights:\n- **Key Risk Factors**: The origin and metastatic potential, histological subtype, genetic mutations, and sampling biases collectively frame the survival landscape for HNSCC patients. Tumor-specific genetic and histological profiles drive treatment resistance and aggressive behavior, while sampling biases in genomic analysis can obscure these critical insights.\n- **Clinical Relevance**: Effective management necessitates early detection, accurate histological assessment, and thorough genomic profiling to tailor treatment strategies. Key gene mutations should guide therapeutic choices and prognostic evaluations, underscoring the need for personalized medicine approaches in HNSCC.\n- **Impact on Survival**: Understanding these principles allows us to intervene more effectively, prognosticate more accurately, and ultimately improve patient survival through targeted therapies and comprehensive care pathways."
        ],
        [
         "12",
         "Blood Derived Normal, Primary Tumor",
         "Kidney renal clear cell carcinoma",
         "TCGA-B2-5636, TCGA-DV-5573, TCGA-DV-5568, TCGA-B8-A54K",
         "To comprehensively understand the impact of Kidney Renal Clear Cell Carcinoma (KIRC) on patient survival, we must evaluate it through multiple facets including tumor origin, histological characteristics, genomic mutations, and inherent biases in genomic data interpretation.\n\n### Tumor Origin:\n1. **Influence on Metastatic Patterns**: KIRC primarily originates in the renal cortex, typically presenting as a clear cell histology due to its lipid-rich cytoplasm. Its propensity to invade renal vasculature facilitates hematogenous dissemination, most commonly to lungs, bones, liver, and brain. This metastatic potential significantly diminishes survival due to the complexity in managing widespread disease.\n   \n2. **Patient Survival and Treatment Accessibility**: Given its origin, KIRC is often asymptomatic in early stages and frequently detected in advanced states, impacting survival negatively. Targeted therapies such as tyrosine kinase inhibitors and immune checkpoint blockers are central treatments but may be inaccessible due to cost or geographical limitations, further affecting outcomes.\n\n### Histology:\n1. **Mutation Profiles and Outcomes**: KIRC is marked by mutations primarily in the VHL gene (von Hippel-Lindau), leading to dysregulation of hypoxia-inducible factors. This alteration drives angiogenesis and tumor proliferation. Other common mutations include PBRM1, SETD2, and BAP1, each correlating variably with survival depending on their influence on chromatin remodeling, DNA repair, and ubiquitination pathways.\n\n2. **Survival Impact**: Higher expression of angiogenesis-related genes and suppression of apoptotic pathways generally correlate with poorer outcomes. Understanding histological influence on these mutation profiles aids in predicting responsiveness to therapies like VEGF inhibitors.\n\n### Sampling Bias:\n1. **Blood Derived Normal vs. Primary Tumor**: Genomic analysis often compares tumor tissue against matched blood-derived normal samples, which can introduce biases as blood may not reflect normal renal cellular genotype. Primary tumors may harbor different mutations or microenvironmental factors influencing survival.\n   \n2. **Genomic Analysis Limitations**: Primary tumor samples may display intratumoral heterogeneity not captured in a single-biopsy sample, potentially skewing interpretations of mutation prevalence or therapeutic targets.\n\n### Key Genes Associated with Survival:\n1. **VHL**: Its mutation leads to increased HIF activity, promoting angiogenesis and tumor growth, negatively impacting survival.\n2. **PBRM1**: Loss of function affects chromatin remodeling, often associated with better prognosis possibly due to distinct inflammatory tumor microenvironment.\n3. **BAP1**: Tumors with loss of BAP1 have more aggressive biology linked with poor outcomes.\n4. **SETD2**: Mutations here affect DNA repair and chromatin structure, potentially inducing genomic instability with negative survival implications.\n5. **MTOR**: Its dysregulation can drive cell growth and survival, impacting responsiveness to mTOR inhibitors.\n6. **CD274 (PD-L1)**: Overexpression on tumor cells can inhibit immune surveillance, tied to worse outcomes unless targeted by checkpoint inhibitors.\n7. **TP53**: Though less common in KIRC, its mutation leads to impaired apoptosis regulation, worsening prognosis.\n8. **PTEN**: Loss of this tumor suppressor is correlated with poor outcomes due to enhanced proliferative signaling.\n\n### Synthesis of Key Survival Risk Factors:\nSurvival in KIRC is intricately tied to the interplay of metastatic potential, mutation profiles, and treatment strategies. Tumor originating from the kidney's anatomically favorable position for vascular invasion drastically affects metastatic burden and therapeutic response. Histologic diversity driven by specific genetic alterations like those in VHL and PBRM1 offers prognostic insights but requires integration with clinical factors for a holistic treatment approach. Sampling biases, especially regarding primary tissue heterogeneity and reliance on blood-normal baselines, call for judicious data interpretation to tailor patient-specific interventions.\n\nUltimately, understanding the convergence of these factors informs clinical decision-making, highlighting the necessity for precision in genomic characterization and personalized treatment to optimize patient survival outcomes."
        ],
        [
         "13",
         "Blood Derived Normal, Primary Tumor",
         "Kidney renal papillary cell carcinoma",
         "TCGA-AL-3468, TCGA-5P-A9KF, TCGA-AL-A5DJ, TCGA-SX-A71W, TCGA-PJ-A8JU, TCGA-B1-A47O",
         "**Tumor Origin and Metastatic Patterns:**\n\nKidney renal papillary cell carcinoma (KPRC) originates from the renal tubules and is a subtype of renal cell carcinoma (RCC). This origin influences its metastatic potential and patterns. Unlike clear cell RCC, which often metastasizes to the lungs and bones, KPRC tends to have less aggressive metastatic behavior but still poses significant survival concerns.\n\n- **Influence on Survival:** The less aggressive nature of KPRC compared to some other RCCs may contribute to relatively better survival outcomes. However, when metastasis occurs, the typical sites like lymph nodes and lungs still signify a poorer prognosis.\n- **Biological Rationale:** The renal origin and path of metastasis are driven by the tumor’s propensity to use the renal veins for dissemination, reflecting in the lymphovascular invasion.\n- **Treatment Accessibility:** Due to its origin, nephron-sparing surgeries or targeted therapies (e.g., anti-VEGF) may be more applicable in early stages, positively influencing survival).\n\n**Histology and Mutation Profiles:**\n\nKPRC is characterized by specific genetic aberrations, notably in the MET proto-oncogene.\n\n- **Influence on Survival:** Histological subtypes (Type 1 and Type 2) significantly influence survival, with Type 1 generally associated with better outcomes.\n- **Biological Rationale:** Type 1 tumors often express alterations in genes involved in the MET pathway, leading to differences in cellular behavior and responsiveness to MET inhibitors, thereby affecting survival.\n- **Mutation Profiles:** Understanding these profiles helps tailor therapies, improving outcomes particularly in MET-driven cases.\n\n**Sampling Bias:**\n\nBiases arise from genomic analyses relying on specific sample types, like blood-derived normal and primary tumor tissues.\n\n- **Limitations & Influences on Survival Interpretation:** Blood-derived samples might not capture the full heterogeneity of the tumor, potentially skewing survival predictions. Additionally, relying solely on primary tumor samples overlooks metastatic site-specific adaptations.\n- **Biological Rationale:** Tumor heterogeneity means that sampling from a single site (e.g., primary tumor) may not reflect aggressive metastatic clones, leading to potential underestimation of the disease severity.\n- **Addressing the Bias:** More comprehensive sampling, including metastatic sites, could offer a generalized genomic landscape, enhancing prognostic accuracy.\n\n**Key Genes in Survival:**\n\nSeveral genes play pivotal roles in KPRC survival by affecting cellular processes:\n\n1. **MET:** Critical for cell proliferation and motility; mutations here are linked to enhanced tumor aggressiveness and poorer survival.\n2. **HIF1A:** Involved in the hypoxia response, this gene modulates angiogenesis, influencing tumor resilience and resistance to therapy.\n3. **VHL:** Altered VHL impacts degradation of hypoxia-inducible factors, perpetuating angiogenesis, thus impacting survival.\n4. **CDKN2A:** Loss might lead to uncontrolled cell cycle progression, contributing to aggressive tumor growth.\n5. **TP53:** Mutations often contribute to reduced apoptosis and increased survival of aberrant cells.\n6. **SETD2:** Involved in chromatin regulation; mutations are linked with altered genomic stability, affecting tumor development and chemosensitivity.\n\n- **Influence on Survival:** Alterations in these genes lead to various biological malfunctions, impacting tumor growth, resistance to apoptosis, and immune evasion, crucially determining survival outcomes.\n\n**Conclusion and Key Survival Factors:**\n\nThe survival in KPRC is influenced by its genetic and histological makeup, metastatic potential, and the extent of sampling biases. Clinically, recognizing MET-driven tumors, understanding histological differences, and using comprehensive sampling is key to improving prognostic assessments and therapeutic strategies. The interplay of genetic alterations like those in MET and TP53 underlies tumor behavior, while addressing sampling limitations enhances our genomic understanding, directly impacting patient survival outcomes by informing more precise treatment strategies."
        ],
        [
         "14",
         "Blood Derived Normal, Primary Tumor",
         "Liver hepatocellular carcinoma",
         "TCGA-G3-A3CG, TCGA-T1-A6J8, TCGA-XR-A8TC, TCGA-CC-A8HS",
         "### Tumor Origin\n\n**Influence on Survival**\n\nLiver hepatocellular carcinoma (HCC) originates primarily in hepatocytes, the main cell type of the liver. The liver's unique blood supply, receiving both oxygen-rich blood from the hepatic artery and nutrient-rich blood from the portal vein, facilitates rapid tumor growth and progression. HCC can be aggressive, with common metastasis to the lungs, lymph nodes, bones, and adrenal glands, significantly impacting survival negatively. \n\n**Biological Rationale**\n\n- **Metastatic Patterns**: The liver's structure and its extensive vascular network allow for efficient dissemination of cancer cells to the bloodstream, promoting distal metastasis.\n- **Survival Impact**: Early metastasis reduces survival rates, as metastatic disease limits treatment options. Patients often present with advanced stages due to asymptomatic nature in early stages.\n\n**Treatment Accessibility**\n\nHCC complexity and late-stage diagnosis often hinder successful surgical resections or liver transplants, particularly affected by socioeconomic factors and geographic access to care, further reducing survival odds.\n\n### Histology\n\n**Interaction with Mutation Profiles**\n\nHCC histology is highly heterogeneous, influenced by both genetic and environmental factors such as HBV/HCV infections and alcohol consumption.\n\n**Survival Outcomes**\n\n- **Clear Cell and Fibrolamellar Variants**: Typically show better prognosis compared to conventional HCC due to distinct molecular pathways and lower metastatic potential.\n- **Mutation Profiles**: TERT promoter mutations and β-catenin mutations (CTNNB1) often indicate poor prognosis due to their roles in uncontrolled proliferation and evasion of apoptosis.\n\n### Sampling Bias\n\n**Genomic Analysis Limitations**\n\n- **Blood Derived Normal**: These samples can overlook intratumoral heterogeneity, missing crucial mutations only present within tumor samples.\n- **Primary Tumor Sampling**: Often represents a single tumor site; thus, it may fail to capture the full genomic landscape due to the multicentric nature of HCC, where multiple tumors may harbor distinct genetic profiles.\n\n**Influence on Survival**\n\nSampling biases may lead to an underestimation or overestimation of actionable mutations, affecting personalized treatment strategies and overall survival predictions.\n\n### Key Genes and Biological Mechanisms\n\n1. **TERT (Telomerase Reverse Transcriptase)**\n   - **Mechanism**: Chromosomal stabilization and replication - upregulation contributes to sustained proliferation.\n   - **Survival Impact**: Promotes immortalization of cancer cells, leading to poor outcomes.\n\n2. **CTNNB1 (β-catenin)**\n   - **Mechanism**: Wnt signaling pathway activation - drives proliferation and invasion.\n   - **Survival Impact**: Associated with aggressive phenotypes and poor prognosis.\n\n3. **TP53**\n   - **Mechanism**: Tumor suppression via apoptosis regulation.\n   - **Survival Impact**: Mutations lead to ineffective cell cycle control and resistance to cell death.\n\n4. **AXIN1**\n   - **Mechanism**: Regulation of Wnt signaling and β-catenin degradation.\n   - **Survival Impact**: Mutations often lead to lymphatic invasion and metastasis.\n\n5. **RB1 (Retinoblastoma 1)**\n   - **Mechanism**: Cell cycle regulation.\n   - **Survival Impact**: Loss of function results in unchecked progression to S phase, reducing survival.\n\n6. **ARID1A**\n   - **Mechanism**: Chromatin remodeling.\n   - **Survival Impact**: Loss-of-function mutations correlate with poor prognosis due to enhanced genomic instability.\n\n### Conclusion: Synthesis of Key Survival Risk Factors\n\nHCC survival is multifactorially determined, involving rapid progression linked to its origin, the impact of histological variants and genetic mutations, and challenges posed by current biases in genomic sampling. The interplay of genes like TERT, CTNNB1, and TP53 with known etiological factors underscores the invasive nature and heterogeneity of HCC. Clinically, improving early detection, tailoring treatments based on more comprehensive genomic profiling, and addressing systemic inequities in treatment accessibility could enhance patient survival outcomes."
        ],
        [
         "15",
         "Blood Derived Normal, Primary Tumor",
         "Lung adenocarcinoma",
         "TCGA-44-6147, TCGA-44-6147, TCGA-44-2661, TCGA-44-6147, TCGA-44-6147, TCGA-44-6147",
         "### Tumor Origin: \n\n1. **Influence on Metastatic Patterns**: Lung adenocarcinoma typically originates in the peripheral lung tissue. Its propensity for early vascular invasion leads to a high rate of distant metastases, commonly to the brain, bone, and adrenal glands. This impacts survival negatively due to the challenges posed by treating widespread disease.\n  \n2. **Patient Survival**: The survival impact is significant, as advanced stage at diagnosis correlates with poorer outcomes. Earlier stage diagnoses tend to have better survival rates due to the possibility of surgical resection.\n\n3. **Treatment Accessibility**: The location of lung adenocarcinoma may limit surgical resectability, and given its metastatic nature, systemic therapies are often required. Access to targeted therapies can be limited by mutation-specific availability, influencing overall survival negatively if such treatments are inaccessible.\n\n### Histology:\n\n1. **Interaction with Mutation Profiles**: Lung adenocarcinoma often presents with specific mutations such as EGFR, ALK, KRAS, and ROS1, which have distinct treatment implications. For instance, EGFR mutations might respond positively to tyrosine kinase inhibitors (TKIs), improving survival.\n\n2. **Survival Outcome Drivers**: The presence of actionable mutations can result in a more favorable prognosis when targeted therapies are available. Conversely, mutations like KRAS are associated with poorer outcomes due to the lack of effective targeted treatments historically.\n\n### Sampling Bias:\n\n1. **Blood Derived Normal vs. Primary Tumor**: Sampling biases arise when comparing genomic data from peripheral blood (Blood Derived Normal) with primary tumor samples. Blood samples might not capture tumor heterogeneity or specific subclonal mutations, leading to inaccurate assessments of mutation burden or clonality.\n   \n2. **Impacts**: These biases could skew survival predictions or treatment responsiveness, as treatments aligned with inaccurate genomic interpretations may not be effective.\n\n### Key Genes:\n\n1. **EGFR**: Mutations lead to uncontrolled proliferation but are targetable; TKIs can improve survival significantly unless resistance develops.\n\n2. **ALK**: Fusion proteins can drive tumorigenesis; ALK inhibitors prolong survival in affected patients but similar resistance issues may arise.\n\n3. **KRAS**: Often associated with poorer prognosis as effective targeted treatments are limited and these mutations contribute to aggressive tumor behavior.\n\n4. **TP53**: Mutations disrupt apoptotic regulation, leading to unchecked cell division and typically a worse prognosis due to treatment resistance.\n\n5. **BRAF**: Though less common, specific mutations can be actionable with targeted therapies, influencing survival positively if treated accordingly.\n\n6. **PIK3CA**: Involvement in downstream signaling pathways with potential to influence survival, though less pronounced due to current therapeutic approaches.\n\n7. **ROS1**: Similar to ALK, translocations can be targeted with specific inhibitors, significantly extending survival.\n\n### Conclusion:\n\nSynthesizing these aspects, the key survival risk factors include the early detection of lung adenocarcinoma, effective use of and access to targeted therapies, and accurate genomic profiling that accounts for potential biases. Successful navigation of these elements causes significant impacts on patient survival. Early-stage detection and the presence of targetable mutations composed the clearest pathways to improving survival outcomes. Thus, ensuring precise genomic analysis and broadening access to targeted therapies remain pivotal in extending survival for lung adenocarcinoma patients."
        ],
        [
         "16",
         "Blood Derived Normal, Primary Tumor",
         "Lung squamous cell carcinoma",
         "TCGA-NK-A5D1, TCGA-21-A5DI, TCGA-96-A4JK, TCGA-77-8146, TCGA-77-A5GA, TCGA-37-A5EM",
         "To thoroughly discuss the impact of Lung Squamous Cell Carcinoma (LSCC) on patient survival, we will dissect it into the specified categories and integrate these findings into a coherent conclusion.\n\n### Tumor Origin and Metastatic Patterns\n\n1. **Survival Impact**:\n   - **Negative Influence**: LSCC is primarily found in central bronchi and tends to remain localized longer than adenocarcinomas. However, when it metastasizes, it often invades lymph nodes and occasionally spreads to the liver and brain. This late metastatic pattern can initially suggest a better prognosis, but once metastasis occurs, survival diminishes rapidly.\n\n2. **Biological Rationale**:\n   - Squamous cells in the lungs are structured to line airways, contributing to a higher likelihood of forming local obstructions and necrosis, compounding respiratory compromise even before metastasis occurs.\n\n3. **Treatment Accessibility**:\n   - Central tumor location can complicate surgical resection and may limit the effectiveness of targeted radiotherapy, often necessitating systemic chemotherapy, which has more generalized side effects.\n\n### Histology and Mutation Interaction\n\n1. **Survival Influence**:\n   - **Negative**: LSCC is often associated with a high degree of cellular differentiation, leading to aggressive growth patterns and poor chemosensitivity. Mutation profiles significantly modulate these properties.\n\n2. **Mutation Profiles**:\n   - Common mutations in LSCC include TP53, CDKN2A, and FGFR1 amplifications. These mutations enhance tumor proliferation, disrupting cell cycle control and attenuating apoptosis.\n\n3. **Biological Rationale**:\n   - For instance, TP53 mutations undermine DNA repair mechanisms, while CDKN2A mutations disrupt cell cycle arrest, both leading to unchecked tumor growth.\n\n### Sampling Bias and Genomic Interpretation\n\n1. **Limitations of Blood-Derived Normals vs. Primary Tumors**:\n   - **Bias Potential**: Blood-derived normative samples may not accurately reflect mutational landscapes specific to the tumor microenvironment, missing pertinent mutation data that influences treatment response and survival predictions.\n\n2. **Impact on Survival Analysis**:\n   - This sampling bias can skew tumor mutation burden assessments, leading to inappropriate therapy choices that don't account for key genomic features (e.g., underestimating the need for immune checkpoint inhibitors).\n\n### Key Genes Influencing Survival\n\n1. **EGFR**:\n   - Survival Impact: Generally less role in LSCC, but mutations can alter responsiveness to tyrosine kinase inhibitors.\n   - Mechanism: Tyrosine kinase signaling promotes proliferation.\n\n2. **TP53**:\n   - Role: Loss-of-function mutations hinder apoptosis, contributing to survival detriment.\n   - Mechanism: Inhibition of p53-mediated transcriptional regulation of apoptotic genes.\n\n3. **CDKN2A**:\n   - Role: Inactivation facilitates cell cycle progression unchecked by Rb pathway.\n   - Mechanism: Loss of G1/S checkpoint control increases proliferation.\n\n4. **FGFR1**:\n   - Role: Amplification can lead to enhanced proliferation and angiogenesis.\n   - Mechanism: FGFR signaling cascade encourages cell growth and vessel formation.\n\n5. **PIK3CA**:\n   - Role: Mutations enhance PI3K pathway signaling, promoting growth and resistance to apoptosis.\n   - Mechanism: Activation of AKT/mTOR signaling for survival and proliferation.\n\n6. **PTEN**:\n   - Role: Loss contributes to unchecked PI3K pathway activity.\n   - Mechanism: Suppression of tumor suppressor leading to enhanced survival pathway signaling.\n\n### Conclusion\n\nThe survival of patients with LSCC is intricately tied to multiple factors, emphasizing the need for comprehensive diagnostic approaches that integrate histological, genetic, and clinical data. Despite its initial centralized growth pattern, LSCC presents severe survival challenges once metastasis occurs. Histological characteristics compounded by specific gene mutations like TP53, CDKN2A, and FGFR1 play critical roles in its aggressive progression and poor treatment response. Sampling biases further complicate genomic interpretations, necessitating careful selection of biological material to accurately predict and tailor therapeutic regimens. Understanding these intricate networks offers pathways to improving patient survival through personalized medicine and targeted interventions, underscoring the ongoing need for precise molecular analyses in the clinical setting."
        ],
        [
         "17",
         "Blood Derived Normal, Primary Tumor",
         "Ovarian serous cystadenocarcinoma",
         "TCGA-24-2036, TCGA-36-2539",
         "### Tumor Origin\n\n1. **Influence on Metastatic Patterns:**\n   - **Impact on Survival:** Ovarian serous cystadenocarcinoma typically originates from the epithelial cells lining the fallopian tube fimbriae and often presents at an advanced stage due to vague early symptoms. It commonly spreads within the peritoneal cavity and the omentum, leading to extensive disease burden.\n   - **Biological Rationale:** The origin from epithelial cells lends the tumor increased potential for epithelial-mesenchymal transition (EMT), facilitating metastasis. This disseminated intra-abdominal spread leads to poorer prognosis and survival rates.\n   - **Treatment Accessibility:** Early detection is difficult, impacting timely intervention. Intraperitoneal chemotherapy is an effective treatment, but the advanced stage at diagnosis often limits surgical options.\n\n### Histology\n\n2. **Interaction with Mutation Profiles:**\n   - **Impact on Survival:** High-grade serous ovarian carcinoma (HGSOC) is characterized by complex chromosomal alterations and mutations in BRCA1/2, often driving aggressive disease progression and resistance.\n   - **Biological Rationale:** BRCA mutations impair DNA repair mechanisms, making tumors susceptible to platinum-based therapies initially, but also lead to rapid development of resistance over time. The presence of p53 mutations further disrupts cell cycle control, exacerbating tumor aggression.\n   - **Potential Biases:** Histological analysis can miss certain molecular features if sampling is not representative, possibly underestimating genomic instability and mutation frequency.\n\n### Sampling Bias\n\n3. **Limitations of Blood Derived Normal, Primary Tumor in Genomic Analysis:**\n   - **Impact on Survival Interpretation:** Comparison of tumor samples against blood-derived normal tissue may overlook tissue-specific genomic variations. Primary tumor samples may fail to capture metastatic diversity.\n   - **Biological Rationale:** The heterogeneity within a tumor means a single biopsy might not reflect the full genomic landscape, potentially underrepresenting actionable mutations that influence therapy decisions.\n   - **Biases:** Sampling biases can lead to skewed interpretations of mutation prevalence and variant impacts, affecting the understanding of survival-linked genetic drivers.\n\n### Key Genes\n\n4. **Survival-Associated Genes:**\n   - **BRCA1/2:** Essential for homologous recombination repair. Mutations here increase initial sensitivity to platinum and PARP inhibitors but later resistance.\n   - **TP53:** Key in maintaining genetic stability. Mutations result in defective apoptosis, leading to unregulated cell growth and survival disadvantage.\n   - **PIK3CA:** Involved in growth signaling pathways; mutations can lead to enhanced growth and survival of cancer cells.\n   - **NRAS/KRAS:** Active in cell proliferation signaling. Mutations promote oncogenic signaling, contributing to aggressive growth and poor outcomes.\n   - **CCNE1:** Overexpression is linked to cell cycle dysregulation and resistance to chemotherapy, reducing survival prospects.\n   - **PTEN:** Tumor suppressor gene involved in cell cycle regulation. Loss-of-function mutations contribute to unchecked proliferation.\n   - **BIRC5 (Survivin):** Inhibits apoptosis, associated with poorer prognosis when upregulated due to enhanced cell survival.\n\n### Synthesis of Key Survival Risk Factors\n\n- **Clinically Relevant Insights:** The most significant survival risk factors in ovarian serous cystadenocarcinoma include advanced stage at diagnosis, specific BRCA1/2 status, and the presence of TP53 mutations. These collectively influence treatment response and survival prospects by dictating sensitivity to chemotherapy and novel targeted agents. \n- **Impact on Patient Survival:** Addressing these factors through personalized medicine approaches, such as the use of PARP inhibitors in BRCA-mutated cases, is crucial. Understanding individual tumor genomics helps in stratifying patients to appropriate therapeutic regimens, ultimately improving overall and progression-free survival outcomes. Integrative approaches that combine histological data with comprehensive genomic profiling can lead to better prognostication and individualized patient care."
        ],
        [
         "18",
         "Blood Derived Normal, Primary Tumor",
         "Pancreatic adenocarcinoma",
         "TCGA-IB-7654",
         "## Tumor Origin\n\n**Impact on Survival:**\n\n1. **Metastatic Patterns:**\n   - Pancreatic adenocarcinoma (PDAC) often originates in the ductal epithelial cells of the pancreas. \n   - It typically metastasizes early, commonly to the liver, peritoneum, and lungs, which leads to a poor prognosis and reduced survival rates.\n\n2. **Survival Influence:**\n   - The propensity for early metastasis results in advanced staging at diagnosis, limiting the effectiveness of local surgical interventions.\n   - Survival is negatively impacted due to limited early diagnosis and the aggressive nature of the origin cells.\n\n3. **Treatment Accessibility:**\n   - Late-stage diagnosis restricts treatment options primarily to systemic therapies, which are less curative and more palliative.\n\n**Biological Rationale:**\n- The tumor origin in the pancreas lends intrinsic resistance to numerous therapies due to its unique stromal environment that supports a pro-survival milieu.\n\n**Potential Biases:**\n- Metastatic spread and treatment resistance might skew clinical trial outcomes, as subsets of patients with indolent disease might be underrepresented.\n\n## Histology\n\n**Interaction with Mutation Profiles:**\n\n1. **Histological Features:**\n   - PDAC is characterized by glandular structures and a desmoplastic stroma, both of which influence therapeutic response and resistance.\n\n2. **Mutation Profile Interaction:**\n   - Common mutations include KRAS, TP53, CDKN2A, and SMAD4. These drive aggressive tumor biology, poor differentiation, and facilitate immune evasion and apoptotic resistance.\n\n3. **Survival Influence:**\n   - Mutations exacerbate the histological complexity, leading to chemoresistance, reduced immune surveillance, and accelerated growth, all of which are detrimental to survival.\n\n**Biological Rationale:**\n- Mutations in genes like KRAS and TP53 lead to uncontrolled proliferation and resistance to cell death, respectively, complicating effective treatment options.\n\n**Potential Biases:**\n- Sampling of the most biologically active regions might overrepresent mutations associated with aggressive behavior vs. benign sections that might have different profiles.\n\n## Sampling Bias\n\n**Limitations in Genomic Analysis:**\n\n1. **Blood-Derived Normals:**\n   - Using blood-derived normal samples as controls may not perfectly mirror the genetic background of pancreatic tissues due to somatic mosaicism.\n\n2. **Primary Tumor Bias:**\n   - Biopsy samples might miss intratumoral heterogeneity, capturing only a subset of the tumor's genetic and histological landscape, leading to biased survival data.\n\n**Impact on Survival Outcomes:**\n- These biases can result in overestimation or underestimation of certain mutation prevalences, subsequently skewing prognostic models and survival predictions.\n\n**Potential Biases:**\n- Tumor heterogeneity and stromal contamination are significant confounders, impacting genomic interpretations and personalized treatment strategies.\n\n## Key Genes\n\n**Survival-Associated Genes:**\n\n1. **KRAS:**\n   - Role: Drives proliferation through continuous activation of signaling pathways (e.g., MAPK/ERK), promoting aggressive tumor growth.\n\n2. **TP53:**\n   - Role: Mutations impair apoptotic regulation, allowing survival of damaged cells, contributing to chemoresistance.\n\n3. **CDKN2A:**\n   - Role: Loss leads to unchecked cellular proliferation due to disabled cell cycle checkpoint control.\n\n4. **SMAD4:**\n   - Role: Loss of this tumor suppressor gene affects TGF-β signaling pathways, facilitating tumor progression and metastasis.\n\n5. **BRCA2:**\n   - Role: Associated with DNA repair dysfunction, enabling genetic instability that accelerates tumor progression.\n\n6. **MUC1:**\n   - Role: Overexpression disrupts cell adhesion, enhancing metastatic potential.\n\n7. **MYC:**\n   - Role: Amplifies growth signals, promoting rapid cell cycle progression and cancer aggressiveness.\n\n**Biological Rationale:**\n- These genes are crucial for cellular processes like the cell cycle, apoptosis regulation, and DNA repair. Their dysregulation fosters an environment conducive to tumor growth, metastasis, and survival inhibition.\n\n**Potential Biases:**\n- The interplay of these genes can vary by tumor microenvironment and patient genetic background, making universal application of findings challenging.\n\n## Synthesis of Key Survival Risk Factors\n\n**Clinically Relevant Insights:**\n\n1. **Early Metastasis:**\n   - Early systemic involvement is a critical determinant of poor prognosis and must be countered with early detection strategies.\n\n2. **Genetic Complexity:**\n   - A combination of mutations results in both therapeutic challenges and opportunities for targeted therapy advancement.\n\n3. **Genomic Understanding:**\n   - Overcoming sampling biases and understanding genetic heterogeneity are essential for more accurate prognostication and treatment planning.\n\nUltimately, the survival impact in pancreatic adenocarcinoma is dominated by its aggressive nature, advanced-stage diagnosis, complex genetic mutations, and limitations in current detection methods. Addressing these challenges could significantly improve survival outcomes and patient management paradigms.\n"
        ],
        [
         "19",
         "Blood Derived Normal, Primary Tumor",
         "Pheochromocytoma and Paraganglioma",
         "TCGA-WB-A820",
         "### Pheochromocytoma and Paraganglioma: Impact on Survival\n\n#### Tumor Origin\n1. **Metastatic Patterns:**\n   - **Pheochromocytoma** primarily originates in the adrenal medulla, whereas **paraganglioma** arises from the extra-adrenal paraganglionic system.\n   - Survival impact is linked to the **site of origin**: adrenal pheochromocytomas are less likely to metastasize compared to extra-adrenal paragangliomas.\n   - Extra-adrenal tumors often manifest aggressive behaviors with distant metastases, particularly to bones, liver, and lungs, negatively influencing survival.\n\n2. **Patient Survival:**\n   - The overall prognosis is stage-dependent: localized tumors have a better prognosis than metastatic or recurrent ones.\n   - Early detection enhances survival via surgical resection, but recurrent or metastatic cases require adjuvant therapies with variable success rates.\n\n3. **Treatment Accessibility:**\n   - Effective treatment relies on surgical possibility and access to targeted therapies, like tyrosine kinase inhibitors, immunotherapy, or PRRT (Peptide Receptor Radionuclide Therapy).\n   - Treatment accessibility impacts disadvantaged patients negatively, exacerbating survival disparities.\n\n#### Histology\n1. **Interaction with Mutation Profiles:**\n   - Pathological features (e.g., necrosis, mitotic rate) integrate with genomic data to refine prognosis.\n   - Specific mutations like SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) are strongly correlated with malignancy, driving poorer outcomes due to aggressive cellular behavior.\n\n2. **Outcomes:**\n   - Tumors exhibiting significant genomic instability and high mitotic index contribute to decreased survival.\n   - Paragangliomas with mutations in genes such as VHL (Von Hippel-Lindau) usually portend worse outcomes due to angiogenesis and proliferation.\n\n#### Sampling Bias\n1. **Blood Derived Normal Bias:**\n   - Genomic analyses often rely on blood-derived DNA, which may not reflect tumor-specific mutations, obscuring mutation prevalence.\n   - These samples cannot assess tumor heterogeneity effectively, potentially leading to underestimation of mutation-driven aggression.\n\n2. **Primary Tumor Analysis:**\n   - Sampling from a primary tumor site may not capture metastatic heterogeneity, leading to misinterpretation of the tumor's malignant potential.\n   - Potential bias arises when comparing samples from diverse tumor microenvironments, as gene expression patterns can vary significantly.\n\n#### Key Genes\n1. **SDHB**: \n   - Drives poor prognosis due to mitochondrial dysfunction leading to oxidative stress and higher metastatic potential.\n   \n2. **VHL**: \n   - Mutations here influence angiogenesis via the HIF (Hypoxia-Inducible Factor) pathway, contributing to aggressive tumor growth.\n\n3. **RET (Rearranged during Transfection)**: \n   - Promotes cell proliferation and differentiation. Mutations often associate with MEN2 syndrome, affecting survival due to early malignancy onset.\n\n4. **NF1 (Neurofibromin 1)**: \n   - NRAS signaling pathway modulation negatively impacts outcomes through unregulated cell cycle progression.\n\n5. **SDHC/D (Another Succinate Dehydrogenase component)**: \n   - Although less common, mutations contribute to defective apoptotic regulation.\n\n6. **MAML3 (Mastermind Like Transcriptional Coactivator 3)**:\n   - Involved in transcriptional dysregulation. Abnormal activity can lead to enhanced tumor cell survival.\n\n### Synthesis of Key Survival Risk Factors\n- **Clinically Relevant Insights:**\n  - Mutation profiles (especially SDHB and VHL) provide substantial survival predictive power.\n  - Histological aggressiveness collates with these mutations, emphasizing the importance of integrative diagnostics.\n  - Accessibility and timing of therapeutic intervention remain crucial for improving outcomes.\n  \n- **Impact on Patient Survival:**\n  - Knowledge of genetic makeup guides personalized treatment plans, aiming to extend survival through targeted therapies and vigilant management of disease progression.\n  - Addressing sampling biases and ensuring inclusive genomic data acquisition will refine prognostic accuracy, enabling better stratification and management.\n\nIn conclusion, the survival impact of pheochromocytoma and paraganglioma is heavily dependent on a combination of genetic, histological, and treatment-access factors. An integrative approach, tackling genetic predispositions and leveraging novel therapeutics, offers the best strategy to enhance patient outcomes."
        ],
        [
         "20",
         "Blood Derived Normal, Primary Tumor",
         "Prostate adenocarcinoma",
         "TCGA-G9-A9S4, TCGA-XK-AAK1, TCGA-XK-AAJ3, TCGA-EJ-7312",
         "Certainly, let's explore Prostate adenocarcinoma and its impact on patient survival by examining tumor origin, histology, sampling biases, and key genetic factors associated with prognosis.\n\n### Tumor Origin\n\n1. **Influences on Metastatic Patterns and Survival**\n   - Prostate adenocarcinoma originates in the epithelial cells of the prostate gland. It is typically an androgen-driven cancer, meaning that androgens fuel tumor growth until resistance develops. This cancer generally progresses slowly but can metastasize to bones, lymph nodes, and other tissues, which significantly worsens prognosis.\n   - **Survival Impact:** Metastasis is a critical determinant of survival. Once the cancer has spread to bones or visceral organs, the 5-year survival rate decreases markedly.\n   - **Treatment Accessibility:** Early detection often allows for localized treatments such as surgery or radiotherapy, which have high cure rates. Advanced stages require systemic therapies like hormone deprivation which can initially be effective but seldom curative.\n\n### Histology\n\n1. **Interaction with Mutation Profiles**\n   - Histologically, prostate adenocarcinoma is characterized by glandular tissue formation. The heterogeneous nature of these tumors implies that drivers like PTEN loss or TMPRSS2-ERG gene fusion can significantly impact outcomes.\n   - **Survival Influence:** Tumors with high-grade histology (Gleason score) suggest more aggressive disease and poorer outcomes. Mutation profiles influence these patterns; for instance, PTEN deletion enhances PI3K/AKT pathway activation, promoting survival and proliferation.\n   - **Biological Rationale:** These mutations influence cellular pathways that regulate cell death, proliferation, and response to androgen deprivation therapy.\n\n### Sampling Bias\n\n1. **Limitations in Genomic Analysis**\n   - **Blood Derived Normals:** These samples provide a reference genome but might not capture intratumoral heterogeneity or somatic mutations exclusive to the tumor.\n   - **Primary Tumor Sampling:** Biopsies might capture only a fraction of tumor diversity, leading to underestimation of genomic alterations relevant for prognosis and treatment.\n   - **Impact on Survival Analysis:** Failure to detect crucial mutations or neoantigens can hinder tailored treatment plans and survival estimations because personalized therapies depend heavily on accurate genomic profiles.\n\n### Key Genes\n\n1. **Survival-Associated Genes**\n   - **TP53, PTEN, BRCA2:** Tumor suppressor genes whose loss is linked to advanced disease and treatment resistance.\n     - **Mechanism:** These genes regulate apoptosis and DNA repair. Mutations lead to unchecked cellular proliferation.\n   - **AR (Androgen Receptor):** Amplification or mutations in AR drive treatment resistance.\n     - **Mechanism:** Promotes survival and growth even in low androgen conditions, posing challenges for androgen deprivation therapy.\n   - **TMPRSS2-ERG Fusion:** Common alteration promoting cancer cell proliferation and invasion.\n   - **MYC:** Overexpression leads to increased tumor aggressiveness.\n   - **RB1:** Loss results in dysregulated cell cycle progression.\n\n### Synthesis of Key Survival Risk Factors\n\n- **Clinically Relevant Insights:**\n  - **Metastasis and Hormone Refractoriness:** Foundation of cancer survival issues as bone metastases drastically reduce survival owing to complications like fractures and marrow infiltration.\n  - **Genetic Landscape:** Identifying mutations such as PTEN, BRCA2, and AR variants is crucial for guiding therapy, particularly in castration-resistant prostate cancer (CRPC).\n  - **Biopsies' Limitations:** Highlight the need for comprehensive genomic profiling, which may require multiple sampling techniques for optimal patient stratification.\n\nIn conclusion, understanding prostate adenocarcinoma’s biological underpinnings and genomic attributes drives effective therapeutic strategies and improves survival predictions, emphasizing precision medicine's importance in oncological care."
        ],
        [
         "21",
         "Blood Derived Normal, Primary Tumor",
         "Rectum adenocarcinoma",
         "TCGA-G5-6235, TCGA-G5-6572, TCGA-AG-A00H, TCGA-AG-3891, TCGA-G5-6233, TCGA-AG-3906, TCGA-AG-A023, TCGA-AG-A014, TCGA-AH-6549, TCGA-BM-6198",
         "### Tumor Origin\n\n**Influence on Survival:**\n- **Metastatic Patterns:** Rectum adenocarcinoma originates in the distal part of the large intestine and has a propensity for metastasis, particularly to the liver and lungs, due to the rich blood supply draining into the portal system. This facilitates hematogenous spread.\n- **Patient Survival:** Early-stage detection generally leads to better outcomes, while advanced metastatic stages significantly reduce survival. Tumor location can affect the feasibility and success of surgical interventions, directly impacting survival rates.\n- **Treatment Accessibility:** The anatomical positioning sometimes restricts surgical options and accurate staging, influencing overall survival.\n\n**Biological Rationale:**\n- Direct invasion of adjacent structures and easier vascular access contribute to rapid dissemination. Accessibility issues, such as proximity to the anal sphincter, influence resectability and meaningful treatment, further impacting prognoses.\n\n**Potential Biases:**\n- Geographic and socioeconomic factors affecting access to specialized surgical and postoperative care might introduce biases in survival data.\n\n### Histology\n\n**Influence on Survival:**\n- **Interactions with Mutation Profiles:** The histological grade of rectum adenocarcinoma correlates with genetic aberrations, influencing the aggressiveness of the disease and therapeutic response. Poorly differentiated tumors often harbor mutations that drive negative survival outcomes.\n\n**Biological Rationale:**\n- Anaplasia in high-grade adenocarcinomas is linked to genetic instability, leading to more aggressive behavior and resistance to treatment modalities.\n\n**Potential Biases:**\n- Sampling from heterogeneous tumor tissues might not accurately reflect the most aggressive components, skewing mutation frequency and their perceived influence on survival.\n\n### Sampling Bias\n\n**Limitations:**\n- **Blood-Derived Normal vs. Primary Tumor:** Blood samples may not effectively represent the tumor genome due to low tumor cell fraction in the circulation.\n\n**Influence on Survival:**\n- Discrepancies between tissue-derived and blood-derived genetic analyses can lead to mischaracterization of actionable mutations or biomarkers influencing treatment strategies and prognostic predictions.\n\n### Key Genes\n\n**Influence on Survival:**\n1. **KRAS:** Mutations result in continued proliferative signaling and therapy resistance, negatively impacting survival.\n2. **TP53:** Loss-of-function mutations prevent proper apoptotic responses, contributing to unchecked growth.\n3. **BRAF:** Mutations may lead to aggressive cancer progression and poor response to therapies, reducing survival.\n4. **APC:** Aberrations precipitate increased Wnt signaling, promoting tumorigenesis.\n5. **SMAD4:** Alterations negatively affect TGF-β pathway integrity, crucial for cell cycle regulation, allowing tumor progression.\n6. **PIK3CA:** Influences survival by enhancing cell survival mechanisms and resistance to apoptosis.\n\n**Biological Mechanisms:**\n- These genes regulate essential processes like cell cycle control, apoptosis, DNA repair, and cellular proliferation. Their mutation profiles offer insights into therapeutic vulnerabilities and survival probabilities.\n\n**Potential Biases:**\n- Tumor heterogeneity, especially sampling depth and variation, could mask or overstate the prevalence of particular genetic mutations.\n\n### Synthesis of Key Survival Risk Factors\n\n**Clinically Relevant Insights:**\n- Early detection and localization can drive effective interventions, underscoring the importance of regular screenings. Highlighting the role of genetic mutations in defining disease aggressiveness clarifies patient stratification for targeted therapies. Precision in sampling methods ensures representative genomic insights, crucial for optimizing treatment plans and improving survival.\n\n**Impact on Patient Survival:**\n- Accurate genetic and histological assessments enable tailored treatment regimens, directly enhancing survival outcomes. Mitigating sampling biases and increasing surgical accessibility are essential steps to improve survival rates among rectum adenocarcinoma patients."
        ],
        [
         "22",
         "Blood Derived Normal, Primary Tumor",
         "Sarcoma",
         "TCGA-PC-A5DM",
         "**Sarcoma: Impact on Survival**\n\n**1. Tumor Origin:**\nSarcoma originates from mesenchymal tissues—such as bone, muscle, fat—which predisposes them to certain metastatic patterns primarily involving lungs and liver. These metastatic sites influence survival negatively due to critical organ involvement and often asymptomatic early spread, leading to delayed diagnosis. \n\n- **Metastatic Patterns:** The mesodermal origin engenders pathways favoring dissemination through vascular systems rather than lymphatic, accelerating metastasis dynamics.\n- **Survival Impact:** Early metastatic spread diminishes survival rates. Treatment is often limited by late presentation and fewer therapeutic agents specific to sarcoma's metastatic biology.\n- **Access to Treatment:** The rarity of sarcoma challenges the availability of targeted therapies or clinical trials, often skewing survival outcomes negatively.\n\n**2. Histology:** \nSarcomas display a broad histologic diversity—such as osteosarcoma, liposarcoma, and leiomyosarcoma—each with unique mutation profiles affecting survival.\n\n- **Mutation Profiles:** Certain histologic subtypes harbor distinct mutations, e.g., MDM2 in liposarcomas or TP53 in high-grade subtypes, which may influence treatment response and thus survival.\n- **Survival Influence:** Histologic subtype dictates treatment protocol efficacy and potential for resistance, impacting prognosis. High-grade histologies often correlate with poorer survival due to aggressive growth and resistance.\n- **Biological Mechanism:** This variety necessitates tailored approaches to control proliferation and enhance chemosensitivity.\n\n**3. Sampling Bias:**\nGenomic analyses may suffer from biases, particularly with Blood Derived Normal (BDN) or Primary Tumor samples.\n\n- **Blood Derived Normal Bias:** Reflects germline variation rather than somatic evolution within tumors, potentially conflating normal background variation with disease-specific mutations.\n- **Primary Tumor vs. Metastatic Lesions:** The primary tumor might not capture the full mutation spectrum crucial to metastatic behavior, misrepresenting targetable mutations and skewing survival predictions.\n- **Genomic Interpretation Biases:** Misinterpretation of mutation burden or clonality due to inadequate sampling can result in suboptimal therapeutic choices, negatively impacting survival.\n\n**4. Key Genes:**\nIdentifying genes such as TP53, RB1, MDM2, KIT, PDGFRA, and CDK4, these genes exhibit varying roles across proliferation, apoptosis, and immune response impacting survival.\n\n- **TP53:** Tumor suppressor, mutations here lead to unchecked proliferation and resistance to apoptosis, heightening malignancy.\n- **RB1:** Regulates cell cycle, loss of function associated with increased proliferation and adverse outcomes.\n- **MDM2:** Overexpression due to amplification leads to TP53 degradation, fostering survival by evading apoptotic pathways.\n- **KIT/PDGFRA:** Oncogenic drivers in gastrointestinal stromal tumors, therapeutically targetable, significantly improves survival if accurately identified.\n- **CDK4:** Cell cycle regulator; high expression levels fuel proliferation, influencing the aggressiveness and survival negatively.\n\n**Synthesis:**\nSurvival in sarcoma is intricately linked to tumor biology—origin, histology, and genetic profile play pivotal roles. Metastatic proclivities coupled with genetic predispositions and histological diversity underscore the survival heterogeneity. Awareness of potential sampling biases in genomic studies aids in accurate gene profiling and treatment alignment. Critical insights into gene impact on proliferation, apoptosis, and immune evasion facilitate more nuanced and effective treatment strategies, ultimately striving to enhance patient survival outcomes. The overarching challenge and opportunity lie in precision oncology—tailoring interventions based on comprehensive, bias-aware genomic and histological understanding—to mitigate the aggressive nature of these malignancies."
        ],
        [
         "23",
         "Blood Derived Normal, Primary Tumor",
         "Skin Cutaneous Melanoma",
         "TCGA-BF-AAOX, TCGA-BF-A9VF, TCGA-EB-A82C, TCGA-EB-A82B, TCGA-XV-A9W2, TCGA-YG-AA3N, TCGA-XV-A9VZ, TCGA-EB-A97M, TCGA-EB-A51B, TCGA-XV-A9W5, TCGA-BF-AAP2, TCGA-BF-AAP8, TCGA-XV-AAZV, TCGA-BF-AAP1, TCGA-XV-AAZW, TCGA-XV-AAZY, TCGA-EB-A550, TCGA-WE-A8K4, TCGA-BF-AAOU, TCGA-EB-A85J, TCGA-DA-A960, TCGA-EB-A85I, TCGA-BF-AAP6, TCGA-HR-A5NC, TCGA-BF-AAP7, TCGA-BF-AAP4, TCGA-GN-A8LN",
         "### Tumor Origin\n\n**Influence on Metastasis and Survival:**\n\n1. **Metastatic Patterns:**\n   - Skin Cutaneous Melanoma originates from melanocytes and is known for its high metastatic potential due to its origin in cells capable of vast migration and interaction within the skin environment. Metastasis typically occurs through lymphatic and hematogenous routes.\n   - **Survival Impact:** High metastatic potential correlates with poorer survival rates as the disease often presents at advanced stages with widespread dissemination.\n\n2. **Treatment Accessibility:**\n   - The cutaneous origin allows for relatively easy access for surgical intervention, especially in early-stage diseases, improving survival if detected early.\n   - **Survival Impact:** Early surgical intervention can significantly improve survival, whereas late detection usually leads to reduced treatment efficacy and survival.\n\n**Biological Rationale:**\n- Melanocytes’ inherent properties, including motility and invasiveness, facilitate early dissemination.\n- Early exposure and accessibility to surgery allow for potentially curative resection, crucial for survival advantages.\n\n### Histology\n\n**Interaction with Mutation Profiles:**\n\n1. **Histopathologic Subtypes:**\n   - Subtypes such as superficial spreading and nodular melanoma present differing growth patterns and propensities for invasion.\n   - **Survival Impact:** Subtypes that grow vertically (e.g., nodular) are associated with poorer outcomes due to deeper tissue invasion prior to detection.\n\n2. **Mutation Profiles:**\n   - Common mutations in genes like BRAF and NRAS are histologically linked to aggressive growth patterns.\n   - **Survival Impact:** Mutated BRAF leads to continuous cell cycle progression, contributing to rapid disease progression and potentially reducing survival.\n\n**Biological Rationale:**\n- Morphologic features align with behavioral aspects of tumors, impacting detection and treatment efficacy.\n- Mutational load impacts proliferation rates and response to targeted therapies, directly influencing survival.\n\n### Sampling Bias\n\n**Limitations in Genomic Analysis:**\n\n1. **Blood Derived Normal vs. Primary Tumor:**\n   - Blood-derived samples may not accurately represent tumor heterogeneity or metastatic clone profiles.\n   - **Survival Impact:** Misleading genomic data can result in inappropriate treatment strategies, impacting survival.\n\n**Potential Limitations:**\n- Primary tumor samples may not capture intratumoral heterogeneity or evolving metastatic signatures.\n- Biased sampling can overlook key resistant clones, affecting both prognostication and treatment planning.\n\n### Key Genes\n\n**Survival-Associated Genes:**\n\n1. **BRAF**\n   - Drives proliferation via MAPK/ERK pathway; mutations lead to enhanced tumor growth.\n   - **Survival Impact:** Targetable with BRAF inhibitors, improving outcomes for patients with specific mutations.\n\n2. **NRAS**\n   - Similar pathway activation as BRAF; contributes to resistance against BRAF-targeted therapies.\n   - **Survival Impact:** Complicates treatment and often associated with poorer response rates, thereby reducing survival.\n\n3. **KIT**\n   - Mutations can lead to aberrant cell signaling and growth, particularly in acral and mucosal melanomas.\n   - **Survival Impact:** Targeted KIT inhibitors can improve outcomes but are not universally applicable due to mutation variability.\n\n4. **CDKN2A**\n   - Key regulator of cell cycle; mutations often confer loss of cell cycle control.\n   - **Survival Impact:** Loss results in unchecked cellular proliferation, reducing survival rates.\n\n5. **TP53**\n   - Central in apoptosis and genomic stability; mutations may lead to resistance to apoptosis.\n   - **Survival Impact:** Commonly associated with aggressive tumor behavior and poorer outcomes.\n\n6. **PTEN**\n   - Tumor suppressor role; loss leads to enhanced PI3K pathway signaling and tumor aggressiveness.\n   - **Survival Impact:** Loss contributes to therapy resistance, challenging management and survival.\n\n### Synthesis and Conclusion\n\n- **Key Risk Factors:**\n  - **Metastatic Propensity:** Early metastatic spread drives survival decline.\n  - **Mutation Profile:** Specific mutations lead to variable prognosis and treatment response, affecting survival.\n  - **Histological Subtype and Growth Pattern:** Influence detection and subsequent therapeutic accessibility.\n  - **Genomic Interpretation Bias:** Accurate genomic profiling is critical for effective therapy planning.\n\n- **Clinically Relevant Insights:**\n  - Understanding the genetic and histological landscape is vital for optimizing treatment.\n  - Early detection and personalized management approach are paramount for improving survival in melanoma patients."
        ],
        [
         "24",
         "Blood Derived Normal, Primary Tumor",
         "Stomach adenocarcinoma",
         "TCGA-HF-7131, TCGA-CG-5716, TCGA-CG-4460",
         "### Tumor Origin\n\n1. **Influence on Survival and Metastatic Patterns:**\n   - **Origin and Spread**: Stomach adenocarcinoma originates from the glandular epithelial cells lining the stomach and often spreads to the liver, peritoneum, and lungs. This metastatic tendency adversely affects survival due to the common nature of distant metastases at diagnosis, which complicates complete surgical resection and effective therapeutic intervention.\n   - **Survival Impact**: The primary origin site, with its proximity to vital structures and rich blood supply, contributes to rapid dissemination. Initial stages may have more favorable prognoses if detected early but later stages reflecting metastatic spread typically result in poor survival outcomes due to limited treatment efficacy.\n\n2. **Treatment Accessibility**: \n   - The location of stomach adenocarcinoma can influence therapeutic strategies, such as surgical feasibility and chemotherapy penetration. Access to centers capable of complex gastrectomies and targeted therapies can improve survival, highlighting disparities in outcomes based on geographic and socioeconomic factors.\n\n### Histology\n\n1. **Histological Subtypes and Mutations**:\n   - **Histological Influence**: Variations such as intestinal or diffuse types impact survival differently; intestinal types usually exhibit better prognoses. This differentiation also guides personalized treatment strategies and prognosis estimates.\n   - **Mutation Profiles**: Common mutations, such as those in TP53, APC, and ARID1A among others, manifest differently across histological subtypes. These mutations can influence tumor behavior and response to treatment, with TP53 mutations often associated with worse outcomes due to their impact on cell cycle control and genomic instability.\n\n2. **Survival and Outcomes**: \n   - Directed use of mutation-specific therapies (e.g., HER2-targeted drugs in HER2-positive cases) can potentially improve survival, while histological resistance patterns require adaptation of treatment protocols.\n\n### Sampling Bias\n\n1. **Limitations in Genomic Analysis**:\n   - **Sample Origin**: Blood-derived normal samples may not capture the complete genetic landscape of the tumor, missing somatic alterations that are tumor-specific. In contrast, primary tumor samples directly reflect tumor genetics but may miss heterogeneity present in metastatic sites.\n   - **Survival Impact**: Biopsy location and timing can introduce biases. Tumors with heterogeneous mutations across metastatic sites can lead to inconsistent treatment responses if such heterogeneity isn't captured in the analyzed sample.\n\n### Key Genes\n\n1. **Survival-Associated Genes and Mechanisms**:\n   - **TP53**: Regulates cell cycle checkpoints and apoptosis. Mutations disrupt these processes, leading to unchecked growth and survival errors, correlating with worse outcomes.\n   - **ERBB2 (HER2)**: Amplification encourages proliferation. Overexpression in subsets of patients allows targeted therapy (e.g., Trastuzumab), improving survival with the correct mutation.\n   - **CDH1**: Mutations influence epithelial-mesenchymal transition (EMT), promoting invasion and metastasis, often seen in diffuse-type gastric cancer with poor prognosis.\n   - **APC**: Involvement in Wnt signaling pathways. Mutations disrupt cell adhesion and promote cancerous growth, negatively impacting survival due to increased tumor aggressiveness.\n   - **ARID1A**: Involves chromatin remodeling. Loss-of-function mutations impair tumor suppression capabilities, leading to worse outcomes.\n   - **PIK3CA**: Engages in cell growth signaling. Mutations can be oncogenic, enhancing tumor proliferation and survival pathways, impacting treatment resistance.\n\n### Synthesis of Key Survival Risk Factors\n\n- **Tumor Origin and Biological Behavior**: Impacts prognosis severely through rapid metastasis and complex therapeutic requirements.\n- **Genomic Insights and Histological Variance**: Highlight the importance of precise mutation identification for effective treatment application, particularly emphasizing personalized and genotype-guided therapy.\n- **Bias and Heterogeneity**: Recognizing sampling biases is crucial in treatment planning to ensure comprehensive management and improve survival odds.\n- **Clinical Implications and Disparities**: Emphasizing early detection and access to specialized treatments can significantly alter survival outcomes, indicating areas where health interventions could be optimized.\n\nBy appreciating these components, oncologists can better tailor interventions, potentially converting poor prognostic factors into manageable conditions with focused treatment strategies. Understanding these dynamics is central to improving patient survival in gastric adenocarcinoma."
        ],
        [
         "25",
         "Blood Derived Normal, Primary Tumor",
         "Testicular Germ Cell Tumors",
         "TCGA-2G-AAFE",
         "### Tumor Origin\n\n**Influence on Survival**:  \nTesticular Germ Cell Tumors (TGCTs) typically arise from germ cells in the testes and can be classified predominantly into seminomas and non-seminomas. These tumors often metastasize through lymphatic and hematogenous routes, significantly influencing survival rates.\n\n**Biological Rationale**:  \n- **Metastatic Patterns**: TGCTs tend to spread early, primarily to retroperitoneal lymph nodes and, less commonly, to lungs and liver. Seminomas usually have a slower progression and respond better to radiotherapy, which positively influences survival.\n- **Patient Survival**: The five-year survival for localized TGCTs is excellent; however, metastatic cases, particularly non-seminomas, have more varied outcomes dependent on the stage and response to treatment.\n\n**Biases in Interpretation**:  \nAccess to healthcare (influencing early diagnosis and treatment) and differential responses to treatment options based on tumor type (seminoma versus non-seminoma) play crucial roles in patient outcomes.\n\n### Histology\n\n**Influence on Survival**:  \nHistological differences between seminomas and non-seminomas lead to variability in treatment responses and outcomes.\n\n**Biological Rationale**:  \n- **Mutation Profiles**: Non-seminomas are often more aggressive, associated with overexpression of oncogenes like *KIT* and alterations in *TP53*, driving poor outcomes.\n- **Treatment Response**: Seminomas are more radiosensitive, which usually results in better prognoses compared to non-seminomas, which might require multi-modal treatment approaches.\n\n**Biases in Interpretation**:  \nStudies often sample primary tumors without considering the heterogeneity within non-seminomas (embryonal carcinoma, yolk sac tumor, choriocarcinoma, teratoma), potentially skewing survival data interpretation.\n\n### Sampling Bias\n\n**Limitations in Genomic Analysis**:  \n- **Blood-Derived Normal Samples vs. Primary Tumors**: Blood samples may not accurately reflect tumor heterogeneity or the genomic landscape of the tumor microenvironment, leading to incomplete insights into mutation impacts.\n  \n**Biological Rationale**:  \n- **Tumor Heterogeneity**: Different subtypes within non-seminomas can show diverse genetic alterations that may be under-represented in blood-derived samples.\n- **Evolutionary Dynamics**: Overlooking tumor evolution during or after treatment due to reliance on initial primary tumor samples instead of metastatic lesions can lead to biases in predicting treatment outcomes.\n\n### Key Genes\n\n1. **KIT**:  \n   - **Influence on Survival**: Mutations lead to uncontrolled cell growth and poor responses to standard therapies.\n   - **Biological Mechanism**: Involved in cell signaling pathways promoting proliferation and survival.\n  \n2. **TP53**:  \n   - **Influence on Survival**: Mutations are associated with treatment resistance and poor prognosis.\n   - **Biological Mechanism**: Tumor suppressor controlling cell cycle and apoptosis.\n  \n3. **BRAF**:  \n   - **Influence on Survival**: Mutations can drive aggressive growth, especially in non-seminomas.\n   - **Biological Mechanism**: Promotes cell proliferation through MAPK/ERK pathway activation.\n  \n4. **KRAS**:  \n   - **Influence on Survival**: Mutations can lead to poor responses to therapies.\n   - **Biological Mechanism**: Involves in signaling pathways that regulate growth and differentiation.\n  \n5. **SOX17**:  \n   - **Influence on Survival**: Overexpression linked to seminoma development and maintenance.\n   - **Biological Mechanism**: Involved in germ cell pluripotency and differentiation control.\n  \n6. **NANOG**:  \n   - **Influence on Survival**: Linked to stem cell-like properties of germ cells, promoting tumor initiation and growth.\n   - **Biological Mechanism**: Regulates embryonic stem cell self-renewal.\n  \n7. **BCL2**:  \n   - **Influence on Survival**: Overexpression inhibits apoptosis, leading to treatment resistance.\n   - **Biological Mechanism**: Regulates mitochondrial pathways of apoptosis.\n\n### Synthesis of Key Survival Factors\n\n**Clinically Relevant Insights**:  \n- **Tumor Type and Stage**: Early-stage TGCTs have high survival rates due to high treatability, but advanced stages, particularly with metastatic non-seminomas, present challenges.\n- **Histological and Genetic Profiles**: Personalized treatment strategies informed by histological type and key mutation profiles (e.g., *KIT*, *TP53*, anti-apoptotic gene expression) improve outcomes.\n- **Sampling and Monitoring**: Comprehensive genomic analyses necessitate considering tumor evolution and heterogeneity to tailor treatment effectively.\n\n**Impact on Patient Survival**:  \nEnhancing strategies for early detection, improving access to healthcare, and implementing advanced genomic profiling are critical for optimizing survival outcomes. Addressing these factors collectively underpins a personalized approach, potentially mitigating metastatic spread and improving overall survival in TGCT patients."
        ],
        [
         "26",
         "Blood Derived Normal, Primary Tumor",
         "Thyroid carcinoma",
         "TCGA-E8-A2JQ, TCGA-EL-A3D5, TCGA-EL-A3D0, TCGA-DJ-A3UV, TCGA-BJ-A0ZF, TCGA-DJ-A3V6, TCGA-EM-A2CM, TCGA-EM-A2CS",
         "**Thyroid Carcinoma and Its Impact on Survival**\n\n**Tumor Origin:**\n\n1. **Metastatic Patterns and Survival:**\n   - **Influence:** Thyroid carcinoma is typically categorized into differentiated (e.g., papillary and follicular) and undifferentiated types (e.g., medullary and anaplastic). Differentiated types have a higher survival rate due to their slower growth and limited metastatic potential, often metastasizing first to regional lymph nodes rather than distant organs.\n   - **Biological Rationale:** The less aggressive nature of differentiated thyroid cancers allows for earlier detection and effective surgical intervention. Anaplastic carcinoma, however, is highly aggressive with a propensity for distant metastasis, critically reducing survival rates.\n   - **Treatment Accessibility:** Differentiated thyroid cancers often respond well to radioactive iodine treatment, enhancing survival. In contrast, anaplastic thyroid cancer's aggressive nature limits effective treatment options, adversely affecting survival.\n\n2. **Histology-Based Interactions with Mutation Profiles:**\n   - **Papillary Thyroid Carcinoma (PTC):** Frequently involves BRAF V600E mutations leading to activation of the MAPK pathway, promoting proliferation.\n   - **Follicular Thyroid Carcinoma (FTC):** Often associated with RAS mutations and PAX8/PPARG rearrangements, altering cellular differentiation.\n   - **Anaplastic Thyroid Carcinoma (ATC):** Characterized by TP53 mutations and TERT promoter mutations which disrupt tumor suppression and enhance replicative immortality.\n   - **Impact on Outcomes:** BRAF mutations correlate with poorer prognosis in PTC while RAS mutations in FTC signify potential benefit from targeted therapies. TP53 mutations in ATC signify aggressive disease with poor survival impact.\n\n**Sampling Bias in Genomic Analysis:**\n\n1. **Blood Derived Normal vs. Primary Tumor:**\n   - **Bias Impact:** Blood-derived normal samples may not fully capture the somatic mutations present within the primary thyroid tumor due to tumor heterogeneity.\n   - **Genomic Misinterpretations:** Such sampling might underestimate intratumoral genetic diversity, leading to an incomplete understanding of mutations driving survival determinants.\n   - **Mitigation:** Inclusion of both normal and tumor-derived samples can enhance the robustness of genomic studies, providing a clearer correlation between mutational landscapes and survival outcomes.\n\n**Key Survival-Associated Genes:**\n\n1. **BRAF:** Mutations often result in enhanced MAPK pathway signaling, driving cell proliferation. Their presence in poorly differentiated tumors correlates with worse outcomes.\n\n2. **TP53:** Loss or mutation of this tumor suppressor gene is linked to genomic instability and poor prognosis, especially in ATC.\n\n3. **TERT:** Promoter mutations increase telomerase activity, resulting in sustained proliferative signaling and significantly impacting survival negatively.\n\n4. **RET/PTC Rearrangements:** Result in constitutive signaling through MAPK and PI3K pathways, common in PTC, influencing differentiation and survival positively under therapeutic management.\n\n5. **RAS Mutations (HRAS, KRAS, NRAS):** Correlated with FTC and aggressive tumor behavior due to alterations in cell signaling pathways, with varied impact on patient survival based on context and treatment strategy.\n\n6. **PIK3CA:** Mutations contribute to oncogenesis via the PI3K pathway, modulating tumor growth and potentially impacting response to targeted therapies.\n\n7. **NTRK Fusions:** Involved in a subset of thyroid cancers, offering a target for specific inhibitors, enhancing survival outcomes where applicable.\n\n**Synthesis of Key Survival Risk Factors:**\n\n- **Differentiated vs. Undifferentiated Tumor Types:** The histological type of thyroid carcinoma dictates survival, with differentiated forms generally associated with better outcomes due to effective treatment regimens.\n- **Genetic Landscape:** Specific mutations and gene rearrangements (e.g., BRAF, TP53, RET/PTC) significantly influence tumor behavior and patient survival. Understanding these can guide therapeutic decisions and prognostic evaluations.\n- **Sampling Considerations:** Accurate genomic profiling is critical, emphasizing tumor-specific considerations to avoid biases that could misguide treatment strategies.\n\nIn conclusion, the interplay between tumor origin, histological characteristics, key genetic mutations, and sampling biases forms the backbone of understanding thyroid carcinoma survival. This integration highlights the importance of precise diagnostic assessments and tailored treatment approaches to optimize patient outcomes."
        ],
        [
         "27",
         "Blood Derived Normal, Primary Tumor",
         "Uterine Corpus Endometrial Carcinoma",
         "TCGA-BG-A0M8, TCGA-BG-A220, TCGA-AP-A053, TCGA-AX-A3G3, TCGA-AX-A2HF, TCGA-AX-A1CR, TCGA-B5-A0KB, TCGA-D1-A3JP, TCGA-BG-A0MS, TCGA-EY-A1G7, TCGA-EY-A1G8, TCGA-BG-A221, TCGA-AX-A1CP",
         "To effectively discuss Uterine Corpus Endometrial Carcinoma (UCEC) and its impact on survival, let's break down the complex interactions between tumor origin, histology, sampling bias, and key genetic factors.\n\n### Tumor Origin\n\n**Influence on Survival:**\n1. **Primary Site and Metastasis**: UCEC originates in the lining of the uterus, primarily impacting organs within the pelvic region upon metastasis, such as the ovaries and fallopian tubes, before potentially spreading to more distant sites like the lungs.\n2. **Treatment Accessibility**: The anatomical location of UCEC facilitates surgical intervention, such as hysterectomy. Early detection and treatment generally offer a positive impact on survival.\n\n**Biological Rationale:**\n- **Local Spread**: Confined local spread increases surgical success rates, leading to better outcomes.\n- **Distant Metastasis Pattern**: Limited to certain pathways due to the primary location, which can be a survival advantage compared to cancers with more widespread early dissemination.\n\n### Histology\n\n**Influence on Survival:**\n1. **Histological Variants**: Endometrioid type generally carries a better prognosis, whereas serous and clear-cell types are associated with poorer outcomes due to aggressive biology.\n2. **Mutation Profiles**: Differentiated by specific histological types, influencing response to therapy and survival rates.\n\n**Biological Rationale:**\n- **Driver Mutations**: Mutations such as PTEN (common in endometrioid) play a role in tumor suppression pathways, whereas TP53 mutations (frequent in serous type) link to more aggressive behavior.\n\n### Sampling Bias\n\n**Limitations in Genomic Analysis:**\n- **Blood Derived Normal (BDN) vs. Primary Tumor**: BDN samples might not reflect true tumor heterogeneity. Primary samples can highlight tumor-specific mutations but may miss clonality variations.\n  \n**Potential Biases:**\n- **Tumor Heterogeneity**: Sole reliance on BDN can lead to an underestimation of genomic alterations unique to the tumor.\n- **Variant Detection**: Primary samples might overestimate tumor homogeneity due to sampling limited to accessible/focal tumor regions.\n\n### Key Genes and Their Impact\n\n1. **PTEN**: Tumor suppressor gene; alterations lead to unchecked cellular proliferation but less aggressive in early stages, influencing positive survival when treated early.\n\n2. **TP53**: Mutations lead to genomic instability. High prevalence in high-grade tumors linked to poor prognosis.\n\n3. **PIK3CA**: Involved in the PI3K/AKT pathway, affecting cell growth and survival; mutations can lead to enhanced proliferative signaling.\n\n4. **KRAS**: A proto-oncogene; mutations contribute to aggressive behavior and poorer outcomes through enhanced proliferation and survival signaling.\n\n5. **ARID1A**: Involved in chromatin remodeling. Loss-of-function mutations correlated with different tumor suppressive roles, affecting transcription and survival negatively.\n   \n6. **CTNNB1**: Part of the Wnt signaling pathway; mutations can lead to reduced cell adhesion and increased proliferation, negatively affecting survival.\n\n### Synthesis of Key Survival Risk Factors\n\n**Clinically Relevant Insights:**\n- Multimodal treatment approaches, including surgical, hormonal, and chemotherapeutic strategies, should be personalized based on histological subtypes and genetic profiles to improve survival.\n- Regular monitoring of genetic markers can inform prognosis and tailor therapeutic regimens, addressing tumor-specific vulnerabilities and potential resistance mechanisms.\n\n**Impact on Patient Survival:**\n- Strategic focus on early detection and understanding genomic indicators can significantly enhance management effectiveness and survival outcomes for patients with UCEC.\n- Awareness of sampling biases and tailoring interventions based on comprehensive genomic insights are crucial to maximize therapeutic efficacy.\n\nIn conclusion, understanding UCEC’s biological, histological, and genetic complexity is key to improving patient survival, underscoring the necessity for personalized medicine approaches in treatment planning."
        ],
        [
         "28",
         "Blood Derived Normal, Recurrent Tumor",
         "Rectum adenocarcinoma",
         "TCGA-G5-6572",
         "Certainly, let's delve into how Rectum adenocarcinoma impacts survival by analyzing each aspect in detail:\n\n### Tumor Origin:\n**Influence on Survival:**\n- **Metastatic Patterns**: Rectum adenocarcinoma typically spreads to nearby lymph nodes, liver, and lungs. These patterns are crucial as liver metastases significantly reduce survival rates compared to lymph node involvement alone.\n  \n- **Survival Impact**: The primary origin in the rectum influences treatment approaches, such as the feasibility of surgical resection which often offers a survival advantage. More advanced disease with systemic spread poses treatment challenges and typically worsens survival odds.\n\n- **Treatment Accessibility**: Anatomical considerations for rectal tumors often necessitate multidisciplinary management involving surgery, radiation, and chemotherapy. Accessibility to such comprehensive care directly affects survival outcomes.\n\n**Biological Rationale**:\n- The vascular supply and proximity to vital structures in the pelvic region facilitate metastasis, dictating a more aggressive clinical course.\n\n### Histology:\n**Interaction with Mutation Profiles:**\n- **Outcome Drivers**: Histological examination often reveals features such as poor differentiation, which correlate with aggressive behavior and adverse prognosis. These are linked with mutations in key genes like KRAS, TP53, and BRAF.\n\n**Influence on Survival:**\n- Histological subtypes like mucinous adenocarcinoma or signet-ring cell type are associated with poorer survival compared to typical adenocarcinomas due to more advanced disease at presentation and resistance to standard therapies.\n\n**Biological Rationale**:\n- Mutational load and specific profiles such as microsatellite instability (MSI) can affect tumor behavior, immune evasion, and response to immunotherapy, typically offering better outcomes in MSI-high tumors.\n\n### Sampling Bias:\n**Limitations in Genomic Analysis:**\n- **Blood Derived Normal**: Utilized as a comparative baseline in genomic analyses, this can only reflect germline mutations and misses tumor-specific changes, potentially skewing survival-linked genomic interpretations.\n\n- **Recurrent Tumor Samples**: Focus primarily on mutations linked to treatment resistance and recurrence but might underrepresent early driver mutations critical for initial tumor growth and metastasis prediction.\n\n**Influence on Survival:**\n- Sampling biases can mislead the relevance of certain genomic alterations to survival by either underestimating or overemphasizing their role, leading to suboptimal personalized therapy.\n\n### Key Survival-Associated Genes:\n**Genes and Biological Mechanisms**:\n1. **TP53**: Governs cell cycle arrest and apoptosis. Mutations lead to unchecked cell proliferation, increasing aggressive behavior and worsening survival.\n   \n2. **KRAS**: Involves in cell signaling pathways. Mutations lead to therapy resistance, notably against EGFR inhibitors, negatively impacting survival.\n\n3. **BRAF**: Particularly the V600E mutation, associated with poor prognosis due to aggressive tumor growth and lack of response to standard therapies.\n\n4. **PIK3CA**: Affects cellular growth and motility. Mutations may confer survival disadvantage through activation of pathways that promote tumor progression and metastasis.\n\n5. **APC**: Typically early inactivation leads to adenomatous polyps; loss contributes to progression, impacting survival by allowing continued tumor evolution.\n\n6. **SMAD4**: Role in TGF-beta signaling and tumor progression. Loss is associated with advanced stage at diagnosis and poorer outcomes.\n\n**Influence on Survival**:\n- Alterations in these genes contribute variably, with some conferring resistance to targeted therapies, impacting overall and disease-free survival.\n\n### Synthesis:\n**Clinically Relevant Insights**:\n- **Genomic Counseling**: Understanding the specific mutational landscape is critical for tailoring precision medicine strategies.\n- **Histological Subtype**: Influence approaches to treatment; more aggressive histological subtypes require early intervention and novel strategies to improve outcomes.\n- **Multidisciplinary Approaches**: Comprehensive care involving surgery, radiation, and systemic therapies, leveraging the understanding of underlying genetic drivers, is crucial for improving survival.\n  \nIn summary, the multifactorial interplay of tumor origin, histological characteristics, genetic mutations, and potential biases in sample acquisition serves as a pivot for understanding survival implications in rectal adenocarcinoma. This understanding informs the development and application of effective, individualized treatment strategies."
        ],
        [
         "29",
         "Primary Tumor, Solid Tissue Normal",
         "Cholangiocarcinoma",
         "TCGA-W7-A93P, TCGA-W7-A93O, TCGA-4G-AAZF, TCGA-W7-A93N, TCGA-4G-AAZR",
         "### Tumor Origin\n\n**Influence on Survival:**\nCholangiocarcinoma (CCA) originates from the biliary epithelium and can be classified primarily into intrahepatic, perihilar, and distal forms based on its anatomical location. These different origins influence survival through varied metastatic patterns and access to treatment. \n\n1. **Intrahepatic CCA** tends to metastasize primarily within the liver and often presents at advanced stages due to nonspecific symptoms, negatively impacting survival.\n2. **Perihilar CCA**, known as Klatskin tumors, impedes bile flow, often leading to jaundice, thus more recognizable, but still presents significant surgical challenges impacting survival.\n3. **Distal CCA** is more accessible surgically but still poses challenges due to its proximity to other vital structures.\n\n**Biological Rationale:**\nThe diverse vascular and lymphatic supply inherent to each anatomical origin influences the pattern of metastatic spread and the tumor's exposure to systemic therapies, with perihilar CCA often demonstrating local spread patterns that can complicate surgical resection efforts.\n\n**Genomic Interpretation Biases:**\nEarly detection often relies on imaging rather than biopsies, potentially leading to sampling biases which might miss genomic alterations important for pinpointing therapeutic targets. These factors contribute to late diagnosis and limited treatment efficacy in many cases.\n\n### Histology and Mutation Profiles\n\n**Influence on Survival:**\nCholangiocarcinoma exhibits diverse histological patterns that correlate with specific genetic mutations, influencing both disease progression and therapeutic responses.\n\n**Biological Rationale:**\nCommon mutations include those in **IDH1, FGFR2, KRAS**, and **BAP1**:\n\n1. **IDH1 Mutations** are found in a subset of intrahepatic CCA and are associated with production of oncometabolites that drive epigenetic alterations, influencing tumor growth negatively for survival.\n2. **FGFR2 Fusions** often lead to an overactive receptor tyrosine kinase signaling pathway promoting proliferation and survival, suggesting targeted therapy can improve outcomes if identified early.\n3. **KRAS Mutations** are associated with aggressive behavior and resistance to therapy, contributing to poorer survival.\n4. **BAP1 Mutations** are linked to chromatin remodeling deficits, potentially impacting DNA repair mechanisms and immune evasion.\n\n**Potential Biases:**\nBiopsies and tissue samples may not capture the full heterogeneity of mutations within the tumor, leading to erroneous assumptions in treatment planning.\n\n### Sampling Bias\n\n**Influence on Survival:**\nSampling in genomic studies often compares tumor tissues with solid tissue normal, possibly missing heterogeneity and borderline lesions. This might underestimate certain genetic variabilities critical for effective personalized treatment.\n\n**Biological Rationale:**\nIt's crucial to consider the spatial heterogeneity of cholangiocarcinoma, which can lead to underrepresentation of aggressive clones or actionable mutations.\n\n### Key Genes and Mechanisms\n\n**Key Genes:**\n1. **TP53**: Tumor suppressor gene affecting cell cycle regulation; common mutations indicate poor prognosis.\n2. **IDH1/IDH2**: Affect cellular metabolism through the enzymatic production of 2-HG, contributing to oncogenesis.\n3. **FGFR2**: Receptor important in cell division, mutations suggest possible efficacy of FGFR inhibitors.\n4. **EGFR**: Mutations or amplifications can offer potential therapeutic targets since EGFR activation drives proliferation.\n5. **BAP1**: Involved in chromatin remodeling; mutations suggest poor prognosis via disrupted DNA repair.\n\n**Mechanisms:**\nThese genes are implicated in pathways controlling abnormal proliferation, evasion from apoptosis, and immune checkpoint dysregulation, which cumulatively dictates aggressive tumor behavior and survival interference.\n\n### Synthesis of Key Survival Risk Factors\n\n**Concluding Insights:**\n- **Tumor Origin and Location**: Significantly impact treatment options and survival. For example, perihilar obstructions and intrahepatic metastasis contribute to poor outcomes.\n- **Histology and Mutation Profiles**: Heavily influence response to targeted therapies; understanding these connections is essential for improving survival.\n- **Sampling Biases**: Present a barrier in tailoring precise treatment, necessitating a strategy that incorporates comprehensive sampling.\n\nClinically, leveraging molecular insights into the genetics of cholangiocarcinoma offers a promising avenue for personalized treatments, potentially improving prognosis and survival. However, understanding the complexity and heterogeneity of these tumors is critical in guiding therapeutic direction."
        ],
        [
         "30",
         "Primary Tumor, Solid Tissue Normal",
         "Colon adenocarcinoma",
         "TCGA-AA-3662, TCGA-G4-6625, TCGA-AA-3697, TCGA-AA-3509, TCGA-AZ-6601, TCGA-AZ-6608",
         "### Tumor Origin\n\n**Influence on Survival**:  \nColon adenocarcinoma originates in the epithelial cells of the colon or rectum. Its survival impact hinges on its propensity for local invasion and distant metastasis, primarily to the liver, lungs, and peritoneum. The metastatic nature dictates prognosis, with liver metastases significantly reducing survival rates. Early diagnosis and potential curative resection improve survival.\n\n**Biological Rationale**:  \nThe vascularity and connectivity of the colon to systemic circulation promote metastasis, particularly to the liver via the portal vein. This explains the aggressive metastatic behavior which impacts overall survival negatively.\n\n**Treatment Accessibility**:  \nGiven its origin, colon adenocarcinoma is accessible to surgical interventions and systemic chemotherapies. However, in metastatic settings, options are limited and more reliant on systemic therapies which often improve survival only modestly.\n\n**Bias and Misinterpretation**:  \nSampling bias may occur in biopsy versus surgical samples, affecting tumor heterogeneity representation, crucial for predicting metastatic behavior.\n\n### Histology\n\n**Influence on Survival**:  \nHistological analysis distinguishes various differentiation patterns, such as well, moderately, or poorly differentiated adenocarcinomas. Poor differentiation correlates with a worse prognosis due to aggressive behavior.\n\n**Biological Rationale**:  \nHistological grading reflects the cell proliferation rate and invasion potential. Poorly differentiated tumors frequently exhibit high mitotic rates and abnormal architecture, facilitating metastatic spread and reducing survival.\n\n**Mutation Interaction**:  \nHistology often aligns with mutation profiles. For example, microsatellite instability (MSI), related to deficient mismatch repair, is more common in poorly differentiated tumors bringing a paradoxical survival benefit because of better responses to immunotherapy.\n\n### Sampling Bias\n\n**Limitations of Primary Tumor and Solid Tissue Normal in Genomic Analysis**:  \nAnalysis may be skewed by intratumoral heterogeneity, where primary samples might not reflect metastatic lesion profiles. Solid tissue normal samples can carry field cancerization effects or early mutation events not pertinent to survival.\n\n**Bias Impact**:  \nThis bias can lead to underestimation or overestimation of mutational burden and tumor behavior, influencing clinical decisions based on potentially inaccurate genomic backgrounds.\n\n### Key Genes\n\n**APC, TP53, KRAS, BRAF, SMAD4, PIK3CA, TGFBR2**:\n\n1. **APC**:  \n   - **Mechanism**: Tumor suppressor; initiates carcinogenesis via Wnt pathway dysregulation.\n   - **Survival Impact**: Negative; mutations drive tumorigenesis but commonly early events.\n\n2. **TP53**:  \n   - **Mechanism**: Regulates apoptosis and cell cycle; mutations lead to unchecked cell division.\n   - **Survival Impact**: Negative; associated with poor prognosis and therapy resistance.\n\n3. **KRAS**:  \n   - **Mechanism**: Oncogene involved in cell signaling; mutations affect treatment response.\n   - **Survival Impact**: Negative in metastatic settings; predicts resistance to EGFR inhibitors.\n\n4. **BRAF**:  \n   - **Mechanism**: Affects MAPK pathway; V600E mutation is critical.\n   - **Survival Impact**: Negative; aggressive phenotype, poor response to conventional therapies.\n\n5. **SMAD4**:  \n   - **Mechanism**: Tumor suppressor; involved in TGF-beta signaling.\n   - **Survival Impact**: Negative; correlates with increased metastasis and poor outcomes.\n\n6. **PIK3CA**:  \n   - **Mechanism**: Part of PI3K/AKT pathway; impacts cell growth.\n   - **Survival Impact**: Variable; may confer sensitivity to specific inhibitors.\n\n7. **TGFBR2**:  \n   - **Mechanism**: Involved in TGF-beta signaling; mutations can disrupt growth inhibition.\n   - **Survival Impact**: Negative; mutations can lead to escape from growth suppression.\n\n### Synthesis\n\nKey survival risk factors in colon adenocarcinoma include the primary tumor's metastatic propensity, histological differentiation, critical genetic mutations, and the potential biases introduced by sampling. Clinically, understanding these factors alongside patient-specific genomic data can optimize treatment strategies leading to improved survival. As precision medicine evolves, a nuanced consideration of these elements will be integral in guiding therapeutic decisions and predicting patient outcomes."
        ],
        [
         "31",
         "Primary Tumor, Solid Tissue Normal",
         "Esophageal carcinoma",
         "TCGA-L5-A88T",
         "Certainly, let's delve into the complex factors surrounding esophageal carcinoma and its impact on survival.\n\n### Tumor Origin\n\n1. **Influence on Metastatic Patterns:**\n   - **Survival Impact:** Esophageal carcinoma typically originates in the mucosal lining of the esophagus, which can rapidly invade local structures due to its anatomical location, leading to advanced-stage disease at diagnosis.\n   - **Biological Rationale:** This propensity for local invasion and rapid metastasis is primarily due to the esophagus's proximity to vital organs and extensive vascular and lymphatic networks.\n   - **Impact on Treatment Accessibility:** The tumor's origin frequently necessitates complex surgical interventions or is often deemed inoperable, limiting the availability and effectiveness of aggressive treatment options, thereby negatively influencing survival.\n\n2. **Histological Interaction:**\n   - **Survival Impact:** Esophageal squamous cell carcinoma (ESCC) and adenocarcinoma (EAC) are the major histological types. Each subtype displays distinct mutation profiles that impact prognosis and treatment responsiveness.\n   - **Biological Rationale:** ESCC often presents with mutations in TP53, while EAC is frequently associated with Barrett’s esophagus and mutations such as KRAS, affecting signaling pathways critical for cell proliferation and apoptosis.\n\n### Sampling Bias\n\n1. **Limitations of Primary Tumor Sampling:**\n   - **Survival Impact:** Traditional genomic analyses may focus on primary tumor samples, which can lead to underrepresentation of metastatic clones, skewing interpretations of disease progression mechanisms.\n   - **Biological Rationale:** Variability in tumor heterogeneity means certain aggressive subclones may not be adequately captured in biopsies, potentially underestimating aggressiveness and influencing survival predictions.\n\n2. **Solid Tissue Normal Sampling:**\n   - **Survival Impact:** Utilizing surrounding normal tissue as a genomic baseline can inadvertently include pre-malignant changes, leading to overinterpretation of mutations as being tumor-specific.\n   - **Biological Rationale:** This misinterpretation can impact biomarker discovery and subsequent survival predictions by inaccurately attributing mutations to cancer cells.\n\n### Key Genes\n\n1. **TP53:**\n   - **Mechanism:** Regulates cell cycle and apoptosis; mutations can lead to unchecked proliferation.\n   - **Survival Impact:** Loss of TP53 function commonly correlates with aggressive disease and poorer survival outcomes.\n\n2. **HER2:**\n   - **Mechanism:** A receptor tyrosine kinase involved in cell growth; amplification can drive tumor progression.\n   - **Survival Impact:** Targetable with trastuzumab, affecting treatment outcomes positively where applicable.\n\n3. **CDH1:**\n   - **Mechanism:** Encodes E-cadherin, a protein critical for cell adhesion; mutations can facilitate metastasis.\n   - **Survival Impact:** Loss enhances invasiveness, typically correlating with a negative prognostic impact.\n\n4. **KRAS:**\n   - **Mechanism:** Part of the RAS/MAPK pathway; mutations drive oncogenic growth signaling.\n   - **Survival Impact:** Historically linked to poor responses to certain targeted therapies, affecting survival negatively.\n\n5. **PIK3CA:**\n   - **Mechanism:** Involved in the PI3K/Akt pathway; mutations can promote survival signaling.\n   - **Survival Impact:** Predictive of responsiveness to PI3K inhibitors, with potential to improve outcomes if targeted.\n\n### Synthesis and Clinical Insights\n\nIn summary, esophageal carcinoma's survival impact is multifactorial, combining influences from tumor origin, histology-specific genomic aberrations, and potential biases in sampling techniques. The interplay between genetic mutations and tumor microenvironment dictates significant variation in survival, highlighting the importance of precise histological and molecular diagnoses. Identifying and targeting specific gene mutations provides a pathway for enhanced therapeutic strategies, potentially improving survival outcomes. Clinically, understanding these complexities aids in tailoring personalized treatment regimens, optimizing patient management, and improving prognosis through more informed decision-making."
        ],
        [
         "32",
         "Primary Tumor, Solid Tissue Normal",
         "Kidney Chromophobe",
         "TCGA-KN-8430",
         "### Tumor Origin\n\n**Impact on Survival:**\n- *Metastatic Patterns and Survival:* Kidney Chromophobe (ChRCC) originates from the distal nephron segment and is generally less aggressive than other renal cell carcinoma (RCC) subtypes such as clear cell RCC. It has a lower propensity for distant metastasis, which positively influences patient survival. The limited spread often makes it more amenable to surgical resection, potentially improving outcomes.\n- *Treatment Accessibility:* Better overall prognosis and generally lower stage at diagnosis improve the chances of successful surgical intervention. Patients with ChRCC often respond well to nephrectomy due to limited metastatic disease compared to other RCC forms.\n\n**Biological Rationale:**\n- The origination from the distal nephron implies a distinct cellular lineage that confers lower metastatic potential, directly impacting survival positively compared to more aggressive subtypes.\n\n### Histology\n\n**Impact on Survival:**\n- *Interaction with Mutation Profiles:* ChRCC is characterized by specific histological features such as perinuclear halos and pale cytoplasm due to its unique cellular makeup. Histologically, these cells often demonstrate minimal mitotic activity, corresponding to a more indolent course.\n- *Mutation Profiles:* Frequently associated mutations in ChRCC include TP53 and PTEN which may influence cell cycle control and apoptotic responses, theoretically contributing to a reduced growth rate and enhanced cell death in the presence of damaging signals.\n\n**Biological Rationale:**\n- Histological features correspond to a lower proliferative index. Paired with specific mutations, this promotes less aggressive tumor behavior, positively influencing survival due to reduced progression rates.\n\n### Sampling Bias\n\n**Limitations of Genomic Analysis:**\n- *Primary Tumor Sampling Bias:* Typically involves tumor tissue without capturing intratumor heterogeneity, potentially obscuring the full mutation spectrum which might include aggressive subclones not sampled.\n- *Solid Tissue Normal Comparisons:* May not always reflect true genetic normality, considering the potential field effect where adjacent “normal” tissues also harbor early changes, leading to misinterpretation of tumor-specific genomic alterations.\n\n**Biological Rationale:**\n- Sampling methodology could lead to underestimations of aggressiveness due to missing genomic data from unsampled regions, potentially influencing both prognostic assessments and treatment strategies.\n\n### Key Genes\n\n**Survival-Associated Genes:**\n1. **TP53:** Regulates cell cycle and apoptosis. Mutations often enhance survivability of mutated cells, affecting how aggressively the tumor behaves.\n2. **PTEN:** Tumor suppressor gene involved in cell cycle regulation. Alterations can lead to unchecked cellular proliferation.\n3. **KIT:** Implicated in cell survival signaling pathways; overexpression or mutations can impact proliferation rates.\n4. **FLCN:** Mutations here are less common but associated with the Birt-Hogg-Dube syndrome, affecting cell growth and survival pathways.\n5. **TSC1/TSC2:** These genes are involved in the mTOR signaling pathway, influencing cellular growth and survival. Alterations may support tumorigenic processes.\n6. **SDHB/SDHC:** Although less frequent in ChRCC, mitochondrial function issues here can influence tumor metabolism and survival rates.\n  \n**Biological Rationale:**\n- These genes collectively orchestrate cellular processes such as growth, apoptosis, and metabolic regulation. Alterations can lead to either slowed tumor dynamics or uncheckable growth, both crucial for predicting survival outcomes.\n\n### Synthesis of Survival Risk Factors\n\nChRCC's relatively indolent course, driven by its tumor origin and distinct histological and genetic profile, generally translates into a favorable survival outlook compared with more aggressive RCC types like clear cell RCC. While the impact of specific gene mutations such as TP53 and PTEN suggests pathways for potential aggressive transformation, the overall survival implications are tempered by ChRCC's intrinsic lower growth and metastatic potential. However, the risks associated with sampling bias in genomic analyses highlight the importance of comprehensive sampling in capturing the full tumor mutational landscape for accurate prognosis and treatment planning. Understanding these nuanced aspects aids in formulating personalized management strategies to optimize patient outcomes."
        ],
        [
         "33",
         "Primary Tumor, Solid Tissue Normal",
         "Kidney renal clear cell carcinoma",
         "TCGA-BP-4986, TCGA-CZ-4865, TCGA-BP-4988, TCGA-BP-4976, TCGA-BP-5199, TCGA-B0-5700, TCGA-BP-5009, TCGA-BP-5006, TCGA-BP-5181, TCGA-BP-4995, TCGA-CW-5590",
         "### Tumor Origin and Impact on Survival\n\n**1. Influence on Metastatic Patterns:**\n   - **Kidney Renal Clear Cell Carcinoma (KIRC)** originates in the epithelial cells of the renal tubules, a region highly vascularized, facilitating early metastasis, particularly to the lungs, bones, and liver. This rapid dissemination negatively impacts patient survival.\n   - **Survival Influence:** Metastatic spread correlates with a more aggressive disease course and reduced survival rates due to increased systemic burden and treatment complexity.\n\n**2. Patient Survival and Treatment Accessibility:**\n   - **Survival Impact:** Treatment accessibility impacts survival significantly. Renal cell carcinomas benefit from targeted therapies such as tyrosine kinase inhibitors, which can be less accessible in resource-limited settings, thus disproportionately affecting survival.\n   - **Biological Rationale:** The tumor's ability to metastasize and its vascular nature require early and aggressive treatment modalities to improve survival outcomes.\n\n### Histology and Mutation Profiles\n\n**1. Interaction with Genetic Mutations:**\n   - **Histological Influence:** KIRC is characterized by clear cytoplasm due to glycogen and lipid content, which is linked with specific genetic mutations such as alterations in the VHL gene.\n   - **Mutational Profiles:** Mutations in key histone-modifying genes and pathways (e.g., PBRM1, SETD2) are common in KIRC and drive tumor aggressiveness.\n\n**2. Outcomes Driven by Histology and Mutation:**\n   - **Survival Influence:** The presence of specific mutations (e.g., VHL inactivation) underpins angiogenesis through the HIF pathway, promoting tumor growth and decreasing survival.\n   - **Biological Rationale:** The convergence of histological factors with mutational profiles facilitates an environment conducive to rapid progression and metastasis.\n\n### Sampling Bias and Genomic Limitations\n\n**1. Limitations of Primary Tumor Sampling:**\n   - **Sampling Bias:** Reliance on primary tumor samples in genomic analyses may not reflect intratumoral heterogeneity or the genetic landscape of metastatic sites.\n   - **Survival Influence:** Biased sampling skews our understanding of therapeutic targets, potentially misestimating survival impacts.\n\n**2. Impact of Solid Tissue Normal Comparisons:**\n   - **Genomic Interpretation Bias:** Comparing tumor tissue to solid tissue normals might overlook genetic alterations common to all renal tissues, misjudging the true oncogenic drivers.\n   - **Survival Influence:** This challenge affects the identification of actionable targets, which could otherwise enhance personalized treatment strategies and improve survival.\n\n### Key Genes and Biological Mechanisms\n\n**1. Survival-Associated Genes:**\n   - **VHL:** Inactivating mutations lead to HIF stabilization, promoting angiogenesis and a nutrient-rich microenvironment, negatively affecting survival.\n   - **PBRM1:** Associated with chromatin remodeling, its inactivation is linked to poor survival due to enhanced cancer cell adaptability.\n   - **SETD2:** Mutations affect genomic stability through impaired histone modification, facilitating tumorigenescence and reducing survival prospects.\n   - **BAP1:** Alterations in this gene impair DNA repair mechanisms, driving aggressive tumor growth and metastasis.\n   - **MTOR:** Pathway activation supports cell growth and proliferation, with mutations indicating reduced therapeutic responsiveness and survival.\n   - **TP53:** Though less common, mutations here indicate poor prognosis due to escape from apoptotic pathways.\n\n**2. Biological Mechanisms:**\n   - **Proliferation Influence:** Many associated genes augment proliferation via metabolic reprogramming and enhanced angiogenesis, directly affecting survival.\n   - **Immune Evasion:** Genetic alterations contribute to immune evasion, downregulating immune surveillance and skewing tumor-immune interactions negatively.\n\n### Synthesis of Key Survival Risk Factors\n\n**Conclusion:**\n- **Key Insights:** Effective management of KIRC hinges on understanding the interplay of genetic mutations with tumor origin and histology. The vascular nature of the tumor, coupled with actionable mutations in VHL, PBRM1, and other pathways, underscores the importance of early detection and therapeutic stratification.\n- **Clinically Relevant Insights:** Survival is adversely impacted by factors such as metastasis propensity, immune evasion, and limited treatment access, emphasizing the need for broad-based genomic approaches that account for heterogeneity and potential sampling biases.\n- **Impact on Patient Survival:** Integrating these insights into clinical practice could enhance personalized treatment approaches, particularly in leveraging targeted therapies that address the specific mutational landscape of KIRC, ultimately improving patient outcomes."
        ],
        [
         "34",
         "Primary Tumor, Solid Tissue Normal",
         "Kidney renal papillary cell carcinoma",
         "TCGA-BQ-7056, TCGA-BQ-7049",
         "### Tumor Origin\n\n**Influence on Survival:**\n\n1. **Metastatic Patterns:**\n   - Kidney renal papillary cell carcinoma (KIRP) originates in the renal pelvis, potentially influencing metastatic routes primarily to the lungs, liver, bones, and sometimes the brain.\n   - A direct impact on survival outcomes is seen through the potential for early metastasis, often before significant local symptoms develop. Early metastasis can drastically decrease survival rates.\n\n2. **Patient Survival:**\n   - The site of origin in the kidney affects how promptly symptoms might prompt diagnostic procedures, influencing stage at diagnosis.\n   - Tumor origin impacts access to surgical interventions; though nephrectomy is often feasible, advanced metastasis limits surgical benefits, thereby decreasing survival rates.\n\n3. **Treatment Accessibility:**\n   - Unlike other renal cancers, KIRP might not respond as effectively to standard RCC treatments like VEGF inhibitors, complicating therapeutic efforts and negatively impacting survival.\n\n**Biological Rationale:**\n- Originating in epithelial cells, KIRP's predilection for early systemic dissemination emphasizes the importance of genetic predisposition and environmental factors in its aggressive nature.\n\n**Genomic Interpretation Bias:**\n- Origin-based bias arises due to uneven sampling of early versus advanced-stage tumors, potentially skewing genomic data towards less aggressive early-stage profiles.\n\n### Histology\n\n**Influence on Survival:**\n\n1. **Mutation Interaction:**\n   - Certain histological subtypes correlate with particular mutation profiles, like alterations in MET gene, which can drive aggressive tumor behavior.\n   - Differential expression related to histological variance could cause varied responsiveness to therapeutic agents, impacting outcomes.\n\n**Biological Rationale:**\n- Histological variants often exhibit unique cellular architecture which can influence how cells proliferate and respond to cancer therapies. Papillary structures might contribute to different rates of nutrient diffusion and microenvironmental conditions, affecting growth rates.\n\n**Bias in Genomic Interpretation:**\n- Sample collections favor certain histological presentations, possibly underrepresenting more aggressive forms in public data sets, causing potential oversight of aggressive genomic signatures.\n\n### Sampling Bias\n\n**Limitations of Genomic Analysis:**\n\n1. **Primary Tumor Bias:**\n   - Analysis often relies on primary tumor samples, possibly missing genetic heterogeneity present in metastatic sites.\n   \n2. **Solid Tissue Normal Bias:**\n   - Comparisons with adjacent “normal” tissues risk mischaracterizing adjacent benign pathology as the baseline, impacting interpretation accuracy.\n\n**Biological Impact:**\n- Genomic data primarily from primary tumors may underestimate survival-associated mutations present in less accessible metastatic sites.\n\n**Impact on Survival:**\n- Sampling bias could obscure key genomic drivers of poor outcomes, affecting prognosis and personalized medicine approaches.\n\n### Key Genes\n\n1. **MET:**\n   - Plays a critical role in cell proliferation and survival. Mutations in MET are often associated with aggressive disease, particularly impacting survival adversely by facilitating rapid tumor growth and metastasis.\n\n2. **FH (Fumarate Hydratase):**\n   - Involvement in metabolic pathways; mutations here can lead to excess fumarate, impacting cellular metabolism and thus contributing to tumorigenic phenotypes associated with aggressive growth.\n\n3. **VHL (Von Hippel-Lindau Tumor Suppressor):**\n   - Although less common in KIRP than clear cell RCC, loss of function mutations can dysregulate angiogenesis, contributing subtly to survival outcomes when present.\n\n4. **CDKN2A:**\n   - Inhibits cell cycle progression; alterations may lead to unchecked proliferation, impacting survival through potential resistance to apoptosis.\n\n5. **NF2 (Neurofibromin 2):**\n   - Functions in cellular adhesion and signaling, where mutations could disrupt cellular structural integrity, impacting metastasis and thereby survival.\n\n6. **TP53:**\n   - Regulates apoptosis; mutations can lead to resistance to cell death, facilitating tumor persistence and relapse.\n\n**Biological Rationale:**\n- These genes play diverse roles from direct regulation of the cell cycle to metabolic signaling, thereby altering tumor behavior in ways that either augment or mitigate survival risks.\n\n**Bias and Survival Impact:**\n- Genetic variation between individuals means that expression or mutation frequencies recorded in studies vary due to ethnic, geographical, or sampling biases, impacting survival statistics and risk assessment.\n\n### Conclusion\n\nIn synthesizing these factors, the key survival risk factors for KIRP emphasize the aggressive nature of the cancer due to its histology and genetic heterogeneity. Patient outcomes are most detrimentally affected by early metastatic potential driven by specific mutations, histological influences, and biases in available genomic data. Clinically, understanding these factors can better inform treatment stratification and patient management, potentially leading to improved survival through targeted therapies and personalized medical approaches."
        ],
        [
         "35",
         "Primary Tumor, Solid Tissue Normal",
         "Liver hepatocellular carcinoma",
         "TCGA-BD-A3ER",
         "### Tumor Origin\n\n**Influence on Survival:**\nLiver hepatocellular carcinoma (HCC), originating in hepatocytes, significantly impacts survival due to its tendency for late diagnosis and propensity for vascular invasion, facilitating metastasis primarily to the lungs and additional sites like bone and adrenal glands.\n\n**Biological Rationale:**\n- **Metastatic Patterns:** The liver's unique dual blood supply from the hepatic artery and portal vein enables hematogenous spread, particularly through the hepatic vein draining into the systemic circulation. This enhances the chance of metastasis, particularly to the lungs.\n- **Treatment Accessibility:** As the liver is a critical organ involved in detoxification and metabolism, its impairment by HCC complicates treatments like systemic chemotherapies, potentially leading to hepatotoxicity, thereby limiting therapeutic options.\n\n**Potential Biases:**\nOften, the diagnosis occurs when the disease is advanced, biasing survival statistics towards poorer outcomes due to advanced-stage presentation at diagnosis.\n\n### Histology\n\n**Influence on Survival:**\nHCC's histological diversity, including variants like fibrolamellar and clear cell subtypes, correlates with distinct genetic alterations, influencing prognosis.\n\n**Biological Rationale:**\n- **Interaction with Mutation Profiles:** Common mutations involve the TERT promoter, TP53, and CTNNB1, each affecting cellular mechanisms like telomere maintenance, DNA repair, and Wnt signaling. For instance, TP53 mutations can lead to treatment resistance and poorer outcomes.\n- **Histological Subtypes:** Variants like fibrolamellar carcinoma, which often presents in younger patients with no liver cirrhosis, generally show better survival outcomes compared to conventional HCC, illustrating how histology can drive prognosis through unique molecular pathways.\n\n**Potential Biases:**\nHistological samples can sometimes underrepresent intratumoral heterogeneity, potentially skewing mutation profiling and consequent clinical decision-making.\n\n### Sampling Bias\n\n**Limitations:**\nIn genomic analyses, using primary tumor or solid tissue normal samples can lead to underappreciation of genetic heterogeneity and tumor evolution, influencing survival predictions.\n\n**Potential Biases:**\n- **Primary Tumor Bias:** These samples can fail to capture metastatic potential since they represent initial tumor genetics rather than subclonal evolution distinctive in metastases.\n- **Solid Tissue Normal Bias:** These samples may not account for field cancerization effects, where adjacent 'normal' tissues harbor pre-malignant changes impacting treatment response and outcome projections.\n\n### Key Genes\n\n**Influence on Survival:**\nHighlighting several key genes provides insight into survival prognosis:\n\n1. **TERT:** Reactivates telomerase, aiding cellular immortality—a hallmark of cancer. Its activation often portends poorer survival due to sustained cellular proliferation.\n\n2. **TP53:** A critical tumor suppressor regulating the cell cycle. Mutations here are associated with poorer survival due to impaired apoptosis and genomic instability.\n\n3. **CTNNB1:** Part of the Wnt signaling pathway, mutations can lead to unchecked cellular proliferation and heterogeneity, typically correlating with variable impact on survival.\n\n4. **AXIN1:** Another Wnt pathway regulator; mutations can negatively impact survival by promoting tumorigenesis.\n\n5. **ARID1A:** Involved in chromatin remodeling, with alterations potentially leading to genomic instability, adversely affecting survival.\n\n6. **VEGFA:** Promotes angiogenesis; overexpression can be linked to poor prognosis due to enhanced vascular supply facilitating tumor growth.\n\n7. **PDGFRB:** Essential for vascular development and angiogenesis, mutations can affect survival by altering tumor microvasculature dynamics.\n\n**Potential Biases:**\nSomatic mutation studies might underrepresent non-coding regions affecting gene regulation, potentially skewing interpretations about their full impact on survival.\n\n### Conclusion\n\nIntegrating these aspects reveals that the prognosis of HCC is dictated by a combination of the primary tumor's aggressive biology, the genetic landscape marked by mutations in key genes, and the inherent limitations of genomic sampling. Importantly, clinical outcomes are often further complicated by the liver’s crucial functions and the late-stage detection of this cancer, emphasizing the necessity for early diagnosis and novel therapeutic strategies leveraging genetic insights. Such detailed understanding aids in developing targeted interventions and tailoring individual treatments to improve patient survival prospects."
        ],
        [
         "36",
         "Primary Tumor, Solid Tissue Normal",
         "Lung adenocarcinoma",
         "TCGA-38-4630, TCGA-05-5420, TCGA-38-4629",
         "Certainly, let's break down how lung adenocarcinoma impacts survival by considering tumor origin, histology, sampling biases, and key genes.\n\n### 1. Tumor Origin\n\n#### Influence on Survival\n- **Impact on Metastatic Patterns:** Lung adenocarcinoma commonly originates in the peripheral zones of the lungs. This origin allows the tumor more opportunities to access the vascular system, facilitating metastasis to distant organs like the brain, liver, and bones, which diminishes survival rates if metastatic foci are untreated.\n- **Treatment Accessibility:** Given its peripheral origin, detecting lung adenocarcinoma early can be challenging, affecting the timely administration of effective therapies. Delays in diagnosis can limit surgical options, impacting survival negatively.\n\n#### Biological Rationale\n- **Metastatic Spread:** The peripheral origin often aligns with early vascular and lymphatic spread, augmented by specific integrins and adhesion molecules enhancing invasion and dissemination.\n- **Detection and Treatment Delays:** Late-stage detection typically coincides with a higher burden of disease, limiting the efficacy of surgeries or localized treatments.\n\n#### Potential Biases\n- **Detection Bias:** Peripheral tumors might evade early detection techniques like chest X-rays but may be caught in late stages using advanced imaging, formulating a bias where more aggressive disease appears more frequently in datasets.\n\n### 2. Histology\n\n#### Influence on Survival\n- **Mutation Profile Interactions:** Histology in lung adenocarcinoma is characterized by glandular differentiation, with certain histological subtypes linked with specific genetic mutations (e.g., EGFR, KRAS). These mutations have a profound impact on prognosis and treatment sensitivity.\n\n#### Biological Rationale\n- **Mutation-Driven Outcomes:** EGFR mutations tend to correlate with better responses to tyrosine kinase inhibitors (TKIs), enhancing survival, whereas KRAS mutations often entail poorer survival due to limited targeted therapy options.\n- **Histological Assessment:** Variations in cellular differentiation impact proliferation rates and metastatic potential, which are critical determinants of prognosis.\n\n#### Potential Biases\n- **Sampling Bias in Biopsy:** Biopsies may not capture intra-tumoral heterogeneity, leading to misrepresentation of mutation load and subsequent treatment resistance prediction limitations.\n\n### 3. Sampling Bias\n\n#### Influence on Survival\n- **Quality and Source of Samples:** Genomic analyses often depend on samples from primary tumors, but these may not reflect the mutational profile of metastatic sites, possibly skewing survival predictions.\n\n#### Biological Rationale\n- **Primary vs Metastatic Tumor Profiles:** Genomic heterogeneity between primary and metastatic lesions can lead to underestimating the systemic burden of the disease and the potential for treatment resistance.\n- **Tissue Sampling Decisions:** Lack of comprehensive sampling from multiple tumor sites limits the full understanding of proliferative and resistance mechanisms throughout disease progression.\n\n#### Potential Biases\n- **Limitations in Genomic Analysis:** Reliance solely on primary tumor samples can obscure drivers of treatment resistance, leading to overly optimistic survival estimations based on incomplete genomic interpretations.\n\n### 4. Key Genes Associated with Survival\n\n#### Influence on Survival\n- **EGFR**: Mutations often improve survival due to responsiveness to TKIs.\n- **TP53**: Mutations usually relate to poor survival, given their role in loss of cell-cycle control.\n- **KRAS**: Frequently associated with aggressive disease and reduced survival due to lack of effective targeted therapies.\n- **ALK**: Positive restructuring is linked with favorable prognosis if proper targeted therapies (e.g., ALK inhibitors) are applied.\n- **PD-L1**: High expression might correlate with better survival in the context of immunotherapy treatment due to improved immune surveillance.\n- **STK11/LKB1**: Mutations can correlate with worse survival as they are often associated with suppression of apoptosis and increased resistance to treatment.\n- **MET**: Amplifications or mutations are often linked with poorer outcomes but represent potential targets for precision therapies.\n\n#### Biological Rationale\n- **Pathways and Mechanisms:** Each gene influences cellular mechanisms differently:\n  - Proliferation: EGFR, KRAS\n  - Immune Response: PD-L1\n  - Apoptosis Regulation: TP53, STK11\n  - Cellular Invasion and Metastasis: MET, ALK\n\n#### Biases in Data Interpretation\n- **Driver vs Passenger Mutations:** Distinction between mutations contributing directly to cancer progression versus those from genomic instability can mislead treatment planning and prognostic predictions.\n\n### Conclusion\n\nSynthesizing the elements of lung adenocarcinoma:\n- **Key Risk Factors:** Tumor location, mutation profile, and histological subtype are critical; peripheral and aggressive histological features with resistant mutations generally confer poorer prognosis.\n- **Clinically Relevant Insights:** Early-stage detection, targeted mutation analysis, and comprehensive sampling frameworks enhance therapeutic approach and potentially improve survival rates.\n- **Impact on Patient Survival:** Optimizing treatment strategies based on detailed genetic and histological information can significantly improve patient management and survival outcomes, underscoring the need for precise and individualized oncological approaches."
        ],
        [
         "37",
         "Primary Tumor, Solid Tissue Normal",
         "Lung squamous cell carcinoma",
         "TCGA-21-1070, TCGA-60-2715, TCGA-21-1078, TCGA-18-3409, TCGA-21-1077, TCGA-21-1083, TCGA-21-1078, TCGA-18-5595, TCGA-21-1077, TCGA-60-2712, TCGA-21-1070, TCGA-60-2715, TCGA-21-1083, TCGA-60-2696, TCGA-51-6867, TCGA-60-2712",
         "Certainly. Let's dive into lung squamous cell carcinoma (LSCC) and its impact on survival through its biological and genomic characteristics, while considering biases and key genetic factors.\n\n### Tumor Origin\n1. **Metastatic Patterns and Patient Survival**: LSCC originates from the epithelial cells in the lining of the airways and is usually centrally located. It tends to metastasize later compared to adenocarcinoma but still exhibits aggressive local invasion. Its central origin can impede surgical access and decrease survival rates due to complications associated with resectability. LSCC often presents with symptoms like coughing or airway obstruction which can prompt earlier detection, but its central location can make surgery risky.\n\n2. **Treatment Accessibility**: Centrally located tumors may respond differently to radiation and are not as frequently amenable to targeted therapies as adenocarcinomas. The lack of approved targeted therapies specific to LSCC historically has led to poorer survival outcomes.\n\n### Histology\n1. **Histological Interactions with Mutations**: LSCC typically exhibits alterations in key pathways such as the PI3K/AKT/mTOR pathway. Unlike adenocarcinomas, EGFR and ALK mutations are rare, limiting the utility of targeted therapies that have transformed treatment in other lung cancer types. The high mutation burden, such as TP53 mutations, contributes to a more aggressive phenotype and resistance to standard therapies, negatively impacting survival.\n\n2. **Survival Outcomes**: Histology influences treatment responsiveness and survival. LSCC’s distinct mutational landscape often reduces effective treatment options beyond chemotherapy and immunotherapy.\n\n### Sampling Bias\n1. **Limitations of Primary Tumor and Solid Tissue Normal**: LSCC sampling often involves core needle biopsies, which may not capture the tumor heterogeneity or mutations present in metastatic sites. Solid tissue normal samples may exhibit field cancerization, where seemingly normal tissues near tumors bear oncogenic changes, complicating genomic interpretation and potentially leading to underestimation of mutation significance.\n\n2. **Genomic Analysis Bias**: Small biopsies may miss relevant subclonal populations, influencing perceived mutation prevalence and interpretation of survival data.\n\n### Key Genes\n1. **TP53**: Frequently mutated in LSCC, this gene’s alteration leads to loss of apoptosis control, resulting in unchecked cell proliferation. Poor prognostic indicator due to enhanced aggressiveness.\n\n2. **FGFR1**: Amplification is common in LSCC and contributes to cell survival and proliferation. Targeting FGFR pathways is currently under investigation, but its amplification correlates with poor outcomes.\n\n3. **PIK3CA**: Mutations drive survival signaling via the PI3K/AKT pathway, enhancing cell cycle progression and survival. These alterations often signify worse prognosis.\n\n4. **SOX2**: Amplification promotes oncogenic transcriptional activity, linked to increased tumor proliferation and decreased survival.\n\n5. **DDR2**: Mutations in this tyrosine kinase receptor can promote metastasis and survival. Clinical trials targeting this pathway show variable outcomes, highlighting survival impact.\n\n6. **KMT2D**: Alterations in this gene, involved in chromatin modification, can lead to dysregulation of gene expression, promoting oncogenesis and impacting survival negatively.\n\n7. **NOTCH1**: Mutations lead to dysregulation of cell differentiation and apoptosis, with varied implications for survival based on the mutational context.\n\n### Synthesis and Clinical Insights\nKey survival risk factors in LSCC include high mutation burden, central tumor location, limited efficacy of targeted therapies, and significant genomic heterogeneity, reflected in poor survival outcomes and response rating. Genetic profiling focusing on pathways such as TP53, FGFR, and PI3K may guide personalized treatment approaches. Clinically, ongoing research into exploiting molecular vulnerabilities, such as FGFR inhibitors and NOTCH pathway modulation, offers prospects for improving LSCC survival outcomes, emphasizing the importance of integrating genomic insights into therapeutic decision-making. \n\nRecognizing the underpinnings of LSCC’s biology and genomic features is crucial for developing novel, more effective therapeutic strategies that could substantially enhance patient survival rates."
        ],
        [
         "38",
         "Primary Tumor, Solid Tissue Normal",
         "Ovarian serous cystadenocarcinoma",
         "TCGA-09-2056",
         "Certainly, I will explain how ovarian serous cystadenocarcinoma influences survival through various aspects:\n\n### Tumor Origin\n\n1. **Metastatic Patterns and Survival Influence:**\n   - **Step-by-step Influence:** Ovarian serous cystadenocarcinoma typically originates from the epithelial cells of the ovary and tends to spread within the peritoneal cavity early in the disease course, often leading to advanced-stage detection.\n   - **Biological Rationale:** The strategic anatomical positioning facilitates early dissemination into the peritoneal cavity and omentum, significantly complicating surgical options and often necessitating aggressive systemic therapies.\n   - **Survival Impact:** This widespread intraperitoneal spread often results in lower survival rates due to the difficulty of achieving complete surgical resection and the potential resistance to chemotherapy at advanced stages.\n\n2. **Treatment Accessibility:**\n   - **Influence:** The disease's progression impacts treatment options, with aggressive therapy needed for optimal outcomes in later stages.\n   - **Potential Barriers:** Limited access to comprehensive treatment facilities may worsen prognosis, especially in lower-resource settings.\n\n### Histology\n\n1. **Interaction with Mutation Profiles:**\n   - **Step-by-step Influence:** Histologically, serous cystadenocarcinomas are characterized by high-grade features and complex genomic alterations, often associated with mutations such as TP53.\n   - **Biological Rationale:** Such mutations contribute to genomic instability and aggressive tumor behavior, impacting both tumor progression and treatment responses.\n   - **Survival Impact:** High-grade histological features coupled with frequent TP53 mutations typically result in poorer outcomes and highlight the necessity of individualized therapeutic approaches.\n\n### Sampling Bias\n\n1. **Limitations in Genomic Analysis:**\n   - **Step-by-step Influence:** Sampling biases can arise due to reliance on primary tumor samples or non-cancerous (solid tissue normal) samples for comparative genomics.\n   - **Biological Rationale:** Primary tumors may not reflect the full heterogeneity of metastatic sites, while solid tissue normal is subject to field effects that may not provide a true control.\n   - **Survival Bias Impact:** These biases can lead to an underestimation of the genetic diversity present in metastatic sites, affecting the understanding of potential therapeutic targets.\n\n### Key Genes\n\n1. **Survival-associated Genes and Mechanisms:**\n   - **BRCA1/2:** Mutations here can impair DNA repair, augmenting genomic instability but may also render tumors more susceptible to PARP inhibitors, potentially improving survival.\n   - **TP53:** Frequently mutated in serous carcinomas, leading to loss of apoptosis regulation and unchecked cell proliferation, associated with aggressive phenotypes.\n   - **NF1:** Loss can result in enhanced RAS activity, promoting proliferation and survival.\n   - **PIK3CA/PTEN:** Aberrations can lead to activation of the PI3K/AKT pathway, promoting survival and chemoresistance.\n   - **RB1:** Inactivation can disrupt cell cycle control, driving aggressive tumor growth.\n   - **CDK12:** Mutations may influence genomic stability and DNA repair necessary for effective response to certain chemotherapeutics.\n   - **NOTCH3:** Overexpression may contribute to cell proliferation and chemoresistance.\n\n### Synthesis of Key Survival Risk Factors\n\n1. **Clinically Relevant Insights:**\n   - **High-Grade Histology and Genomic Instability:** These are primary factors contributing to poor prognosis.\n   - **Genomic Profile Adaptation:** Understanding the comprehensive mutation landscape is critical for tailoring targeted therapies, such as PARP inhibitors for BRCA mutation carriers.\n   - **Resource Accessibility:** Ensures patients can receive optimal care and therapeutic interventions, directly affecting survival rates.\n   - **Sampling Consideration Requirements:** Using representative tissues for genomic analysis can enhance personalized medicine approaches.\n\n**Conclusion:** Key survival risk factors in ovarian serous cystadenocarcinoma revolve around the high-grade nature of the tumor, genomic instability due to specific mutations, and thorough analysis of not only the primary but also metastatic sites. These factors are crucial for developing targeted treatment strategies that could ultimately improve patient outcomes. Understanding and addressing sampling biases, alongside expanding access to comprehensive cancer care, remain pivotal in optimizing treatment efficacy and survival rates."
        ],
        [
         "39",
         "Primary Tumor, Solid Tissue Normal",
         "Rectum adenocarcinoma",
         "TCGA-AF-3913, TCGA-AF-3914, TCGA-AG-A036",
         "### Tumor Origin\n\nRectum adenocarcinoma, a subset of colorectal cancer, originates in the epithelial cells lining the rectum. Its origin influences survival by dictating metastatic pathways, treatment options, and to some extent, early detection strategies.\n\n1. **Metastatic Patterns**: Rectum adenocarcinomas tend to metastasize primarily to regional lymph nodes and the liver. This progression affects survival negatively as metastatic disease is often less responsive to local treatments like surgery or radiation.\n\n2. **Patient Survival**: The anatomical proximity to vital structures and the lymphatic drainage pattern result in early spread, complicating early-stage intervention and reducing survival likelihood compared to more distally located colorectal cancers.\n\n3. **Treatment Accessibility**: Rectal cancer often requires multimodal treatment (surgery, radiation, and chemotherapy), which is complex and resource-intensive, impacting patient outcomes based on healthcare access.\n\n### Histology and Mutation Profiles\n\nThe histological nature of rectum adenocarcinoma involves glandular formation, which often correlates with specific mutation profiles influencing prognosis.\n\n1. **Histological Features**: Well-differentiated tumors (more glandular) typically indicate better outcomes, while poorly differentiated tumors correlate with more aggressive behavior and worse survival.\n\n2. **Interaction with Mutations**: Common mutations include KRAS, NRAS, and BRAF; mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) can predict responsiveness to immunotherapy and thus improve survival.\n\n3. **Impact on Outcomes**: For instance, mutated KRAS or NRAS ties to reduced effectiveness of certain targeted therapies (e.g., EGFR inhibitors). Conversely, MSI-H status can improve survival through enhanced immunotherapy efficacy.\n\n### Sampling Bias: Limitations of Primary Tumor and Solid Tissue Normal\n\n1. **Sample Source**: Differences in molecular profiles between primary tumors and metastatic sites can lead to biased results if only primary tumor samples are analyzed.\n\n2. **Solid Tissue Normal Comparisons**: These controls might not fully represent genetically \"normal\" tissues, potentially skewing interpretations of mutational impacts.\n\n3. **Interpretation Bias**: Such biases may affect the clinical utility of genomic results, leading to inappropriate prognostic or treatment decisions.\n\n### Key Survival-Associated Genes\n\n1. **APC**: Mutation in this tumor suppressor often initiates the adenoma-carcinoma sequence, driving proliferation and early tumorigenesis.\n   \n2. **TP53**: A key regulator of apoptosis, TP53 mutations can lead to unchecked cell cycle progression, contributing to worse prognosis.\n\n3. **KRAS**: Involved in cell signaling, KRAS mutations promote uncontrolled cell growth and are associated with resistance to EGFR-targeted therapies.\n\n4. **BRAF**: Mutations in this gene lead to downstream signaling activation, correlating with poor prognosis, particularly in V600E mutations.\n\n5. **PIK3CA**: Alters cell survival signals, with mutations potentially indicating poor response to certain therapies but accessible to specific PI3K inhibitors.\n   \n6. **MLH1**: Involved in DNA mismatch repair, its deficiency correlates with MSI-H status, better survival with immunotherapy in select cases.\n\n### Synthesis of Key Survival Risk Factors\n\n- **Metastatic Dissemination**: Primary rectal tumor characteristics driving early spread, impacting available treatment windows and long-term outcomes.\n- **Histological Implication**: The interplay between differentiation and mutational landscape critically determines treatment efficacy and survival.\n- **Genomic Sample Bias**: Understand that locational and histologic selection biases can obscure true genomic predictions impacting clinical strategies.\n- **Gene Profiles Impacting Survival**: Identifying key genes aids in predicting prognosis and shaping individualized treatment strategies, crucial for improving patient survival.\n\nIn conclusion, integrating tumor biology with technological understanding of genomics provides a clear pathway to optimizing rectum adenocarcinoma patient outcomes through precision approaches, improved diagnosis metrics, and individualized treatment plans."
        ],
        [
         "40",
         "Primary Tumor, Solid Tissue Normal",
         "Sarcoma",
         "TCGA-IF-A4AK",
         "To comprehensively address how Sarcoma impacts survival, it is essential to examine various elements affecting outcomes, including tumor origin, histology, potential sampling biases, and key genetic mutations. Each factor plays a critical role in understanding patient prognosis and therapy options, which I'll detail below.\n\n### Tumor Origin\n\n1. **Metastatic Patterns:**\n   - **Influence on Survival:** Sarcomas originate from mesenchymal tissue, affecting bones, muscles, and connective tissues, which inherently leads to distinct metastatic patterns when compared to carcinomas. They often metastasize hematogenously, leading to secondary growths primarily in the lungs, influencing survival negatively.\n   - **Biological Rationale:** The mesenchymal origin facilitates certain pathways for dissemination. The absence of lymphatic spread mechanisms common in carcinomas might make early detection of metastases more challenging.\n   - **Treatment Accessibility:** Due to their rare nature and varied presentation, the accessibility and development of targeted therapies are limited, negatively impacting survival rates.\n\n### Histology\n\n1. **Mutation Profiles and Outcome:**\n   - **Influence on Survival:** Different sarcoma subtypes express diverse histological features with varied prognostic implications. For instance, leiomyosarcoma and liposarcoma demonstrate distinct genetic mutations affecting survival.\n   - **Biological Rationale:** Histological variation results from mutations in key signaling pathways, such as those affecting cell differentiation or proliferation. This diversity makes uniform treatment difficult, leading to differential survival outcomes.\n   - **Patient Outcome Driven by Mutations:** Certain mutations, like those in the TP53 gene, can predispose cells to higher malignancy or aggressive behavior, worsening prognosis.\n\n### Sampling Bias\n\n1. **Primary Tumor and Solid Tissue Normal:**\n   - **Influence on Survival Analysis:** Genomic analyses often sample from primary tumors without accounting for heterogeneity or presence of clonal evolution that occurs as the tumor metastasizes.\n   - **Biological Rationale:** Primary tumors may not fully represent the genetic landscape of metastatic sites. Solid tissue normals are often used to compare, potentially masking genetic drivers present only in the tumor.\n   - **Potential Biases:** Results may underestimate pathogenic mutations leading to improper assessment of oncogenic pathways and hence treatment inefficacies.\n\n### Key Genes Affecting Survival\n\n1. **TP53:** Regulates cell cycle arrest and apoptosis. Mutations here often lead to unchecked cell proliferation, leading to poorer outcomes.\n2. **RB1:** Controls progression through the cell cycle. Loss of function can lead to increased malignancy.\n3. **MDM2:** Often amplified in sarcomas, this gene inhibits p53, enhancing survival, growth, and metastasis of cancer cells.\n4. **CDK4:** Involved in cell cycle regulation, its amplification can lead to increased cell division rates.\n5. **KIT:** Mutations can drive oncogenic signaling in gastrointestinal stromal tumors (GISTs), affecting treatment response and survival.\n6. **PDGFRA:** Like KIT, mutations contribute to increased oncogenic signaling in GISTs, influencing survival and responsiveness to tyrosine kinase inhibitors.\n7. **AXL:** Involved in EMT and metastasis, often associated with resistance to certain therapies.\n8. **PTEN:** Tumor suppressor gene; loss leads to unchecked PI3K/AKT pathway activation, enhancing survival negatively.\n\n### Synthesis and Clinical Relevance\n\nIn conclusion, sarcoma survival is influenced by a complex interplay of origin, histology, and genetic mutations. The mesenchymal origin predisposes sarcomas to different metastatic behaviors, while histological variability complicates treatment strategies. Key mutations in pathways involving cell cycle control and survival (such as TP53, RB1, and KIT) highlight critical molecular targets for therapy.\n\nWhile genomic studies greatly enhance our understanding, inherent sampling biases in primary tumors can misrepresent the metastatic landscape, necessitating more comprehensive profiling. Clinically, improving targeted therapy requires enhanced genomic analyses across all tumor sites and incorporating emerging insights into standard care.\n\nFocusing on these survival risk factors enables better-identifying patients at risk and tailoring treatments, improving overall outcomes for sarcoma patients."
        ],
        [
         "41",
         "Primary Tumor, Solid Tissue Normal",
         "Uterine Corpus Endometrial Carcinoma",
         "TCGA-AX-A2H8",
         "### Tumor Origin\nUterine Corpus Endometrial Carcinoma (UCEC) originates from the lining of the uterus and impacts survival primarily through its metastatic pattern. \n\n1. **Metastatic Patterns**: The primary route of metastasis is through local invasion and subsequent spread to pelvic and para-aortic lymph nodes. Hematogenous spread, although less common, can occur, affecting organs such as the lungs and liver.\n   - **Influence on Survival**: Early stage detection often correlates with better outcomes due to localized confinement, while advanced stages with metastasis show poorer prognosis.\n   - **Biological Rationale**: The endometrial lining's proximity to a rich network of blood vessels and lymphatics facilitates easier dispersal of cancerous cells.\n   - **Impact on Treatment Accessibility**: Stage at diagnosis significantly influences treatment options, with early stage allowing for potentially curative surgery, while advanced stages may require more extensive systemic therapies.\n\n### Histology\nThe histological subtype of UCEC plays a crucial role in survival outcomes through its interaction with mutation profiles.\n\n1. **Subtypes**: Common subtypes include endometrioid, serous, and clear cell carcinoma.\n   - **Influence on Survival**: Endometrioid carcinoma is often associated with better prognosis due to its generally lower grade and less aggressive behavior, unlike serous and clear cell types which are aggressive and have a poorer prognosis.\n   - **Biological Rationale**: These subtypes are driven by different genetic landscapes—endometrioid often presents with PTEN mutations, while serous types frequently harbor TP53 mutations, influencing proliferation and apoptosis resistance.\n   - **Mutation Profiles**: These profiles guide targeted therapy options—e.g., PI3K inhibitors in PTEN-mutated tumors can be explored to improve outcomes.\n\n### Sampling Bias\nGenomic analyses in UCEC can be affected by sampling bias.\n\n1. **Primary Tumor vs. Solid Tissue Normal**: Reliance on primary tumor samples without adequate representation of adjacent normal tissues can skew mutation prevalence assessments.\n   - **Potential Bias**: This may lead to over- or underestimation of mutation frequency, affecting the identification of actionable targets.\n   - **Influence on Interpretation**: Misclassification can occur if somatic mutations are mischaracterized as germline or vice versa, potentially impacting therapeutic decision-making.\n\n### Key Genes\nSeveral genes are crucial in determining UCEC survival, influencing processes like proliferation, immune response, and apoptosis.\n\n1. **PTEN**: Involved in cell cycle regulation and apoptosis.\n   - **Impact**: Loss-of-function mutations often result in uncontrolled cell proliferation.\n   \n2. **PIK3CA**: Part of the PI3K/AKT pathway, pivotal in cell growth and survival.\n   - **Impact**: Activating mutations can drive oncogenic proliferation and correlate with poor prognosis.\n\n3. **TP53**: Crucial for genome integrity and apoptosis.\n   - **Impact**: Mutations often found in serous subtypes lead to aggressive tumor behavior.\n\n4. **ARID1A**: Involved in chromatin remodeling.\n   - **Impact**: Mutations can lead to transcriptional dysregulation, impacting tumor progression.\n\n5. **MSI (Microsatellite Instability)**: Often associated with MMR (mismatch repair) deficiency.\n   - **Impact**: High MSI correlates with better immunotherapy responses due to heightened immunogenicity.\n\n6. **CTNNB1**: Affects the Wnt signaling pathway.\n   - **Impact**: Mutations can lead to aberrant cell signaling and increased tumor invasiveness.\n\n### Conclusion\nSurvival in UCEC is multifactorial, influenced by tumor origin, histological subtype, and genomic alterations. Early detection and identification of key genetic drivers are imperative for improved prognostic stratification and personalized treatment regimens. Addressing sampling biases and understanding mutation landscapes in diverse histological contexts are critical for developing effective therapies, ultimately enhancing patient outcomes. Emphasizing regular screening and sophisticated molecular profiling can aid in tailoring interventions that align with the underlying biological mechanisms of each case."
        ]
       ],
       "shape": {
        "columns": 4,
        "rows": 42
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Normalized Sample Type</th>\n",
       "      <th>Study Name</th>\n",
       "      <th>Case IDs</th>\n",
       "      <th>generated_description</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Blood Derived Normal, Metastatic</td>\n",
       "      <td>Skin Cutaneous Melanoma</td>\n",
       "      <td>TCGA-WE-A8ZR</td>\n",
       "      <td>## Tumor Origin and Its Influence on Survival\\...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Blood Derived Normal, Metastatic</td>\n",
       "      <td>Thyroid carcinoma</td>\n",
       "      <td>TCGA-EM-A2CS</td>\n",
       "      <td>Thyroid carcinoma showcases distinct influence...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Adrenocortical carcinoma</td>\n",
       "      <td>TCGA-P6-A5OG</td>\n",
       "      <td>### Tumor Origin\\n\\n**Influence on Survival:**...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Bladder Urothelial Carcinoma</td>\n",
       "      <td>TCGA-E7-A8O8</td>\n",
       "      <td>### Tumor Origin and Metastatic Patterns\\n\\n**...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Brain Lower Grade Glioma</td>\n",
       "      <td>TCGA-HT-A619, TCGA-R8-A73M</td>\n",
       "      <td>### Tumor Origin\\n\\n**Influence on Survival:**...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Breast invasive carcinoma</td>\n",
       "      <td>TCGA-AR-A2LR, TCGA-D8-A146, TCGA-BH-A0B6, TCGA...</td>\n",
       "      <td>### Tumor Origin and Its Influence on Survival...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Cervical squamous cell carcinoma and endocervi...</td>\n",
       "      <td>TCGA-C5-A902, TCGA-VS-A8EK, TCGA-C5-A901, TCGA...</td>\n",
       "      <td>Sure, let's analyze the impact of cervical squ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Cholangiocarcinoma</td>\n",
       "      <td>TCGA-5A-A8ZF, TCGA-4G-AAZG, TCGA-W5-AA2J, TCGA...</td>\n",
       "      <td>### Tumor Origin\\n\\n**Influence on Survival:**...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Colon adenocarcinoma</td>\n",
       "      <td>TCGA-G4-6314, TCGA-AA-3815, TCGA-AA-3967, TCGA...</td>\n",
       "      <td>**Tumor Origin and Metastatic Patterns:**\\n\\n1...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Esophageal carcinoma</td>\n",
       "      <td>TCGA-IC-A6RF</td>\n",
       "      <td>Certainly, let's delve into the complexities o...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Glioblastoma multiforme</td>\n",
       "      <td>TCGA-06-6391, TCGA-19-1788, TCGA-06-0209, TCGA...</td>\n",
       "      <td>### Tumor Origin\\n\\n**Influence on Survival:**...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Head and Neck squamous cell carcinoma</td>\n",
       "      <td>TCGA-BA-4075, TCGA-CX-7082, TCGA-CQ-A4C7, TCGA...</td>\n",
       "      <td>### Tumor Origin\\n\\n1. **Metastatic Patterns a...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Kidney renal clear cell carcinoma</td>\n",
       "      <td>TCGA-B2-5636, TCGA-DV-5573, TCGA-DV-5568, TCGA...</td>\n",
       "      <td>To comprehensively understand the impact of Ki...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Kidney renal papillary cell carcinoma</td>\n",
       "      <td>TCGA-AL-3468, TCGA-5P-A9KF, TCGA-AL-A5DJ, TCGA...</td>\n",
       "      <td>**Tumor Origin and Metastatic Patterns:**\\n\\nK...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Liver hepatocellular carcinoma</td>\n",
       "      <td>TCGA-G3-A3CG, TCGA-T1-A6J8, TCGA-XR-A8TC, TCGA...</td>\n",
       "      <td>### Tumor Origin\\n\\n**Influence on Survival**\\...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Lung adenocarcinoma</td>\n",
       "      <td>TCGA-44-6147, TCGA-44-6147, TCGA-44-2661, TCGA...</td>\n",
       "      <td>### Tumor Origin: \\n\\n1. **Influence on Metast...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Lung squamous cell carcinoma</td>\n",
       "      <td>TCGA-NK-A5D1, TCGA-21-A5DI, TCGA-96-A4JK, TCGA...</td>\n",
       "      <td>To thoroughly discuss the impact of Lung Squam...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Ovarian serous cystadenocarcinoma</td>\n",
       "      <td>TCGA-24-2036, TCGA-36-2539</td>\n",
       "      <td>### Tumor Origin\\n\\n1. **Influence on Metastat...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Pancreatic adenocarcinoma</td>\n",
       "      <td>TCGA-IB-7654</td>\n",
       "      <td>## Tumor Origin\\n\\n**Impact on Survival:**\\n\\n...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Pheochromocytoma and Paraganglioma</td>\n",
       "      <td>TCGA-WB-A820</td>\n",
       "      <td>### Pheochromocytoma and Paraganglioma: Impact...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Prostate adenocarcinoma</td>\n",
       "      <td>TCGA-G9-A9S4, TCGA-XK-AAK1, TCGA-XK-AAJ3, TCGA...</td>\n",
       "      <td>Certainly, let's explore Prostate adenocarcino...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Rectum adenocarcinoma</td>\n",
       "      <td>TCGA-G5-6235, TCGA-G5-6572, TCGA-AG-A00H, TCGA...</td>\n",
       "      <td>### Tumor Origin\\n\\n**Influence on Survival:**...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Sarcoma</td>\n",
       "      <td>TCGA-PC-A5DM</td>\n",
       "      <td>**Sarcoma: Impact on Survival**\\n\\n**1. Tumor ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Skin Cutaneous Melanoma</td>\n",
       "      <td>TCGA-BF-AAOX, TCGA-BF-A9VF, TCGA-EB-A82C, TCGA...</td>\n",
       "      <td>### Tumor Origin\\n\\n**Influence on Metastasis ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Stomach adenocarcinoma</td>\n",
       "      <td>TCGA-HF-7131, TCGA-CG-5716, TCGA-CG-4460</td>\n",
       "      <td>### Tumor Origin\\n\\n1. **Influence on Survival...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Testicular Germ Cell Tumors</td>\n",
       "      <td>TCGA-2G-AAFE</td>\n",
       "      <td>### Tumor Origin\\n\\n**Influence on Survival**:...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Thyroid carcinoma</td>\n",
       "      <td>TCGA-E8-A2JQ, TCGA-EL-A3D5, TCGA-EL-A3D0, TCGA...</td>\n",
       "      <td>**Thyroid Carcinoma and Its Impact on Survival...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>Blood Derived Normal, Primary Tumor</td>\n",
       "      <td>Uterine Corpus Endometrial Carcinoma</td>\n",
       "      <td>TCGA-BG-A0M8, TCGA-BG-A220, TCGA-AP-A053, TCGA...</td>\n",
       "      <td>To effectively discuss Uterine Corpus Endometr...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>Blood Derived Normal, Recurrent Tumor</td>\n",
       "      <td>Rectum adenocarcinoma</td>\n",
       "      <td>TCGA-G5-6572</td>\n",
       "      <td>Certainly, let's delve into how Rectum adenoca...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Cholangiocarcinoma</td>\n",
       "      <td>TCGA-W7-A93P, TCGA-W7-A93O, TCGA-4G-AAZF, TCGA...</td>\n",
       "      <td>### Tumor Origin\\n\\n**Influence on Survival:**...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Colon adenocarcinoma</td>\n",
       "      <td>TCGA-AA-3662, TCGA-G4-6625, TCGA-AA-3697, TCGA...</td>\n",
       "      <td>### Tumor Origin\\n\\n**Influence on Survival**:...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Esophageal carcinoma</td>\n",
       "      <td>TCGA-L5-A88T</td>\n",
       "      <td>Certainly, let's delve into the complex factor...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Kidney Chromophobe</td>\n",
       "      <td>TCGA-KN-8430</td>\n",
       "      <td>### Tumor Origin\\n\\n**Impact on Survival:**\\n-...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Kidney renal clear cell carcinoma</td>\n",
       "      <td>TCGA-BP-4986, TCGA-CZ-4865, TCGA-BP-4988, TCGA...</td>\n",
       "      <td>### Tumor Origin and Impact on Survival\\n\\n**1...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Kidney renal papillary cell carcinoma</td>\n",
       "      <td>TCGA-BQ-7056, TCGA-BQ-7049</td>\n",
       "      <td>### Tumor Origin\\n\\n**Influence on Survival:**...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Liver hepatocellular carcinoma</td>\n",
       "      <td>TCGA-BD-A3ER</td>\n",
       "      <td>### Tumor Origin\\n\\n**Influence on Survival:**...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Lung adenocarcinoma</td>\n",
       "      <td>TCGA-38-4630, TCGA-05-5420, TCGA-38-4629</td>\n",
       "      <td>Certainly, let's break down how lung adenocarc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Lung squamous cell carcinoma</td>\n",
       "      <td>TCGA-21-1070, TCGA-60-2715, TCGA-21-1078, TCGA...</td>\n",
       "      <td>Certainly. Let's dive into lung squamous cell ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Ovarian serous cystadenocarcinoma</td>\n",
       "      <td>TCGA-09-2056</td>\n",
       "      <td>Certainly, I will explain how ovarian serous c...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Rectum adenocarcinoma</td>\n",
       "      <td>TCGA-AF-3913, TCGA-AF-3914, TCGA-AG-A036</td>\n",
       "      <td>### Tumor Origin\\n\\nRectum adenocarcinoma, a s...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Sarcoma</td>\n",
       "      <td>TCGA-IF-A4AK</td>\n",
       "      <td>To comprehensively address how Sarcoma impacts...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>Primary Tumor, Solid Tissue Normal</td>\n",
       "      <td>Uterine Corpus Endometrial Carcinoma</td>\n",
       "      <td>TCGA-AX-A2H8</td>\n",
       "      <td>### Tumor Origin\\nUterine Corpus Endometrial C...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                   Normalized Sample Type  \\\n",
       "0        Blood Derived Normal, Metastatic   \n",
       "1        Blood Derived Normal, Metastatic   \n",
       "2     Blood Derived Normal, Primary Tumor   \n",
       "3     Blood Derived Normal, Primary Tumor   \n",
       "4     Blood Derived Normal, Primary Tumor   \n",
       "5     Blood Derived Normal, Primary Tumor   \n",
       "6     Blood Derived Normal, Primary Tumor   \n",
       "7     Blood Derived Normal, Primary Tumor   \n",
       "8     Blood Derived Normal, Primary Tumor   \n",
       "9     Blood Derived Normal, Primary Tumor   \n",
       "10    Blood Derived Normal, Primary Tumor   \n",
       "11    Blood Derived Normal, Primary Tumor   \n",
       "12    Blood Derived Normal, Primary Tumor   \n",
       "13    Blood Derived Normal, Primary Tumor   \n",
       "14    Blood Derived Normal, Primary Tumor   \n",
       "15    Blood Derived Normal, Primary Tumor   \n",
       "16    Blood Derived Normal, Primary Tumor   \n",
       "17    Blood Derived Normal, Primary Tumor   \n",
       "18    Blood Derived Normal, Primary Tumor   \n",
       "19    Blood Derived Normal, Primary Tumor   \n",
       "20    Blood Derived Normal, Primary Tumor   \n",
       "21    Blood Derived Normal, Primary Tumor   \n",
       "22    Blood Derived Normal, Primary Tumor   \n",
       "23    Blood Derived Normal, Primary Tumor   \n",
       "24    Blood Derived Normal, Primary Tumor   \n",
       "25    Blood Derived Normal, Primary Tumor   \n",
       "26    Blood Derived Normal, Primary Tumor   \n",
       "27    Blood Derived Normal, Primary Tumor   \n",
       "28  Blood Derived Normal, Recurrent Tumor   \n",
       "29     Primary Tumor, Solid Tissue Normal   \n",
       "30     Primary Tumor, Solid Tissue Normal   \n",
       "31     Primary Tumor, Solid Tissue Normal   \n",
       "32     Primary Tumor, Solid Tissue Normal   \n",
       "33     Primary Tumor, Solid Tissue Normal   \n",
       "34     Primary Tumor, Solid Tissue Normal   \n",
       "35     Primary Tumor, Solid Tissue Normal   \n",
       "36     Primary Tumor, Solid Tissue Normal   \n",
       "37     Primary Tumor, Solid Tissue Normal   \n",
       "38     Primary Tumor, Solid Tissue Normal   \n",
       "39     Primary Tumor, Solid Tissue Normal   \n",
       "40     Primary Tumor, Solid Tissue Normal   \n",
       "41     Primary Tumor, Solid Tissue Normal   \n",
       "\n",
       "                                           Study Name  \\\n",
       "0                             Skin Cutaneous Melanoma   \n",
       "1                                   Thyroid carcinoma   \n",
       "2                            Adrenocortical carcinoma   \n",
       "3                        Bladder Urothelial Carcinoma   \n",
       "4                            Brain Lower Grade Glioma   \n",
       "5                           Breast invasive carcinoma   \n",
       "6   Cervical squamous cell carcinoma and endocervi...   \n",
       "7                                  Cholangiocarcinoma   \n",
       "8                                Colon adenocarcinoma   \n",
       "9                                Esophageal carcinoma   \n",
       "10                            Glioblastoma multiforme   \n",
       "11              Head and Neck squamous cell carcinoma   \n",
       "12                  Kidney renal clear cell carcinoma   \n",
       "13              Kidney renal papillary cell carcinoma   \n",
       "14                     Liver hepatocellular carcinoma   \n",
       "15                                Lung adenocarcinoma   \n",
       "16                       Lung squamous cell carcinoma   \n",
       "17                  Ovarian serous cystadenocarcinoma   \n",
       "18                          Pancreatic adenocarcinoma   \n",
       "19                 Pheochromocytoma and Paraganglioma   \n",
       "20                            Prostate adenocarcinoma   \n",
       "21                              Rectum adenocarcinoma   \n",
       "22                                            Sarcoma   \n",
       "23                            Skin Cutaneous Melanoma   \n",
       "24                             Stomach adenocarcinoma   \n",
       "25                        Testicular Germ Cell Tumors   \n",
       "26                                  Thyroid carcinoma   \n",
       "27               Uterine Corpus Endometrial Carcinoma   \n",
       "28                              Rectum adenocarcinoma   \n",
       "29                                 Cholangiocarcinoma   \n",
       "30                               Colon adenocarcinoma   \n",
       "31                               Esophageal carcinoma   \n",
       "32                                 Kidney Chromophobe   \n",
       "33                  Kidney renal clear cell carcinoma   \n",
       "34              Kidney renal papillary cell carcinoma   \n",
       "35                     Liver hepatocellular carcinoma   \n",
       "36                                Lung adenocarcinoma   \n",
       "37                       Lung squamous cell carcinoma   \n",
       "38                  Ovarian serous cystadenocarcinoma   \n",
       "39                              Rectum adenocarcinoma   \n",
       "40                                            Sarcoma   \n",
       "41               Uterine Corpus Endometrial Carcinoma   \n",
       "\n",
       "                                             Case IDs  \\\n",
       "0                                        TCGA-WE-A8ZR   \n",
       "1                                        TCGA-EM-A2CS   \n",
       "2                                        TCGA-P6-A5OG   \n",
       "3                                        TCGA-E7-A8O8   \n",
       "4                          TCGA-HT-A619, TCGA-R8-A73M   \n",
       "5   TCGA-AR-A2LR, TCGA-D8-A146, TCGA-BH-A0B6, TCGA...   \n",
       "6   TCGA-C5-A902, TCGA-VS-A8EK, TCGA-C5-A901, TCGA...   \n",
       "7   TCGA-5A-A8ZF, TCGA-4G-AAZG, TCGA-W5-AA2J, TCGA...   \n",
       "8   TCGA-G4-6314, TCGA-AA-3815, TCGA-AA-3967, TCGA...   \n",
       "9                                        TCGA-IC-A6RF   \n",
       "10  TCGA-06-6391, TCGA-19-1788, TCGA-06-0209, TCGA...   \n",
       "11  TCGA-BA-4075, TCGA-CX-7082, TCGA-CQ-A4C7, TCGA...   \n",
       "12  TCGA-B2-5636, TCGA-DV-5573, TCGA-DV-5568, TCGA...   \n",
       "13  TCGA-AL-3468, TCGA-5P-A9KF, TCGA-AL-A5DJ, TCGA...   \n",
       "14  TCGA-G3-A3CG, TCGA-T1-A6J8, TCGA-XR-A8TC, TCGA...   \n",
       "15  TCGA-44-6147, TCGA-44-6147, TCGA-44-2661, TCGA...   \n",
       "16  TCGA-NK-A5D1, TCGA-21-A5DI, TCGA-96-A4JK, TCGA...   \n",
       "17                         TCGA-24-2036, TCGA-36-2539   \n",
       "18                                       TCGA-IB-7654   \n",
       "19                                       TCGA-WB-A820   \n",
       "20  TCGA-G9-A9S4, TCGA-XK-AAK1, TCGA-XK-AAJ3, TCGA...   \n",
       "21  TCGA-G5-6235, TCGA-G5-6572, TCGA-AG-A00H, TCGA...   \n",
       "22                                       TCGA-PC-A5DM   \n",
       "23  TCGA-BF-AAOX, TCGA-BF-A9VF, TCGA-EB-A82C, TCGA...   \n",
       "24           TCGA-HF-7131, TCGA-CG-5716, TCGA-CG-4460   \n",
       "25                                       TCGA-2G-AAFE   \n",
       "26  TCGA-E8-A2JQ, TCGA-EL-A3D5, TCGA-EL-A3D0, TCGA...   \n",
       "27  TCGA-BG-A0M8, TCGA-BG-A220, TCGA-AP-A053, TCGA...   \n",
       "28                                       TCGA-G5-6572   \n",
       "29  TCGA-W7-A93P, TCGA-W7-A93O, TCGA-4G-AAZF, TCGA...   \n",
       "30  TCGA-AA-3662, TCGA-G4-6625, TCGA-AA-3697, TCGA...   \n",
       "31                                       TCGA-L5-A88T   \n",
       "32                                       TCGA-KN-8430   \n",
       "33  TCGA-BP-4986, TCGA-CZ-4865, TCGA-BP-4988, TCGA...   \n",
       "34                         TCGA-BQ-7056, TCGA-BQ-7049   \n",
       "35                                       TCGA-BD-A3ER   \n",
       "36           TCGA-38-4630, TCGA-05-5420, TCGA-38-4629   \n",
       "37  TCGA-21-1070, TCGA-60-2715, TCGA-21-1078, TCGA...   \n",
       "38                                       TCGA-09-2056   \n",
       "39           TCGA-AF-3913, TCGA-AF-3914, TCGA-AG-A036   \n",
       "40                                       TCGA-IF-A4AK   \n",
       "41                                       TCGA-AX-A2H8   \n",
       "\n",
       "                                generated_description  \n",
       "0   ## Tumor Origin and Its Influence on Survival\\...  \n",
       "1   Thyroid carcinoma showcases distinct influence...  \n",
       "2   ### Tumor Origin\\n\\n**Influence on Survival:**...  \n",
       "3   ### Tumor Origin and Metastatic Patterns\\n\\n**...  \n",
       "4   ### Tumor Origin\\n\\n**Influence on Survival:**...  \n",
       "5   ### Tumor Origin and Its Influence on Survival...  \n",
       "6   Sure, let's analyze the impact of cervical squ...  \n",
       "7   ### Tumor Origin\\n\\n**Influence on Survival:**...  \n",
       "8   **Tumor Origin and Metastatic Patterns:**\\n\\n1...  \n",
       "9   Certainly, let's delve into the complexities o...  \n",
       "10  ### Tumor Origin\\n\\n**Influence on Survival:**...  \n",
       "11  ### Tumor Origin\\n\\n1. **Metastatic Patterns a...  \n",
       "12  To comprehensively understand the impact of Ki...  \n",
       "13  **Tumor Origin and Metastatic Patterns:**\\n\\nK...  \n",
       "14  ### Tumor Origin\\n\\n**Influence on Survival**\\...  \n",
       "15  ### Tumor Origin: \\n\\n1. **Influence on Metast...  \n",
       "16  To thoroughly discuss the impact of Lung Squam...  \n",
       "17  ### Tumor Origin\\n\\n1. **Influence on Metastat...  \n",
       "18  ## Tumor Origin\\n\\n**Impact on Survival:**\\n\\n...  \n",
       "19  ### Pheochromocytoma and Paraganglioma: Impact...  \n",
       "20  Certainly, let's explore Prostate adenocarcino...  \n",
       "21  ### Tumor Origin\\n\\n**Influence on Survival:**...  \n",
       "22  **Sarcoma: Impact on Survival**\\n\\n**1. Tumor ...  \n",
       "23  ### Tumor Origin\\n\\n**Influence on Metastasis ...  \n",
       "24  ### Tumor Origin\\n\\n1. **Influence on Survival...  \n",
       "25  ### Tumor Origin\\n\\n**Influence on Survival**:...  \n",
       "26  **Thyroid Carcinoma and Its Impact on Survival...  \n",
       "27  To effectively discuss Uterine Corpus Endometr...  \n",
       "28  Certainly, let's delve into how Rectum adenoca...  \n",
       "29  ### Tumor Origin\\n\\n**Influence on Survival:**...  \n",
       "30  ### Tumor Origin\\n\\n**Influence on Survival**:...  \n",
       "31  Certainly, let's delve into the complex factor...  \n",
       "32  ### Tumor Origin\\n\\n**Impact on Survival:**\\n-...  \n",
       "33  ### Tumor Origin and Impact on Survival\\n\\n**1...  \n",
       "34  ### Tumor Origin\\n\\n**Influence on Survival:**...  \n",
       "35  ### Tumor Origin\\n\\n**Influence on Survival:**...  \n",
       "36  Certainly, let's break down how lung adenocarc...  \n",
       "37  Certainly. Let's dive into lung squamous cell ...  \n",
       "38  Certainly, I will explain how ovarian serous c...  \n",
       "39  ### Tumor Origin\\n\\nRectum adenocarcinoma, a s...  \n",
       "40  To comprehensively address how Sarcoma impacts...  \n",
       "41  ### Tumor Origin\\nUterine Corpus Endometrial C...  "
      ]
     },
     "execution_count": 42,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "description_meta"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "ename": "OSError",
     "evalue": "Cannot save file into a non-existent directory: '/home/chb3333/yulab/chb3333/gem-patho/data_extraction/cancertype_location_description/location_description_withoutICD'",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mOSError\u001b[0m                                   Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[43], line 1\u001b[0m\n\u001b[0;32m----> 1\u001b[0m \u001b[43mdescription_meta\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mto_parquet\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m      2\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43m/home/chb3333/yulab/chb3333/gem-patho/data_extraction/cancertype_location_description/location_description_withoutICD/description_meta_with_answers.parquet\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[1;32m      3\u001b[0m \u001b[43m    \u001b[49m\u001b[43mindex\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;28;43;01mFalse\u001b[39;49;00m\n\u001b[1;32m      4\u001b[0m \u001b[43m)\u001b[49m\n\u001b[1;32m      5\u001b[0m description_meta\u001b[38;5;241m.\u001b[39mto_parquet(\n\u001b[1;32m      6\u001b[0m     \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m/home/chb3333/yulab/chb3333/gem-patho/data_extraction/cancertype_location_description/location_description_withoutICD/description_meta.parquet\u001b[39m\u001b[38;5;124m\"\u001b[39m,\n\u001b[1;32m      7\u001b[0m     index\u001b[38;5;241m=\u001b[39m\u001b[38;5;28;01mFalse\u001b[39;00m\n\u001b[1;32m      8\u001b[0m )\n\u001b[1;32m      9\u001b[0m \u001b[38;5;28mprint\u001b[39m(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mUpdated description_meta saved successfully.\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n",
      "File \u001b[0;32m~/.conda/envs/nns/lib/python3.12/site-packages/pandas/util/_decorators.py:333\u001b[0m, in \u001b[0;36mdeprecate_nonkeyword_arguments.<locals>.decorate.<locals>.wrapper\u001b[0;34m(*args, **kwargs)\u001b[0m\n\u001b[1;32m    327\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mlen\u001b[39m(args) \u001b[38;5;241m>\u001b[39m num_allow_args:\n\u001b[1;32m    328\u001b[0m     warnings\u001b[38;5;241m.\u001b[39mwarn(\n\u001b[1;32m    329\u001b[0m         msg\u001b[38;5;241m.\u001b[39mformat(arguments\u001b[38;5;241m=\u001b[39m_format_argument_list(allow_args)),\n\u001b[1;32m    330\u001b[0m         \u001b[38;5;167;01mFutureWarning\u001b[39;00m,\n\u001b[1;32m    331\u001b[0m         stacklevel\u001b[38;5;241m=\u001b[39mfind_stack_level(),\n\u001b[1;32m    332\u001b[0m     )\n\u001b[0;32m--> 333\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mfunc\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43margs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[0;32m~/.conda/envs/nns/lib/python3.12/site-packages/pandas/core/frame.py:3113\u001b[0m, in \u001b[0;36mDataFrame.to_parquet\u001b[0;34m(self, path, engine, compression, index, partition_cols, storage_options, **kwargs)\u001b[0m\n\u001b[1;32m   3032\u001b[0m \u001b[38;5;250m\u001b[39m\u001b[38;5;124;03m\"\"\"\u001b[39;00m\n\u001b[1;32m   3033\u001b[0m \u001b[38;5;124;03mWrite a DataFrame to the binary parquet format.\u001b[39;00m\n\u001b[1;32m   3034\u001b[0m \n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m   3109\u001b[0m \u001b[38;5;124;03m>>> content = f.read()\u001b[39;00m\n\u001b[1;32m   3110\u001b[0m \u001b[38;5;124;03m\"\"\"\u001b[39;00m\n\u001b[1;32m   3111\u001b[0m \u001b[38;5;28;01mfrom\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;21;01mpandas\u001b[39;00m\u001b[38;5;21;01m.\u001b[39;00m\u001b[38;5;21;01mio\u001b[39;00m\u001b[38;5;21;01m.\u001b[39;00m\u001b[38;5;21;01mparquet\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;28;01mimport\u001b[39;00m to_parquet\n\u001b[0;32m-> 3113\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mto_parquet\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m   3114\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[1;32m   3115\u001b[0m \u001b[43m    \u001b[49m\u001b[43mpath\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m   3116\u001b[0m \u001b[43m    \u001b[49m\u001b[43mengine\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m   3117\u001b[0m \u001b[43m    \u001b[49m\u001b[43mcompression\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mcompression\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m   3118\u001b[0m \u001b[43m    \u001b[49m\u001b[43mindex\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mindex\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m   3119\u001b[0m \u001b[43m    \u001b[49m\u001b[43mpartition_cols\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mpartition_cols\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m   3120\u001b[0m \u001b[43m    \u001b[49m\u001b[43mstorage_options\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstorage_options\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m   3121\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mkwargs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m   3122\u001b[0m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\n",
      "File \u001b[0;32m~/.conda/envs/nns/lib/python3.12/site-packages/pandas/io/parquet.py:480\u001b[0m, in \u001b[0;36mto_parquet\u001b[0;34m(df, path, engine, compression, index, storage_options, partition_cols, filesystem, **kwargs)\u001b[0m\n\u001b[1;32m    476\u001b[0m impl \u001b[38;5;241m=\u001b[39m get_engine(engine)\n\u001b[1;32m    478\u001b[0m path_or_buf: FilePath \u001b[38;5;241m|\u001b[39m WriteBuffer[\u001b[38;5;28mbytes\u001b[39m] \u001b[38;5;241m=\u001b[39m io\u001b[38;5;241m.\u001b[39mBytesIO() \u001b[38;5;28;01mif\u001b[39;00m path \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m \u001b[38;5;28;01melse\u001b[39;00m path\n\u001b[0;32m--> 480\u001b[0m \u001b[43mimpl\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mwrite\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m    481\u001b[0m \u001b[43m    \u001b[49m\u001b[43mdf\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    482\u001b[0m \u001b[43m    \u001b[49m\u001b[43mpath_or_buf\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    483\u001b[0m \u001b[43m    \u001b[49m\u001b[43mcompression\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mcompression\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    484\u001b[0m \u001b[43m    \u001b[49m\u001b[43mindex\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mindex\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    485\u001b[0m \u001b[43m    \u001b[49m\u001b[43mpartition_cols\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mpartition_cols\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    486\u001b[0m \u001b[43m    \u001b[49m\u001b[43mstorage_options\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstorage_options\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    487\u001b[0m \u001b[43m    \u001b[49m\u001b[43mfilesystem\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mfilesystem\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    488\u001b[0m \u001b[43m    \u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mkwargs\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    489\u001b[0m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    491\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m path \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[1;32m    492\u001b[0m     \u001b[38;5;28;01massert\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(path_or_buf, io\u001b[38;5;241m.\u001b[39mBytesIO)\n",
      "File \u001b[0;32m~/.conda/envs/nns/lib/python3.12/site-packages/pandas/io/parquet.py:198\u001b[0m, in \u001b[0;36mPyArrowImpl.write\u001b[0;34m(self, df, path, compression, index, storage_options, partition_cols, filesystem, **kwargs)\u001b[0m\n\u001b[1;32m    195\u001b[0m     merged_metadata \u001b[38;5;241m=\u001b[39m {\u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mexisting_metadata, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mdf_metadata}\n\u001b[1;32m    196\u001b[0m     table \u001b[38;5;241m=\u001b[39m table\u001b[38;5;241m.\u001b[39mreplace_schema_metadata(merged_metadata)\n\u001b[0;32m--> 198\u001b[0m path_or_handle, handles, filesystem \u001b[38;5;241m=\u001b[39m \u001b[43m_get_path_or_handle\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m    199\u001b[0m \u001b[43m    \u001b[49m\u001b[43mpath\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    200\u001b[0m \u001b[43m    \u001b[49m\u001b[43mfilesystem\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    201\u001b[0m \u001b[43m    \u001b[49m\u001b[43mstorage_options\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstorage_options\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m    202\u001b[0m \u001b[43m    \u001b[49m\u001b[43mmode\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mwb\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m,\u001b[49m\n\u001b[1;32m    203\u001b[0m \u001b[43m    \u001b[49m\u001b[43mis_dir\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mpartition_cols\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01mis\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;129;43;01mnot\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mNone\u001b[39;49;00m\u001b[43m,\u001b[49m\n\u001b[1;32m    204\u001b[0m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    205\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m (\n\u001b[1;32m    206\u001b[0m     \u001b[38;5;28misinstance\u001b[39m(path_or_handle, io\u001b[38;5;241m.\u001b[39mBufferedWriter)\n\u001b[1;32m    207\u001b[0m     \u001b[38;5;129;01mand\u001b[39;00m \u001b[38;5;28mhasattr\u001b[39m(path_or_handle, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mname\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n\u001b[1;32m    208\u001b[0m     \u001b[38;5;129;01mand\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(path_or_handle\u001b[38;5;241m.\u001b[39mname, (\u001b[38;5;28mstr\u001b[39m, \u001b[38;5;28mbytes\u001b[39m))\n\u001b[1;32m    209\u001b[0m ):\n\u001b[1;32m    210\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28misinstance\u001b[39m(path_or_handle\u001b[38;5;241m.\u001b[39mname, \u001b[38;5;28mbytes\u001b[39m):\n",
      "File \u001b[0;32m~/.conda/envs/nns/lib/python3.12/site-packages/pandas/io/parquet.py:140\u001b[0m, in \u001b[0;36m_get_path_or_handle\u001b[0;34m(path, fs, storage_options, mode, is_dir)\u001b[0m\n\u001b[1;32m    130\u001b[0m handles \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mNone\u001b[39;00m\n\u001b[1;32m    131\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m (\n\u001b[1;32m    132\u001b[0m     \u001b[38;5;129;01mnot\u001b[39;00m fs\n\u001b[1;32m    133\u001b[0m     \u001b[38;5;129;01mand\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m is_dir\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m    138\u001b[0m     \u001b[38;5;66;03m# fsspec resources can also point to directories\u001b[39;00m\n\u001b[1;32m    139\u001b[0m     \u001b[38;5;66;03m# this branch is used for example when reading from non-fsspec URLs\u001b[39;00m\n\u001b[0;32m--> 140\u001b[0m     handles \u001b[38;5;241m=\u001b[39m \u001b[43mget_handle\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m    141\u001b[0m \u001b[43m        \u001b[49m\u001b[43mpath_or_handle\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mmode\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mis_text\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;28;43;01mFalse\u001b[39;49;00m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mstorage_options\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mstorage_options\u001b[49m\n\u001b[1;32m    142\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    143\u001b[0m     fs \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mNone\u001b[39;00m\n\u001b[1;32m    144\u001b[0m     path_or_handle \u001b[38;5;241m=\u001b[39m handles\u001b[38;5;241m.\u001b[39mhandle\n",
      "File \u001b[0;32m~/.conda/envs/nns/lib/python3.12/site-packages/pandas/io/common.py:749\u001b[0m, in \u001b[0;36mget_handle\u001b[0;34m(path_or_buf, mode, encoding, compression, memory_map, is_text, errors, storage_options)\u001b[0m\n\u001b[1;32m    747\u001b[0m \u001b[38;5;66;03m# Only for write methods\u001b[39;00m\n\u001b[1;32m    748\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mr\u001b[39m\u001b[38;5;124m\"\u001b[39m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;129;01min\u001b[39;00m mode \u001b[38;5;129;01mand\u001b[39;00m is_path:\n\u001b[0;32m--> 749\u001b[0m     \u001b[43mcheck_parent_directory\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;28;43mstr\u001b[39;49m\u001b[43m(\u001b[49m\u001b[43mhandle\u001b[49m\u001b[43m)\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    751\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m compression:\n\u001b[1;32m    752\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m compression \u001b[38;5;241m!=\u001b[39m \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mzstd\u001b[39m\u001b[38;5;124m\"\u001b[39m:\n\u001b[1;32m    753\u001b[0m         \u001b[38;5;66;03m# compression libraries do not like an explicit text-mode\u001b[39;00m\n",
      "File \u001b[0;32m~/.conda/envs/nns/lib/python3.12/site-packages/pandas/io/common.py:616\u001b[0m, in \u001b[0;36mcheck_parent_directory\u001b[0;34m(path)\u001b[0m\n\u001b[1;32m    614\u001b[0m parent \u001b[38;5;241m=\u001b[39m Path(path)\u001b[38;5;241m.\u001b[39mparent\n\u001b[1;32m    615\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m parent\u001b[38;5;241m.\u001b[39mis_dir():\n\u001b[0;32m--> 616\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mOSError\u001b[39;00m(\u001b[38;5;124mrf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mCannot save file into a non-existent directory: \u001b[39m\u001b[38;5;124m'\u001b[39m\u001b[38;5;132;01m{\u001b[39;00mparent\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m'\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n",
      "\u001b[0;31mOSError\u001b[0m: Cannot save file into a non-existent directory: '/home/chb3333/yulab/chb3333/gem-patho/data_extraction/cancertype_location_description/location_description_withoutICD'"
     ]
    }
   ],
   "source": [
    "description_meta.to_parquet(\n",
    "    \"/home/chb3333/yulab/chb3333/gem-patho/data_extraction/cancertype_location_description/location_desciption_withoutICD/description_meta_with_answers.parquet\",\n",
    "    index=False\n",
    ")\n",
    "description_meta.to_parquet(\n",
    "    \"/home/chb3333/yulab/chb3333/gem-patho/data_extraction/cancertype_location_description/location_desciption_withoutICD/description_meta.parquet\",\n",
    "    index=False\n",
    ")\n",
    "print(\"Updated description_meta saved successfully.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.8"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
